atomoxetine hydrochloride has been researched along with ADDH in 895 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (0.22) | 18.2507 |
| 2000's | 325 (36.31) | 29.6817 |
| 2010's | 464 (51.84) | 24.3611 |
| 2020's | 104 (11.62) | 2.80 |
| Authors | Studies |
|---|---|
| Banaschewski, T; Bölte, S; Buitelaar, JK; Coghill, D; Cortese, S; Häge, A; Hohmann, S; Jonsson, U; Nobel Norrman, H; Pan, PY; Şahpazoğlu Çakmak, SS | 1 |
| Alunno, A; Hughes, M; Matucci-Cerinic, M; Sandler, RD; Umair, HM | 1 |
| Kondrakhin, EA; Kovalev, GI; Salimov, RM; Sukhorukova, NA; Vasileva, EV | 1 |
| Jain, SB; Manikkara, G; Motiwala, FB; Muzwagi, AB; Rizvi, A; Rush, AJ; Varela, MA; Zafar, MK | 1 |
| El Agami, O; Gamal, F; Salamah, A | 1 |
| Holden, JM | 1 |
| Cai, M; Cui, LB; Hu, Y; Li, G; Lv, S; Peng, ZW; von Deneen, KM; Wang, HN; Wu, WJ; Xu, JY; Zhang, WC; Zhang, Y; Zhu, CZ | 1 |
| Li, M; Liang, B; Shan, J; Shen, J; Tang, H; Zhang, D; Zhong, L | 1 |
| Arnold, LE; Arns, M; Breteler, R; DeBeus, R; Denys, D; du Jour, P; Gordon, E; Griffiths, KR; Jansen, J; Korgaonkar, MS; Loo, SK; Michelini, G; Palmer, D; van Dijk, H; van Ruth, R; van Wingen, G; Voetterl, H | 1 |
| Hamner, M; Myers, US; Wang, Z; Zuschlag, ZD | 1 |
| Bachmann, C; Biscaldi-Schäfer, M; Clement, HW; Fleischhaker, C; Geffert, C; Haberhausen, M; Ruppert, K; Schulz, E | 1 |
| Iwanami, A; Kishimoto, K; Kogo, M; Koya, H; Kurihara, T; Nagai, T; Nakano, Y; Ota, H; Sambe, T; Sugisawa, S; Uchida, N | 1 |
| Dal, F; Demirci, E; Gul, MK; Onal, MG; Sener, EF | 1 |
| Cortese, S; Groom, MJ | 1 |
| Cao, Q; Fu, Z; Hu, N; Pei, X; Wang, Y; Xie, R; Xu, C; Yang, L; Yuan, J; Zhang, K; Zhao, Y | 1 |
| Higgins, GA; Silenieks, LB | 1 |
| Jain, S; Rizvi, A; Srinivas, S | 1 |
| Khan, YS; Khoodoruth, MAS; Ouanes, S | 1 |
| Dittmann, RW; Krone, B; Newcorn, JH | 1 |
| Coffey, BJ; Jaffe, RJ | 1 |
| Surman, CBH; Walsh, DM | 2 |
| Andersen, JH; Cesta, CE; Furu, K; Hartz, I; Rasmussen, L; Reutfors, J; Sørensen, AMS; Wesselhöeft, R | 1 |
| Chaplin, MM; León-Barriera, R; Modesto-Lowe, V; Ortegon, RS | 1 |
| Paric, A; Patterson, B; Pipe, A; Ravindran, AV; Ravindran, N; Van Ameringen, M | 1 |
| Brown, JT | 1 |
| Böker, KO; Di Fazio, P; Jäckle, K; Lehmann, W; Schilling, AF; Wagener, N; Weiser, L | 1 |
| Chatterjee, M; Maitra, S; Mukhopadhyay, K; Ray, A; Saha, S; Sinha, S | 1 |
| Beltran-Navarro, B; Galvez-Contreras, AY; Gonzalez-Castaneda, RE; Gonzalez-Perez, O; Vargas-de la Cruz, I | 1 |
| Andriambeloson, E; Christensen, C; Karlsson, KÆ; Lavalou, P; Norton, WHJ; Parker, MO; Shkumatava, A; Sveinsdóttir, HS; Wagner, S; Þorsteinsson, H | 1 |
| Gether, U; Hervig, ME; Petersen, A; Robbins, TW; Toschi, C; Vangkilde, S | 1 |
| Cesta, CE; Cohen, JM; Furu, K; Karlstad, Ø; Reutfors, J; Srinivas, C | 1 |
| Hu, X; Li, W; Pan, L | 1 |
| Chen, F; Fang, WR; Fu, D; Guo, HL; Hu, YH; Liu, QQ; Wu, DD; Xu, J | 1 |
| Redding, ZV; Sabol, KE | 1 |
| Chen, F; Fu, D; Guo, HL; Hu, YH | 1 |
| Ba-M'hamed, S; Bennis, M; Landry, M; Sifeddine, W | 1 |
| Chutko, LS; Surushkina, SY | 1 |
| Gau, SS; Hsu, CN; Liao, HC; Lin, FJ; Wang, CC | 1 |
| Gillies, D; Leach, MJ; Perez Algorta, G | 1 |
| Becker, SP; Froehlich, TE; Wiggs, KK | 1 |
| Bellato, A; Cortese, S; Faraone, SV; Khoury, NM; Radonjić, NV | 1 |
| Bueno, CDF; Correa, RDESA; Dias, ACM; Rocha, NS | 1 |
| Price, MZ; Price, RL | 1 |
| Criaud, M; Cubillo, AI; Giampietro, V; Kowalczyk, OS; Mehta, MA; O'Daly, OG; Rubia, K | 1 |
| Andreasen, JT; Caballero-Puntiverio, M; Kyriakidou, M; Thomsen, M | 1 |
| Alamiri, B; Naguy, A | 1 |
| Balatacı, U; Kapıcı, Y; Küçükkelepçe, O; Kurt, F; Öz, E; Parlak, ME | 1 |
| Abdelmageed, RI; Elhossiny, RM; Elshahawy, HH; Mohamed, HM | 1 |
| Andreasen, JT; Arvastson, L; Aznar, S; Caballero-Puntiverio, M; Lerdrup, LS | 1 |
| de Vries, F; Houghton, R; Loss, G | 1 |
| Contreras, D; Hardy, P; Morales, B; Piña, R; Rojas, P; Rozas, C; Ugarte, G; Zeise, ML | 1 |
| Coghill, D; Efron, D; Hearps, S; Hiscock, H; Mulraney, M; Sciberras, E | 1 |
| Wu, LH; Zhang, F; Zhu, P | 1 |
| Castells, X; Cunill, R; Olivé, C; Ramon, M; Serrano, D | 1 |
| Nakano, A; Notsu, Y; Ota, M; Sasaki, T; Shimizu, M; Yamazaki, H; Yoshida, S | 1 |
| Küçük, Ö; Şahbudak, B; Yaylacı, F | 1 |
| Banaschewski, T; Häge, A; Hohmann, S; Millenet, S | 1 |
| Baweja, R; Hameed, U; Klein, M; Mattison, RE; Mayes, SD; Memon, H; Waschbusch, D; Waxmonsky, JG | 1 |
| Sarıgedik, E; Tufan, AE; Yektaş, Ç | 1 |
| Hagiwara, M; Kimura, R; Maegawa, S; Nakata, M; Suzuki, S | 1 |
| Cubuk, M; Gunes, S; Guvenmez, O | 1 |
| Ergün, MA; Güney, E; Okur, İ; Özaslan, A; Yapar, D | 1 |
| Miller, J; Perera, B; Shankar, R | 1 |
| Barzi, M; Bissig, KD; Jung, SY; Li, F; MacKenzie, KR; Maletic-Savatic, M; Wang, J; Zhao, M | 1 |
| Hackett, A; Joseph, R; Nicholas, J; Robinson, K; Schmidt, E; Welsh, J | 1 |
| Grimmsmann, T; Himmel, W | 1 |
| Ameis, SH; Anagnostou, E; Anderson, KK; Beswick, A; Gorman, DA; Lai, MC; Rodrigues, R; Szatmari, P | 1 |
| Didenko, E; Maw, K; Meleshkina, D; Najib, J; Ramnarain, J; Tabassum, M; Yusupov, K | 1 |
| Campbell, TJ; McGrane, IR | 1 |
| Je, NK; Kim, E; Kim, Y; Park, S | 1 |
| Cortese, S | 1 |
| Fuermaier, ABM; Groen, Y; Kok, FM; Tucha, O | 1 |
| Choudhury, ME; Eguchi, M; Fukuda, M; Ishii, E; Jogamoto, T; Kihara, N; Kubo, M; Miyanishi, K; Nagai, M; Nomoto, M; Sato, A; Shimizu, YI; Tanaka, J; Utsunomiya, R; Yano, H | 1 |
| Ballard, R; Janiczak, D; Perez-Reisler, M | 1 |
| Bai, Z; Charach, A; Chojecki, D; Eagles, C; Elliott, J; Hossain, A; Hsieh, SC; Husereau, D; Johnston, A; Kelly, SE; Mamdani, M; Skidmore, B; Tsakonas, E; Wells, GA | 1 |
| Cui, YH; Fang, F; Jiang, L; Jiang, YW; Liu, ZS; Lu, Q; Luo, R; Peng, J; Qin, J; Sun, D; Wang, JQ; Zheng, Y; Zhou, SZ | 1 |
| Cutler, AJ; Jain, R; Mattingly, GW; O'Neal, W | 1 |
| Castellanos, FX; de Castro-Manglano, P; Franco, AR; Milham, MP; Pereira-Sanchez, V; Soutullo, C; Vieira, D | 1 |
| Cengiz, M; Gür, B; Gür, F | 1 |
| Erkayman, B; Gür, B; Gür, F; Halıcı, Z; Karakoç, A | 1 |
| Biederman, J; Firmin, ES; Hoskova, B; Joshi, G; Wilens, T | 1 |
| Bloch, MH; Farhat, LC | 1 |
| Hayakawa, S; Hino, H; Ito, M; Kikuchi, D; Miura, R; Obara, T; Shiozawa, M; Takahashi, A; Tokunaga, M; Watanabe, Y | 1 |
| Iannucci, GJ; Lynn, M; McCracken, CM; Oster, ME; Pierick, AR | 1 |
| Adil, KJ; Cheong, JH; Han, SH; Jeon, SJ; Kim, HJ; Kim, HY; Kim, R; Kwon, KJ; Mabunga, DFN; Park, D; Ryu, O; Shin, CY; Valencia, S | 1 |
| Pang, L; Sareen, R | 1 |
| Demirci, E; Gul, MK; Onal, MG; Sener, EF | 1 |
| Abrams, M; Hasan, S; Mehta, A | 1 |
| Chen, F; Chen, J; Guo, HL; Hu, YH; Ji, X; Long, JY; Xia, Y | 1 |
| Bérard, A; Boukhris, T; Lemelin, M; Sheehy, O; Zhao, JP | 1 |
| Hakosima, Y; Harada, I; Inazaki, K; Itagaki, K; Kurokouchi, T; Mizumoto, Y; Namekata, S; Okada, T; Saito, K; Sasaki, S; Sasaki, Y; Shinohara, R; Sugimoto, K; Sunakawa, H; Takahashi, M; Tanase, S; Toguchi, Y; Tsujii, N; Usami, M; Yoshida, Y; Yoshimura, Y | 1 |
| Avillach, P; Feroe, AG; Greenspun, P; Gutiérrez-Sacristán, A; Kohane, IS; Mousavi, S; Surati, R; Uppal, N | 1 |
| Arranz, B; Arrojo, M; Becoña, E; Bernardo, M; Castells, X; Cunill, R; Flórez, G; Fonseca, F; Garriga, M; Goikolea, JM; González-Pinto, A; López, A; Sáiz, PA; San, L; Tirado-Muñoz, J; Torrens, M; Zorrilla, I | 1 |
| Banaschewski, T; Häge, A; Hohmann, S; Mechler, K | 1 |
| Fife, D; Hardin, J; Rofael, H; Ryan, PB; Solomon, ID; Stang, P; Voss, EA | 1 |
| Chen, J; Chen, L; Cheng, Q; Deng, L; Li, T; Yang, T; Zhang, Y; Zhao, Q; Zhou, P; Zhu, L | 1 |
| Egawa, J; Hayashi, T; Inoue, Y; Ono, S; Orime, N; Someya, T; Sugai, T; Sugimoto, A; Suzuki, Y; Yoshinaga, K | 1 |
| Faltraco, F; Palm, D; Simon, F; Thome, J; Tucha, O; Uzoni, A | 1 |
| Akmatov, MK; Bätzing, J; Holstiege, J | 1 |
| Coghill, D; Cortese, S; Newcorn, JH | 1 |
| Stevenson, J | 1 |
| Alkam, T; Aoyama, Y; Hiramatsu, M; Kihara, D; Kim, HC; Kimura, N; Mamiya, T; Nabeshima, T; Tsunoda, Y; Yoshida, A | 1 |
| Borges Dos Reis, C; Chierrito de Oliveira, D; Cristina Conegero Sanches, A; Fernandez-Llimos, F; Guerrero de Sousa, P; Maria Steimbach, L; Pontarolo, R; Tonin, FS; Virtuoso, S | 1 |
| Locatelli, I; Stuhec, M | 2 |
| Cao, Q; Chang, S; Duan, Q; Jia, T; Li, Y; Liu, D; Lu, L; Lu, Q; Qian, Y; Schumann, G; Sun, X; Wang, J; Wang, Y; Wu, Z; Xu, B; Yang, L; Zhang, K; Zhang, Y | 1 |
| Robbins, TW | 1 |
| Bushe, C; Dittmann, RW; Escobar, R; Greenhill, LL; Heinloth, AN; Lipsius, S; Tanaka, Y; Thome, J; Upadhyaya, H | 1 |
| Aman, MG; Arnold, LE; Brown, NV; Buchan-Page, KA; Corbett-Dick, P; Handen, BL; Hellings, J; Hollway, JA; Hyman, SL; Lecavalier, L; McAuliffe-Bellin, S; Pan, X; Rice, RR; Ryan, MM; Smith, T; Tumuluru, RV; Williams, C | 1 |
| Blanco, L; Capellà, D; Castells, X; Cunill, R; Riera, M; Tobias, A | 1 |
| Lee, EK; Lee, MS; Shin, JY; Song, I | 1 |
| Asherson, P; Cooper, RE; Moran, P; Moukhtarian, TR; Vassos, E | 1 |
| White, T | 1 |
| Bédard, AV; Fan, J; Halperin, JM; Hildebrandt, TB; Ivanov, I; Newcorn, JH; Schulz, KP; Stein, MA | 1 |
| Chou, TL; Fan, LY; Gau, SS | 1 |
| Almqvist, C; Cederlöf, M; D'Onofrio, BM; Larsson, H; Lichtenstein, P; Lu, Y; Sjölander, A | 1 |
| Chang, Z; D'Onofrio, BM; Gibbons, RD; Hur, K; Lahey, BB; Larsson, H; Lichtenstein, P; Quinn, PD; Rickert, ME; Sjölander, A | 1 |
| Baskin, BM; Dwoskin, LP; Kantak, KM; Nic Dhonnchadha, BÁ | 1 |
| Cheong, JH; de la Peña, JB; Dela Peña, I; Dela Peña, IJ; Han, DH; Kim, BN; Kim, HJ; Ryu, JH; Shin, CY | 1 |
| Ermer, D; Vik, T | 1 |
| Cortese, S; Harris, J; Lenzi, F; Masi, G | 1 |
| Naguy, A | 1 |
| Gandhi, R; Lippmann, S; Narang, P | 1 |
| Clarke, SD; Griffiths, KR; Jurigova, BG; Kohn, MR; Leikauf, JE; Palmer, D; Teber, ET; Tsang, TW; Williams, LM | 1 |
| Akaltun, İ; Kara, T | 1 |
| Aman, MG; Andridge, R; Arnold, LE; Handen, B; Hollway, JA; Lecavalier, L; Mendoza-Burcham, M; Silverman, L; Smith, T; Williams, C | 1 |
| Bateman, BT; Cohen, JM; Desai, RJ; Gray, KJ; Hernández-Díaz, S; Huybrechts, KF; Mogun, H; Park, Y; Patorno, E | 1 |
| Alkam, T; Kim, HC; Mamiya, T; Nabeshima, T; Nitta, A; Tanaka, J; Toriumi, K | 1 |
| Charman, T; Findon, JL; Howes, OD; King, BH; Loth, E; McAlonan, GM; McCracken, JT; Murphy, DG; Parr, JR; Povey, C; Rogdaki, M; Santosh, P; Simonoff, E; Wallace, S; Wichers, RH | 1 |
| Alatorre, CI; Faries, DE; Gelwicks, S; Haynes, VS; Kelsey, DK; Molife, C; Nyhuis, A | 1 |
| Hogan, MK; Rao, NP | 1 |
| Borel, P; D'Amelio, R; Feige, B; Hoxhaj, E; Matthies, S; Müller, H; Philipsen, A; Sadohara, C; Sobanski, E | 1 |
| Anagnostou, E | 1 |
| Geyer, MA; Phillips, AG; Robbins, TW | 1 |
| Bai, YM; Chang, WH; Chen, MH; Chen, TJ; Hsu, JW; Huang, KL; Li, CT; Lin, WC; Su, TP; Tsai, SJ; Wei, HT | 1 |
| Farsky, I; Hrtanek, I; Marcincakova Husarova, V; Nosalova, G; Ondrejka, I; Snircova, E | 1 |
| Cichocki, A; Hasegawa, M; Hiroyama, S; Horiuchi, M; Jurica, P; Li, J; Nishitomi, K; Ogawa, K; Struzik, ZR; Takahara, Y; Yokota, T | 1 |
| Goodloe, R; Kellier-Steele, NA; Kryzhanovskaya, LA; Liles-Burden, MA; Mancini, M; Meyers, KJ; Upadhyaya, HP | 1 |
| Jang, B; Jeong, B; Joung, YS; Kim, J; Kim, K; Kim, S; Kim, YH; Kwon, JY; Lee, J; Oh, Y; Shin, HY; Song, J; Yoo, JH | 1 |
| Clarke, S; Efron, D; Griffiths, KR; Hermens, DF; Kohn, MR; Leikauf, JE; Tsang, TW; Williams, LM | 1 |
| Aman, MG; Arnold, LE; Handen, B; Hollway, J; Hyman, SL; Lecavalier, L; Ober, N; Page, K; Pan, X; Rice, R; Smith, T | 1 |
| Casavant, MJ; Chounthirath, T; Hodges, NL; King, SA; Smith, GA; Spiller, HA | 1 |
| Fujita, J; Iida, J; Negoro, H; Okada, T; Okumura, Y; Saito, T; Tsujii, N; Usami, M | 1 |
| Antoniazzi, S; Carnovale, C; Clementi, E; Gentili, M; Nobile, M; Peeters, GGAM; Pozzi, M; Radice, S | 1 |
| Akutagava-Martins, GC; Campani, F; Cortese, S; Massuti, R; Moreira-Maia, CR; Rohde, LA; Tessari, L | 1 |
| Osland, ST; Pringsheim, T; Steeves, TD | 1 |
| Sharma, A | 1 |
| Ho, CS; Ho, RC; Liang, EF; Lim, SZ; McIntyre, RS; Tam, WW; Zhang, MW | 1 |
| Schell, M; Stern, L | 1 |
| Bahmanyar, S; Berard, A; Bilder, S; Boukhris, T; Bushnell, G; Chan, EW; Coghill, D; Crystal, S; Furu, K; Ip, P; KaoYang, YH; Karlstad, Ø; Kieler, H; Kubota, K; Lai, EC; Macias Saint-Gerons, D; Man, KKC; Martikainen, JE; Maura, G; Montero, D; Moore, N; Nakamura, H; Neumann, A; Pate, V; Pottegård, A; Pratt, NL; Raman, SR; Roughead, EE; Sturkenbroom, MCJM; Stürmer, T; Su, CC; Wong, ICK; Zoega, H | 1 |
| Howes, CF; Sharp, C | 2 |
| Bastiaens, L; Galus, J; Scott, O | 1 |
| Ebata, R; Fujii, K; Kobayashi, H; Kobayashi, M; Okunushi, K; Saito, N; Sawada, D; Shimojo, N; Shiohama, T | 1 |
| Brambilla, P; Crippa, A; Grazioli, S; Maggioni, E; Mauri, M; Molteni, M; Nobile, M | 1 |
| Chierrito, D; Fernandez-Llimos, F; Sanches, ACC; Tonin, FS; Villas-Boas, CB | 1 |
| Gau, SS; Shang, CY; Shih, HH | 1 |
| Kirubakaran, R; Nebhinani, N; Patra, S; Viswanathan, A | 1 |
| Andreasen, JT; Caballero-Puntiverio, M; Dietz, AG; Grupe, M; Larsen, CW; Lerdrup, LS | 1 |
| Su, CC; Tsai, CY; Tsai, IJ; Tsai, TH | 1 |
| Andreasen, JT; Fitzpatrick, CM | 1 |
| Cardo-Jalón, E; López-López, A; López-Pisón, J; Poch-Olivé, ML | 1 |
| Bishop, JR; Brown, JT; Caudle, KE; de Leon, J; Dinh, JC; Gaedigk, A; Klein, TE; Leeder, JS; McCracken, JT; Mueller, DJ; Nurmi, EL; Sangkuhl, K | 1 |
| Cao, P; Cheng, Q; Dai, L; Kang, Q; Song, Z; Sun, X; Wang, L; Zhou, X | 1 |
| Kikuchi, S; Mano, N; Morikawa, Y; Obara, T; Ooba, N; Satoh, M; Yamaguchi, H; Yoshida, M | 1 |
| Chierrito, D; de Mello, JCP; Fernandez-Llimos, F; Sanches, ACC; Tonin, FS; Villas-Boas, CB | 1 |
| Coskun, M; Gülle, ZN; Karayagmurlu, A | 1 |
| Munasur-Naidoo, AP; Truter, I | 1 |
| Adorjan, K; Erbas, B; Hantschk, I; Karch, S; Koller, G; Martin, G; Plörer, D; Pogarell, O; Winter, C | 1 |
| Barrett, N; Brammer, M; Cubillo, AI; Giampietro, V; Kowalczyk, OS; Rubia, K; Simmons, A; Smith, A | 1 |
| Lensing, MB; Opjordsmoen, S; Sandvik, L; Zeiner, P | 1 |
| Stuhec, M; Svab, V | 1 |
| Connor, DF; Faraone, SV; Jensen, PS; Miesle, LM; Rostain, A | 1 |
| Asherson, P; Hodgkins, P; McCarthy, S; Murray, M; Wilton, L; Wong, IC | 1 |
| Bushe, CJ; Savill, NC | 1 |
| Barzman, DH; Patel, BD | 1 |
| Alvarez-Gomez, MJ; Soutullo, C | 1 |
| Bloch, MH; Reichow, B; Volkmar, FR | 1 |
| Gau, SS; Huang, HC; Lin, YJ; Ni, HC; Yang, LK | 1 |
| Albayrak, O; Hebebrand, J; Hinney, A; Pauli-Pott, U; Pott, W | 1 |
| Bahali, K; Ipek, H; Uneri, OS | 1 |
| Altin, M; Dueñas, HJ; Gau, SS; Lin, CC; Méndez, L; Monk, JA; Montgomery, W; Treuer, T; Wu, S | 1 |
| Buitelaar, JK; Harfterkamp, M; Hoekstra, PJ; Minderaa, RB; van de Loo-Neus, G; van der Gaag, RJ | 1 |
| Barrett, N; Brammer, M; Cubillo, A; Giampietro, V; Rubia, K; Simmons, A; Smith, AB | 1 |
| Gau, SS; Huang, HC; Lin, YJ; Ni, HC; Shang, CY; Yang, LK | 1 |
| Anand, E; Cardo, E; Escobar, R; Fuentes, J; Montoya, A; Porsdal, V; Quail, D; Steer, C | 1 |
| Feldman, PD; Jin, L; Rohde, LA; Tanaka, Y; Upadhyaya, HP | 1 |
| Barrett, N; Brammer, M; Cubillo, A; Giampietro, V; Rubia, K; Simmons, A; Smith, A | 1 |
| Akyol Ardic, U; Basay, O; Ercan, E; Ercan, ES; Kabukcu Basay, B | 1 |
| Deberdt, W; Kutzelnigg, A; Montoya, A; Ramos-Quiroga, JA; Sobanski, E | 1 |
| Arcieri, R; Panei, P | 1 |
| Capellà, D; Castells, X; Cunill, R; Tobias, A | 1 |
| Dwoskin, LP; Jordan, CJ; Kantak, KM; Somkuwar, SS | 1 |
| Hogmark, Å; Isaksson, J; Lindblad, F; Nilsson, KW | 1 |
| Chung, SK; Gau, SS; Goto, T; Takahashi, M; Takita, Y; Wang, Y | 1 |
| Miyajima, T; Tanaka, H | 1 |
| Calleja-Pérez, B; Fernández-Jaén, A; Fernández-Perrone, AL; López-Arribas, S; Martín Fernández-Mayoralas, D; Muñoz-Jareño, N | 1 |
| Carson, RE; Ding, YS; Gallezot, JD; Huang, Y; Laruelle, M; Lin, SF; McCarthy, TJ; Nabulsi, N; Naganawa, M; Ropchan, J; Weinzimmer, D | 1 |
| Holzer, B; Lehman, R; Lopes, V | 1 |
| Baweja, R; Petrovic-Dovat, L | 1 |
| Coşkun, Ş; Gökçen, C; Kutuk, MO | 1 |
| Anderson, CS; Bloomfield, R; Caballero, B; Cardo, E; Civil, R; Coghill, D; Dittmann, RW; Higgins, N; Hodgkins, P; Lyne, A; Nagy, P | 1 |
| Berquin, P; Cardo, E; Danckaerts, M; De Bruyckere, K; Escobar, R; Fuentes, J; Montoya, A; Puvanendran, K; Quail, D | 1 |
| Dammerman, R; Erder, MH; Findling, RL; Hodgkins, P; Lu, M; Signorovitch, J; Sikirica, V; Wu, EQ; Xie, J | 1 |
| Dalsgaard, S; Nielsen, HS; Simonsen, M | 1 |
| Althaus, M; Buitelaar, JK; de Ruiter, SW; de Sonneville, LM; Donders, AR; Harfterkamp, M; Hoekstra, PJ; Rommelse, NN; van de Loo-Neus, G; van der Meer, JM | 1 |
| Buitelaar, JK; Slaats-Willemse, D; van Dongen-Boomsma, M; Vollebregt, MA | 1 |
| Arcieri, R; Bonati, M; Chiarotti, F; Germinario, EA; Masi, G; Panei, P; Vella, S; Zuddas, A | 2 |
| Castellanos, FX; Meyer, E | 1 |
| Alda, JA; Anand, E; Cardo, E; Escobar, R; Montoya, A; Quail, D | 1 |
| Reddy, DS | 1 |
| Bosch, R; Casas, M; Corominas-Roso, M; Corrales, M; Gomez-Barros, N; Nogueira, M; Palomar, G; Ramos-Quiroga, JA; Ribases, M; Sanchez-Mora, C; Valero, S | 1 |
| Allen, AJ; Gau, SS; Goto, T; Hirata, Y; Ichikawa, H; Song, DH; Takahashi, M; Takita, Y; Trzepacz, PT | 1 |
| Karabekiroğlu, K; Müjdeci, M; Oran, M; Say, GN; Yüce, M | 1 |
| Dunn, D; Hooper, SR; McBurnett, K; Shaywitz, B; Shaywitz, S; Wietecha, L; Wigal, SB; Williams, D | 1 |
| Bahali, K; Ipek, H; Orum, O; Yalcin, O | 1 |
| Swanson, JM; Volkow, ND | 1 |
| Kinugawa, Y; Kumaki, S; Nagumo, K; Nakashima, T; Yamaguchi, H | 1 |
| Couture, J; Sharma, A | 1 |
| Benegal, V; Chakraborty, V; Jose, SP; Kandavel, T; Kesavan, M; Narayanaswamy, JC; Sankar, D; Viswanath, B | 1 |
| Boeckers, TM; Dreyhaupt, J; Föhr, KJ; Henes, C; Liebau, S; Ludolph, AG; Udvardi, PT | 1 |
| Allen, AJ; Goto, T; Hirata, Y; Ichikawa, H; Takahashi, M; Takita, Y; Trzepacz, PT | 1 |
| Chen, TH; Dixon, SG; Gilbert, DL; Huddleston, DA; Sallee, FR; Sarvis, AR; Shahana, N; Welge, JA; Wu, SW | 1 |
| Allen, AJ; Greenhill, LL; Newcorn, JH; Ruff, DD; Wietecha, LA | 1 |
| Bloch, MH | 1 |
| Correll, CU; Schwartz, S | 1 |
| Madias, JE | 1 |
| Guney, E; Uneri, OS | 1 |
| Akbulat, A; Gürsöz, H; Karadağ, H; Kerman, S; Öner, Ö; Türkçapar, H; Vural, EH; Vural, M; Yilmaz, EŞ | 1 |
| Ishizaki, A; Sugama, M | 1 |
| Hodgkins, P; Roskell, NS; Setyawan, J; Zimovetz, EA | 1 |
| Evans, SW; Kuriyan, AB; Sibley, MH; Smith, BH; Waxmonsky, JG | 1 |
| Ago, Y; Fujita, K; Hasebe, S; Higashino, K; Matsuda, T; Takuma, K; Umehara, M | 1 |
| Bittsansky, M; Dobrota, D; Husarova, V; Ondrejka, I | 1 |
| Geirs, DP; Halldórsson, M; Pottegård, A; Zoëga, H | 1 |
| Altin, M; Desaiah, D; El-Shafei, A; Faries, D; Feng, Q; Gado, M; Serebryakova, E; Treuer, T; Wu, S | 1 |
| Banaschewski, T; Dittmann, RW; Schacht, A; Wehmeier, PM | 3 |
| Berg, A; Bråtane, E; Brudvik, C; Hirth, A; Odland, HH; Rosland, B | 1 |
| Cook, IA; Deldar, A; Durell, TM; Glaser, PE; Hunter, AM; Korb, AS; Leuchter, AF; McGough, JJ | 1 |
| Aman, MG; Arnold, LE; Corbett-Dick, P; Handen, B; Hollway, JA; Hyman, SL; Lecavalier, L; Levato, L; Mendoza-Burcham, M; Mruzek, DW; Pan, X; Silverman, LB; Smith, T; Tumuluru, R | 1 |
| Bonati, M; Clavenna, A | 1 |
| Araki, A; Azuma, H; Ikegami, M; Matsumoto, N; Okayama, A; Takahashi, M; Takahashi, S | 1 |
| Jotwani, VM; Perrin, AE | 1 |
| Baskin, BB; Dwoskin, LP; Harvey, RC; Jordan, CJ; Kantak, KM | 1 |
| Huemer, J; Sibitz, I | 1 |
| Davies, W; Eddy, JB; Humby, T; Ojarikre, OA; Trent, S; Wilkinson, LS | 1 |
| Barnes, SA; Grayson, B; Harte, MK; Marsh, S; Marshall, KM; Neill, JC; Tomlinson, A | 1 |
| Chen, Q; D'Onofrio, BM; Larsson, H; Lichtenstein, P; Runeson, B; Sjölander, A | 1 |
| Bédard, AC; Halperin, JM; Krone, B; Newcorn, JH; Rajwan, E; Stein, MA | 1 |
| Fleisher, C; McGough, J | 1 |
| Adler, L; Allen, AJ; Escobar, R; Goto, T; Tanaka, Y; Trzepacz, PT; Upadhyaya, HP; Williams, D | 1 |
| Bell, EA; Eiland, LS; Erramouspe, J | 1 |
| Heyd, A; Nohr, FI; Norum, J; Olsen, AI; Totth, A | 1 |
| Bangs, ME; Buchanan, AS; Kelsey, DK; Wang, S; Wietecha, LA | 1 |
| Chen, YS; Lan, CC; Liu, CC | 1 |
| Arun, P; Chavan, BS; Garg, J | 1 |
| Asherson, P; Bushe, C; Deberdt, W; Saylor, K; Tanaka, Y; Upadhyaya, H | 1 |
| Adeyi, B; Anderson, CS; Caballero, B; Cardo, E; Civil, R; Coghill, DR; Dittmann, RW; Hodgkins, P; Nagy, P | 1 |
| Aagaard, L; Hansen, EH; Warrer, P | 1 |
| Awudu, GA; Besag, FM | 1 |
| Adler, LA; Clemow, DB; Durell, TM; Williams, DW | 1 |
| Huang, TS; Lin, CC; Liu, YP; Tung, CS | 1 |
| Arcieri, R; Capuano, A; Panei, P; Rafaniello, C; Rossi, F; Scavone, C | 1 |
| Brenner, LA; Cusick, C; Gerber, D; Harrison-Felix, C; Morey, CE; Pretz, CR; Ripley, DL; Wesnes, K | 1 |
| Percinel, I; Yazici, KU | 1 |
| Bjerregaard, BK; Kortegaard, LS; Pottegård, A; Zoëga, H | 1 |
| Alegría, AA; Brinson, H; Rubia, K | 1 |
| Gandía-Benetó, R; Mulas, F; Ortiz-Sánchez, P; Roca, P; Ros-Cervera, G | 1 |
| Camporeale, A; D'Souza, D; Ghuman, J; Kratochvil, C; Lipsius, S; Tanaka, Y; Upadhyaya, H | 1 |
| Bahn, GH; Han, J; Hong, M; Kim, CJ; Lee, YJ; Moon, SJ | 1 |
| Li, R; Yang, R | 1 |
| Houmann, T; Plessen, KJ; Thomsen, PH | 1 |
| Fox, BK; Shaywitz, BA; Wietecha, LA; Williams, DW | 1 |
| Durand, M; Gow, R; Guertin, J; Holbrook, A; LeLorier, J; Levine, M | 1 |
| McLennan, JD; Vallerand, IA; Wagner, DJ | 1 |
| Bahn, GH; Goto, T; Hirata, Y; Hwang, JW; Kim, JH; Lee, JI; Lee, S; Lee, SI; Lee, YS; Park, TW; Shin, DW; Song, DH; Takahashi, M; Takita, Y; Treuer, T; Yook, KH | 1 |
| Jörgens, G; Pagsberg, AK; Resen, K | 1 |
| Iida, J; Kishimoto, N; Kishimoto, T; Matsuura, H; Nakanishi, Y; Negoro, H; Ota, T; Sawada, S; Ueda, S; Uratani, M; Yamamuro, K | 1 |
| Day, KA; Kelsey, D; Saylor, KE; Wang, S; Wietecha, LA; Wu, SH | 1 |
| Dan, H; Dan, I; Gunji, Y; Hirano, D; Kyutoku, Y; Mizutani, T; Momoi, MY; Monden, Y; Nagashima, M; Shimoizumi, H; Taniguchi, T; Tsuzuki, D; Watanabe, E; Yamagata, T | 1 |
| Banaschewski, T; Dittmann, RW; Wehmeier, PM | 1 |
| Clemow, DB | 1 |
| Camporeale, A; De Bruyckere, K; Deberdt, W; Deix, C; Porsdal, V; Tanaka, Y; Upadhyaya, H | 1 |
| Dahl, AA; Fredriksen, M; Haavik, J; Klungsøyr, O; Martinsen, EW; Peleikis, DE | 1 |
| Bloomfield, R; Hervas, A; Huss, M; Johnson, M; Lyne, A; McNicholas, F; Robertson, B; Sikirica, V; Sreckovic, S; van Stralen, J | 1 |
| Bhattacharya, A; Praharaj, SK; Sinha, VK | 1 |
| Adler, LA; Brod, M; Heinloth, AN; Lipsius, S; Tanaka, Y; Upadhyaya, H | 1 |
| Alexander, ME; Babalola, R; Hammerness, PG; Karampahtsis, C | 1 |
| Asherson, P; Berggren, L; Deberdt, W; Kutzelnigg, A; Nilsson Markhed, M; Stes, S; Svanborg, P | 1 |
| Garbe, E; Horn, J; Langner, I; Lindemann, C; Mikolajczyk, R; Schmedt, N | 1 |
| Anand, E; Buitelaar, JK; Coghill, D; Day, KA; Savill, NC; Treuer, T; Upadhyaya, HP | 1 |
| Hägglöf, B; Jacobsson, L | 1 |
| Dalhoff, KP; Jensen, LS; Pagsberg, AK | 1 |
| Locatelli, I; Štuhec, M; Švab, V | 1 |
| Locatelli, I; Munda, B; Stuhec, M; Svab, V | 1 |
| French, WP | 1 |
| Brod, M; Lane, JR; Tanaka, Y; Upadhyaya, H | 1 |
| Endo, T; Matsumoto, K; Someya, T; Sugimoto, A; Sugiyama, T; Suzuki, Y | 1 |
| Gardner, D; Gorman, DA; Hirsch, L; Pringsheim, T | 1 |
| Gao, W; Li, R; Yang, R; Zhao, Z | 1 |
| García-Gil, M; Izquierdo-María, R; Librero, J; Peiró, S | 1 |
| Ahl, J; Fijal, BA; Goto, T; Guo, Y; Li, SG; Nisenbaum, LK; Tanaka, Y; Upadhyaya, HP | 1 |
| Buitelaar, JK; Harfterkamp, M; Hoekstra, PJ; Minderaa, RB; van der Loo-Neus, G; van der Meer, D | 1 |
| Adeyi, B; Anderson, CS; Caballero, B; Cardo, E; Coghill, DR; Häge, A; Nagy, P; Sikirica, V | 1 |
| Peruzzolo, TL; Rodrigues, RB; Rohde, LA; Tramontina, S; Zeni, CP | 1 |
| Bhargava, R; Dhawan, A; Gupta, A; Mandal, P; Pattanayak, RD; Sagar, R | 1 |
| Abikoff, H; Greenhill, LL; Kollins, SH; Lazzaretto, D; McCracken, JT; McGough, JJ; Paykina, N; Riddle, MA; Vitiello, B; Wigal, S; Wigal, T; Yershova, K | 1 |
| Akdeniz, C; Bahali, K; Ergul, Y; Gunes, H; Ozturk, E; Tanidir, C; Tanidir, IC; Tuzcu, V; Uneri, OS | 1 |
| Bilgiç, A; Türkoğlu, S; Uzun, N | 1 |
| Anand, E; Haynes, V; Lopez-Romero, P | 1 |
| Ince Tasdelen, B; Karakaya, E; Oztop, DB | 1 |
| Gau, SS; Huang, LW; Lin, HY; Pan, YL; Shang, CY | 1 |
| Atar, B; Aydin, C; Kose, S; Ozbaran, B; Yuzuguldu, O | 1 |
| Dalsgaard, S; Leckman, JF; Mortensen, PB; Nielsen, HS; Simonsen, M | 1 |
| Arcieri, R; Capuano, A; Chiarotti, F; Cortese, S; Curatolo, P; Germinario, EA; Margari, L; Panei, P | 1 |
| Bishop, JR; Brown, JT | 1 |
| Allen, AJ; Escobar, R; Kryzhanovskaya, LA; Lane, JR; Lipsius, S; Tanaka, Y; Trzepacz, PT; Upadhyaya, H | 1 |
| Alatorre, C; Clemow, DB; Farr, AM; Kabul, S; Montejano, LB | 1 |
| Clemow, DB; Day, KA; Mason, O; Walker, DJ | 1 |
| Bushe, CJ; Clemow, DB | 1 |
| Perugi, G; Vannucchi, G | 1 |
| Gau, SS; Lin, HY | 1 |
| Fredriksen, M; Peleikis, DE | 1 |
| Chia, S; Chou, TL; Gau, SS; Shang, CY | 1 |
| Lee, MJ; Lee, SY; Lee, TL; Shyu, YC; Wang, LJ; Yang, CJ; Yang, KC; Yuan, SS | 1 |
| Cao, Q; Chen, M; Fang, Y; Ji, N; Su, Y; Wang, Y; Yang, L | 1 |
| Araujo, AB; Barnes, JM; Berman, BD; Clemow, DB; Donnelly, CL; Holland, DS; Mason, OW; Robb, AS; Ruff, DD; Sarkis, EH; Schuh, KJ | 1 |
| Aman, MG; Arnold, LE; Brown, NV; Buchan-Page, KA; Corbett-Dick, P; Handen, BL; Hellings, J; Hollway, JA; Hurt, EA; Hyman, SL; Lecavalier, L; Levato, L; McAuliffe-Bellin, S; Mruzek, DW; Pan, X; Rice, RR; Ryan, MM; Silverman, LB; Smith, T; Tumuluru, RV | 1 |
| Berggren, L; Bushe, C; Casillas, M; Deberdt, W; Leppämäki, S; Sobanski, E | 1 |
| Barkla, XM; McArdle, PA; Newbury-Birch, D | 1 |
| Lee, SY; Lee, TL; Shyu, YC; Wang, LJ; Yang, CJ; Yang, KC; Yuan, SS | 3 |
| Hrtanek, I; Kulhan, T; Marcincakova-Husarova, V; Nosalova, G; Ondrejka, I; Snircova, E | 1 |
| Chen, W; Huss, M; Ludolph, AG | 1 |
| Abdel-Rahman, SM; Brown, JT; Gaedigk, A; Leeder, JS; Lin, YS; van Haandel, L | 1 |
| Chen, Y; Montgomery, W; Treuer, T; Wang, F; Wang, K; Wang, WQ; Wu, SH | 1 |
| Childress, A; DeSousa, NJ; Faraone, SV; Kollins, SH; McDonnell, MA; Sallee, FR; Wigal, SB | 1 |
| Cao, Q; Stein, MA; Su, Y; Wang, Y; Yang, L | 1 |
| Aman, MG; Arnold, LE; Handen, BL; Hollway, JA; Lecavalier, L; Mendoza-Burcham, MI; Page, K; Sayre, P; Silverman, L; Smith, T; Tumuluru, R | 1 |
| Merrill, RM; Palmer, CA; Thygerson, SM | 1 |
| Li, GF; Markowitz, JS; Yu, G | 1 |
| Aagaard, L; Dalsgaard, S; Hansen, EH; Rasmussen, HB; Thomsen, PH; Wallach Kildemoes, H; Warrer, P | 1 |
| Gau, SS; Huang, HC; Hwang Gu, SL; Lin, HY; Lin, YJ; Ni, HC; Yang, LK | 1 |
| Buchanan, AS; Clemow, DB; Findling, RL; Sarkis, EH; Wietecha, LA; Young, JL | 1 |
| Bonati, M; Cartabia, M; Didoni, A; Fortinguerra, F; Mondini, M; Reale, L; Zanetti, M | 1 |
| Berggren, L; Bushe, C; Day, K; Haynes, V; Karlsdotter, K; Pitcher, A; Reed, V; Televantou, F | 1 |
| Dinh, JC; Gaedigk, A; Leeder, JS; Pearce, RE; Van Haandel, L | 1 |
| Berggren, L; Bushe, C; Coghill, D; De Bruyckere, K; Leppämäki, S; Sobanski, E | 1 |
| Şanlı, I; Semerci, B; Taskıran, S; Tufan, E | 1 |
| Chabot, R; Chiarenza, GA; Chiarenza, MP; Isenhart, R; Montaldi, L; Prichep, LS; Torto, MG | 1 |
| Al-Mutairi, H; Al-Tajali, A; Naguy, A | 1 |
| Blumenschein, K; Moga, DC; Sohn, M; Talbert, J | 1 |
| Chan, E; Fogler, JM; Hammerness, PG | 1 |
| Bartel, C; Berggren, L; Bushe, C; De Bruyckere, K; Dittmann, RW; Kan, CC | 1 |
| Kilincaslan, A; Mukaddes, NM; Mutluer, TD; Pasabeyoglu, B; Tutkunkardas, MD | 1 |
| Jillani, S; Kamath, J; Patel, P; Trestman, R | 1 |
| Bussing, R; Gerhard, T; Kubilis, P; Linden, S; Segal, R; Shuster, JJ; Winterstein, AG | 1 |
| Fluegge, K | 1 |
| Anand, E; Buitelaar, JK; Coghill, DR; Day, KA; Kryzhanovskaya, LA; Reed, VA; Savill, NC; Treuer, T; Upadhyaya, HP | 1 |
| Akın, E; Demirkaya, M; Demirkaya, SK; Yusufoğlu, C | 1 |
| Iida, J; Kishimoto, N; Kishimoto, T; Matsuura, H; Nakanishi, Y; Okazaki, K; Ota, T; Tanaka, S; Uratani, M; Yamamuro, K | 1 |
| Hooper, SR; Kronenberger, WG; McBurnett, K; Shaywitz, B; Shaywitz, S; Wietecha, L; Wigal, S; Williams, D | 1 |
| Chou, MC; Chou, WJ; Huang, TS; Lee, MJ; Lee, SY; Lee, TL; Shyu, YC; Wang, LJ; Yang, CJ; Yang, KC; Yuan, SS | 1 |
| Demirci, E; Erdogan, A | 1 |
| Clemow, DB; Nyhuis, AW; Robinson, RL | 1 |
| Bahn, GH; Bhang, SY; Choi, HY; Chung, US; Hong, M; Hwang, JW; Joung, YS; Kim, B; Kwak, YS; Lee, S; Lee, YJ; Oh, IH; Sohn, SH; Yang, J | 1 |
| Bozkurt, H; Şahin, S | 1 |
| Ohtomo, Y | 1 |
| Bussing, R; Kubilis, P; Liu, X; Winterstein, AG | 1 |
| Beard, SM; Bischof, M; Hodgkins, P; Mauskopf, JA; Setyawan, J; Zimovetz, EA | 1 |
| Castellanos, FX; Gau, SS; Lin, HY; Shang, CY; Tseng, WY; Yan, CG | 1 |
| Bahmanyar, S; Furu, K; Karlstad, Ø; Kieler, H; Martikainen, JE; Pottegård, A; Zoëga, H | 2 |
| Chandra, A; Erder, MH; Shafrin, J; Shrestha, A; Sikirica, V | 1 |
| Aman, MG; Arnold, LE; Brown, NV; Buchan-Page, KA; Handen, BL; Hellings, J; Hollway, J; Hyman, SL; Lecavalier, L; Pan, X; Rice, RR; Silverman, LB; Smith, T; Tumuluru, R | 1 |
| Compagno, E; Di Cesare Mannelli, L; Ghelardini, C; Grassi, G; Micheli, L; Pallanti, S; Righi, L | 1 |
| Gao, J; He, S; Li, Y; Wang, Q; Zhang, Y | 1 |
| Kapellen, TM; Kiess, W; Kostev, K; Reimann, R | 1 |
| Coughtrie, A; Davies, M; Layton, D; Shakir, SA | 1 |
| Chen, YJ; Curtice, TG; Greven, P; Makin, C; Sikirica, V | 1 |
| Jain, R; Katic, A | 1 |
| Barkley, R; Clemow, D; McBurnett, K; Villodas, M; Wietecha, L; Williams, D | 1 |
| Csemy, L; Dezortova, M; Hajek, M; Kohoutova, M; Kollarova, P; Paclt, I; Pribilova, N | 1 |
| Han, DH; Lee, YS; Park, JH; Sohn, JH | 1 |
| Shin, JY; Song, I | 1 |
| Benegal, V; Chowdappa, SV; Muralidharan, K; Ravishankar, V | 1 |
| Egawa, J; Hayashi, T; Inoue, Y; Orime, N; Someya, T; Sugai, T; Sugimoto, A; Suzuki, Y; Tajiri, M | 1 |
| Anderson, RH; Mattingly, GW | 1 |
| Fang, Q; Liu, Q; Qin, L; Zhang, H | 1 |
| Escobar, R; Tanaka, Y; Upadhyaya, HP | 1 |
| Ayyagari, R; Joseph, A; Mauskopf, JA; Zimovetz, EA | 1 |
| Gayleard, JL; Mychailyszyn, MP | 1 |
| Alonzo, J; Aparasu, RR; Chan, W; Chen, H; Medhekar, R; Ochoa-Perez, M; Patel, A; Sherer, JT | 1 |
| Bakker, MJ; Banaschewski, T; Buitelaar, JK; Carucci, S; Coghill, D; Danckaerts, M; Dittmann, RW; Hennissen, L; Hollis, C; Kovshoff, H; McCarthy, S; Nagy, P; Rosenthal, E; Sonuga-Barke, E; Wong, IC; Zuddas, A | 1 |
| Vitiello, B | 2 |
| Findling, RL | 1 |
| Wilens, TE | 3 |
| Darling, J; McGaughy, J; Newman, LA | 1 |
| Banaschewski, T; Döpfner, M; Rothenberger, A; Steinhausen, H- | 1 |
| Asherson, P; Banaschewski, T; Buitelaar, J; Coghill, D; Danckaerts, M; Döpfner, M; Faraone, SV; Rothenberger, A; Santosh, P; Sergeant, J; Sonuga-Barke, EJ; Steinhausen, HC; Taylor, E; Zuddas, A | 2 |
| Ayyash, HF; Banerjee, S | 1 |
| Anisimova, TI; Chutko, LS; Iakovenko, EA; Lapshina, OV; Nikishena, IS; Surushkina, SIu | 1 |
| Raj, YP | 1 |
| Holdridge, KC; Hornbuckle, K; Johannes, CB; McAfee, AT; Walker, AM | 1 |
| Kendall, T; Perez, A; Taylor, C; Taylor, E | 1 |
| Kay, GG; Michaels, MA; Pakull, B | 1 |
| Suvorinova, NIu; Zavadenko, NN | 1 |
| Campbell, TS; Harris, DK; Párraga, HC; Párraga, KL | 1 |
| Alhatem, FJ; Decker, DH | 1 |
| Cranswick, NE; Paxton, GA | 1 |
| Geffken, GR; Goldstein, RB; Goodman, WK; Lehmkuhl, H; Murphy, TK; Storch, EA | 1 |
| Ershova, A | 1 |
| Stafford, N | 1 |
| Chutko, LS; Surushkina, SIu | 1 |
| Aĭtbekov, KA; Anisimova, TI; Chutko, LS; Iakovenko, IS; Iur'eva, RG; Nikishena, iS; Surushkina, SIu | 1 |
| Adler, LA; Brown, TE; Holdnack, J; Kelsey, D; Saylor, K; Schuh, K; Spencer, T; Trzepacz, PT; Williams, DW | 1 |
| Levy, F | 1 |
| Gustafsson, PA; Hägglöf, B; Kadesjö, B; Poole, L; Svanborg, P; Thernlund, G | 1 |
| Fegert, J; Kratochvil, CJ; Vaughan, B | 1 |
| Daughton, JM; Kratochvil, CJ | 1 |
| Asherson, P; Coghill, D; de Soysa, R; Hollis, C; McCarthy, S; Murray, M; Potts, L; Sayal, K; Taylor, E; Williams, T; Wong, IC | 1 |
| Chutko, LS; Iakovenko, EA; Kropotov, IuD; Nikishina, IS; Surushina, SIu | 1 |
| Izaguerri-Gracia, AC; Valdizán, JR | 1 |
| Aston-Jones, G; Gold, JI | 1 |
| Buitelaar, JK; Feldman, PD; Ning, Y; Wilens, TE; Zhang, S | 1 |
| Newcorn, JH; Sumner, CR; Sutton, VK; Weiss, MD | 1 |
| Kirchheiner, J; Rodriguez-Antona, C | 1 |
| Faber, A; Janknegt, R; Kalverdijk, LJ; Rodrigues Pereira, R | 1 |
| Aman, MG; Fort, C; Gelenberg, A; Ghuman, HS; Ghuman, JK; Reichenbacher, T; Rice, S; Wright, R | 1 |
| Chen, CY; Gerhard, T; Winterstein, AG | 1 |
| Myrén, KJ; Nylén, A; Schacht, A; Svanborg, P; Thernlund, G | 1 |
| Belousova, MB; Morozova, EA | 1 |
| Arellano, J; Dilla, T; Hong, J | 1 |
| Biederman, J; Doyle, R; Georgiopoulos, A; Hammerness, P; Joshi, G; Kotarski, M; Zeitlin, S | 1 |
| Allen, AJ; Boni, C; Close, SL; Downing, AM; Gorwood, P; Hamon, M; Peters, SL; Prokop, AM; Purper-Ouakil, D; Ramoz, N | 1 |
| Einecke, U | 1 |
| Allen, AJ; Block, SL; Coury, D; Kelsey, D; Lewis, D; Quintana, H; Schuh, K; Sumner, C; Sutton, V | 1 |
| Garnock-Jones, KP; Keating, GM | 2 |
| Hadijikoumi, I; Keen, D | 2 |
| Areskoug, B; Cederlund, M; Gillberg, C; Johnson, M; Råstam, M | 1 |
| Hilt, R; Kwan, AC; Lee, T; McClellan, J; Thompson, JN; Trupin, E; Varley, CK | 1 |
| Gustafsson, PA; Hägglöf, B; Kadesjö, B; Schacht, A; Svanborg, P; Thernlund, G | 1 |
| Emmerson, NA; Henker, B; Ishikawa, SS; Johnston, JA; Swindle, R; Whalen, CK | 1 |
| Dopheide, JA; Pliszka, SR | 1 |
| Artigas, J; Cardo, E; Escobar, R; Fuentes, J; Hervas, A; Montoya, A; Polavieja, P | 1 |
| Cheng, AT; Chou, WJ; Tang, CS | 1 |
| Akhondzadeh, S; Ghanizadeh, A | 1 |
| Faber, A; Meijer, WM; Tobi, H; van den Ban, E | 1 |
| Bardenstein, LM; Jarkova, NB; Kozlova, IA; Martenyi, F; Maslova, OI; Neznanov, NG; Petrukhin, AS; Soldatenkova, VO; Sukchotina, NK; Yarosh, AA; Zavadenko, NN; Zykov, VP | 1 |
| Arellano, J; Libretto, SE; Prasad, S; Steer, C | 1 |
| Jensen, PS | 1 |
| Dopheide, JA | 1 |
| Bloch, MH; Landeros-Weisenberger, A; Leckman, JF; Panza, KE | 1 |
| Besana, D; Curatolo, P; Dell'Agnello, G; Masi, G; Rossi, A; Zuddas, A | 1 |
| Barry, RJ; Bruggemann, JM; Clarke, AR; Hajos, M; McCarthy, R; Selikowitz, M | 1 |
| Allen, AJ; Hayashi, T; Ichikawa, H; Kambayashi, Y; Koeda, T; Oki, J; Saito, K; Takahashi, M; Takeshita, K; Takita, Y; Yamazaki, K | 1 |
| Adler, L; Durell, T; Paczkowski, M; Schuh, K; Wilens, T | 1 |
| Besana, D; Bravaccio, C; Calamoneri, F; Curatolo, P; Dell'Agnello, G; Escobar, R; Mancini, F; Maschietto, D; Masi, G; Poole, L; Rossi, A; Zuddas, A | 1 |
| Gorbunova, ZKh; Nikiforova, EIu; Ponomarenko, EI; Vakula, IN; Vasianina, IuSh | 1 |
| Fegert, JM; Kölch, M; Ludolph, AG; Plener, PL; Schulze, UM; Spröber, N | 1 |
| Cheetham, SC; Heal, DJ; Smith, SL | 1 |
| Alda, JA; Artigas, J; Cardo, E; Escobar, R; García-Polavieja, MJ; Gastaminza, X; Gilaberte, I; Hervas, A; Mardomingo, MJ; Montoya, A | 1 |
| Adler, LA; Brown, TE; Holdnack, JA; Kelsey, DK; Saylor, KE; Schuh, KJ; Spencer, TJ; Trzepacz, PT | 1 |
| Niederhofer, H | 3 |
| Cranswick, N; McCarthy, S; Potts, L; Taylor, E; Wong, IC | 1 |
| Buitelaar, J; Medori, R | 1 |
| Gau, SS; Shang, CY | 2 |
| Banaschewski, T; Buitelaar, J; Coghill, DR; Sergeant, JA; Sonuga-Barke, E; Taylor, E; Zuddas, A | 1 |
| Pliszka, SR | 3 |
| Tryon, WW | 1 |
| Allen, AJ; D'souza, DN; Emslie, GJ; Kratochvil, C; Newcorn, JH; Schuh, LM; Sutton, VK; Wilens, T; Zhang, S | 1 |
| Brodziak, K; Doyle, RL; Georgiopoulous, A; Hammerness, P; Martelon, M; Schillinger, M; Utzinger, L; Wilens, TE | 1 |
| Biederman, J; Brodziak, K; Doyle, RL; Georgiopoulos, A; Hammerness, P; Martelon, M; Schillinger, M; Utzinger, L; Wilens, TE | 1 |
| Chang, K; Howe, M; Nayar, D; Rana, M | 1 |
| Asherson, P; Bilbow, A; Clifford, S; Coghill, D; DeSoysa, R; Hollis, C; McCarthy, S; Murray, M; Planner, C; Potts, L; Sayal, K; Taylor, E; Wong, IC | 1 |
| Adler, L; Brown, TE; Holdnack, J; Kelsey, D; Padival, AK; Saylor, K; Schuh, K; Spencer, T; Trzepacz, PT; Williams, DW | 1 |
| Kratochvil, CJ; May, DE | 1 |
| Al-Hakim, M; Allen, AJ; Amin, A; de Jong, CG; Knijff, S; Oosterlaan, J; Raymaekers, R; Rodriques-Pereira, R; Roeyers, H; Sergeant, JA; Smit, LM; Temmink, AH; ter Schuren, L; Van De Voorde, S; van Welsen, I; Vandenberghe, D; Verhelst, H; Vlasveld, L | 1 |
| Davis, L; Dickson, R; Lee, B; Maziade, M; Rogers, A; Rouleau, N | 1 |
| Greenbaum, M; Herbert, M; Melmed, RD; Schuh, K; Wietecha, LA; Williams, DW | 1 |
| Ball, SG; Bangs, M; Donnelly, C; Jin, L; Spencer, TJ; Trzepacz, P; Witte, MM; Zhang, S | 1 |
| Faraone, SV; Glatt, SJ | 1 |
| Meyer, JS | 1 |
| Biederman, J; Chu, N; Doyle, R; Gebhard, N; Hammerness, P; Petty, C; Surman, C; Williams, C | 1 |
| Froehlich, TE; McGough, JJ; Stein, MA | 1 |
| Aitbekov, KA; Anisimova, TI; Chutko, LS; Nikishena, IS; Surushkina, SY; Yakovenko, IS; Yur'eva, RG | 1 |
| Arra, C; Carboni, E; Carnevale, UA; Ibba, M; Melisi, D; Ruocco, LA; Sadile, AG; Schirru, C; Treno, C | 1 |
| Egberts, T; Heerdink, R; Souverein, P; Swaab, H; van den Ban, E; van Engeland, H | 1 |
| Swann, AC | 1 |
| Christensen, L; Harley, C; Hodgkins, P; Sasané, R; Tetali, S | 1 |
| Crystal, S; Gerhard, T; Huang, C; Olfson, M; Saidi, A; Winterstein, AG | 1 |
| Becker, K; D'Souza, DN; Dittmann, RW; Hazell, P; Long, A; Nikkanen, EA; Ponsler, G; Tabas, L; Tanaka, Y; Trzepacz, PT; Witcher, J | 1 |
| Dittmann, RW; Lehmann, M; Lehmkuhl, G; Schacht, A; Wehmeier, PM | 1 |
| Genro, JP; Hutz, MH; Kieling, C; Rohde, LA | 1 |
| Arns, M; Hegerl, U; Olbrich, S; Sander, C | 1 |
| Hu, TW; Lang, HC; Scheffler, RM | 1 |
| Arai, Y; Hiraga, H; Murai, S; Nakagawasai, O; Niijima, F; Saito, H; Tadano, T; Tan-No, K; Watanabe, H | 1 |
| Adolph, O; Boeckers, TM; Fegert, JM; Föhr, KJ; Henes, C; Ludolph, AG; Schaz, U; Udvardi, PT; Weigt, HU | 1 |
| Mikulich-Gilbertson, SK; Riggs, PD; Salomonsen-Sautel, S; Thurstone, C | 1 |
| Bigarella, MP; Hutz, MH; Polanczyk, G; Rohde, LA | 1 |
| Escobar, R; Schacht, A; Wagner, T; Wehmeier, PM | 2 |
| Buitelaar, J; Casas, M; Konofal, E; Rösler, M | 1 |
| Block, SL; Donnelly, CL; Dunn, DW; Ruberg, SJ; Saylor, KE; Williams, D | 1 |
| Alda, JÁ; Artigas, J; Cardo, E; Escobar, R; García, M; García-Polavieja, MJ; Gastaminza, X; Gilaberte, I; Lachno, DR; Montoya, A | 1 |
| Kjar, D; Rajab, MH; Ripperger-Suhler, J; Scott, NG | 1 |
| Chen, VC; Chou, JY; Robson, D; Yu, SH | 1 |
| Bilker, WB; Cziraky, MJ; Daniel, GW; Guevara, J; Hennessy, S; Kimmel, SE; Schelleman, H; Strom, BL | 1 |
| Roman, MW | 1 |
| Greenbaum, M; Saylor, K; Schuh, KJ; Wietecha, L; Williams, DW | 1 |
| Draganac-Cardona, L; Pelham, WE; Rotella, B; Ryan, L; Waschbusch, DA; Waxmonsky, JG | 1 |
| Charnsil, C | 1 |
| Caffino, L; Carboni, E; Cattaneo, A; Fumagalli, F; Gennarelli, M; Ibba, M; Racagni, G; Riva, MA | 1 |
| Cobbaert, CM; Koeken, A; Temmink, AH; ter Laak, MA; van 't Veer, NE; van Hattum, PR | 1 |
| Besag, FM; Stiefel, G | 1 |
| Dickson, R; Granger, RE; Hazell, PL; Kohn, MR; Walton, RJ; Wyk, GW | 1 |
| Arnsten, AF; Gamo, NJ; Wang, M | 1 |
| Haynes, VS; Newcorn, JH; Sumner, CR; Teicher, MH | 1 |
| Spencer, TJ; Wilens, TE | 1 |
| Hodgkins, P; Meijer, W; Sasané, R | 1 |
| Katz, JL; Koffarnus, MN | 1 |
| Calleja Pérez, B; Campos Díaz, Mdel R; Fernández-Jaén, A; Fernández-Mayoralas, DM; Muñoz Jareño, N | 1 |
| Findling, RL; Rowles, BM | 1 |
| Banaschewski, T; Buitelaar, J; Coghill, D; Danckaerts, M; Dittmann, RW; Döpfner, M; Graham, J; Hamilton, R; Hollis, C; Holtmann, M; Hulpke-Wette, M; Lecendreux, M; Rosenthal, E; Rothenberger, A; Santosh, P; Sergeant, J; Simonoff, E; Sonuga-Barke, E; Steinhausen, HC; Taylor, E; Wong, IC; Zuddas, A | 1 |
| Bizot, JC; David, S; Trovero, F | 1 |
| Bullinger, M; Dittmann, RW; Helsberg, K; Lehmann, M; Ravens-Sieberer, U; Schacht, A; Schneider-Fresenius, C; Wehmeier, PM | 1 |
| Gonzalez-Heydrich, J; Lobel, R; Rao, S; Tilley, C; Torres, A; Whitney, J | 1 |
| Abi-Saab, WM; Apostol, G; Bensman, L; Childress, A; Garimella, TS; Gault, LM; Hall, CM; Kratochvil, CJ; Olson, E; Robieson, WZ; Saltarelli, MD; Wilens, TE | 1 |
| Agaoglu, B; Karakaya, I; Memik, NC; Sismanlar, SG; Yildiz, O | 1 |
| Curatolo, P; D'Agati, E; Moavero, R | 1 |
| Chae, S; Patel, A; Steinberg-Epstein, R; Wigal, SB | 1 |
| Avestimehr, S; Dib, H; Griffith, H; Seifi, A | 1 |
| Egberts, TC; Heerdink, ER; Souverein, PC; Swaab, H; van den Ban, E; van Engeland, H | 1 |
| Goto, T; Ichikawa, H; Matsumoto, H; Saito, K; Takahashi, M; Takita, Y; Tanaka, Y | 1 |
| Kaplan, G; Newcorn, JH | 1 |
| Akinnusi, O; Pelham, WE; Waschbusch, DA; Waxmonsky, JG | 1 |
| Granger, RE; Hazell, PL; Kohn, MR; van Wyk, GW; Walton, RJ | 1 |
| Arnsten, AF; Pliszka, SR | 1 |
| Kratochvil, CJ; March, JS; Vaughan, BS | 1 |
| Acosta, MT; Castellanos, FX | 2 |
| Gjevik, E; Weidle, B; Zeiner, P | 1 |
| Clark, CR; Clarke, SD; Cranswick, N; Efron, D; Hermens, DF; Kohn, MR; Lamb, C; Tsang, TW; Williams, LM | 1 |
| Chrisman, AK; Daughton, JM; Faircloth, MA; Fried, J; Greenhill, LL; Itchon-Ramos, NB; Kollins, SH; Kotler, LA; Kratochvil, CJ; Lubberstedt, BD; Maayan, LA; March, JS; Murray, DW; Stoner, JA; Vaughan, BS | 1 |
| Bastiaens, L | 2 |
| Halls, C; Kondo, D; Marchant, BK; Reimherr, FW; Robison, RJ; Soni, P; Strong, RE; Williams, ED | 1 |
| Newcorn, JH | 2 |
| Niederkirchner, K; Rettig, K; Schäuble, B; Slawik, L; Wermelskirchen, D | 1 |
| Banaschewski, T; Holtmann, M; Poustka, L | 1 |
| Dittmann, RW; Helsberg, K; Lehmann, M; Lehmkuhl, G; Schacht, A; Schneider-Fresenius, C; Wehmeier, PM | 1 |
| Arnsten, AF | 1 |
| Hodgkins, P; Meijer, WM; Sasané, R | 1 |
| Bonati, M; Didoni, A; Panei, P; Sequi, M | 1 |
| Lv, XZ; Shu, Z; Wu, SS; Zhan, SY; Zhang, YW | 1 |
| Bidwell, LC; Kollins, SH; McClernon, FJ | 1 |
| Franke, AG; Huss, M; Konrad, A; Lieb, K | 1 |
| Ahn, HS; Cheong, JH; dela Peña, IC; Park, IH; Ryu, JH; Shin, CY | 1 |
| Cocuzza, M; Mannino, V; Mazzone, L; Reale, L; Vitiello, B | 1 |
| Bilezikci, B; Calik, M; Erdogan, A; Haberal, M; Karaman, MG; Ozcay, F; Piskin, E; Tekin, I | 1 |
| Huang, YS; Tsai, MH | 1 |
| Gabriel, A; Violato, C | 1 |
| Aypar, E; Gokcen, C; Odabas, D; Sert, A | 1 |
| Canagaratnam, M; Santosh, PJ; Sattar, S | 1 |
| Barner, JC; Khoza, S; Oladapo, A | 1 |
| Bangs, ME; Desaiah, D; Spencer, TJ; Trzepacz, PT; Witte, MM; Zhang, S | 1 |
| Cao, Q; Chan, RC; Li, H; Shuai, L; Wang, Y; Yang, L | 1 |
| Aznar, G; Farrè, M; Garcia-Algar, O; Marchei, E; Mortali, C; Pacifici, R; Papaseit, E; Pichini, S | 1 |
| Adler, LA; D'Souza, DN; Gutkin, SW; Tanaka, Y; Upadhyaya, HP; Wilens, TE; Xiao, F | 1 |
| Banaschewski, T; Dittmann, RW; Otto, WR; Schacht, A; Wehmeier, PM; Wolff, C | 1 |
| de Silva, V; Hanwella, R; Senanayake, M | 1 |
| Cho, SC; Harrison, G; Huang, YS; Jin, X; Mendez, L; Singh, P | 1 |
| Chen, H; Chen, YH; Hong, YL; Lin, GX; Lin, XX; Liu, YY; Wei, LX | 1 |
| Alm, B; Baehr, C; Dittmann, RW; Sabljic, D; Skopp, G; Sobanski, E; Strohbeck-Kuehner, P | 1 |
| Cavanna, AE; Rickards, H; Worrall, R | 1 |
| Handen, BL; Taylor, J; Tumuluru, R | 1 |
| Nielsen, NP; Wiig, EH | 1 |
| Baack, J; Erbe, K; Heinrich, H; Kratz, O; Malcherek, S; Moll, GH; Studer, P | 1 |
| Howland, RH | 1 |
| Dickson, R; Escobar, R; Hervas, A; Schacht, A; Wehmeier, PM | 1 |
| Adler, LA; D'Souza, DN; Dittmann, RW; Durell, TM; Schuh, L; Wilens, T; Zhang, S | 1 |
| Li, R; Mao, S; Yang, R; Zhao, Z | 1 |
| Adler, LA; Chen, C; Feltner, DE; Smith, MD; Sutherland, SM | 1 |
| Dockstader, C; Duerden, EG; Tannock, R | 1 |
| Karila, L | 1 |
| Calleja-Pérez, B; Campos Díaz, Mdel R; Fernández-Jaén, A; Fernández-Mayoralas, DM; López-Arribas, S; Muñoz-Jareño, N | 1 |
| Bosch, R; Casas, M; Chalita, PJ; Palomar, G; Prats, L; Ramos-Quiroga, JA; Vidal, R | 1 |
| Schell, M; Stern, LA | 1 |
| Hergüner, A; Hergüner, S | 1 |
| Bowen, KA; Castillo, LV; Oganov, AM; Robison, LM; Schmidt, JM; Sclar, DA | 1 |
| Chung, K; Duong, S; Wigal, SB | 1 |
| Drago, F; Mazzola, C; Micale, V; Salomone, S; Tamburella, A | 1 |
| Al-Alami, AA | 1 |
| Bally-Cuif, L; Chaminade, M; Coolen, M; Lange, M; Lesch, KP; Merker, S; Norton, W; Proft, F; Schmitt, A; Vernier, P | 1 |
| Cooper, K; Daly, EJ; Gassmann-Mayer, C; Pandina, GJ; Weisler, RH | 1 |
| Ghanizadeh, A | 1 |
| Erder, MH; Hodgkins, PS; Lu, M; Signorovitch, J; Sikirica, V; Wu, EQ; Xie, J | 1 |
| Farré, M; Garcia-Algar, O; Marchei, E; Pacifici, R; Papaseit, E; Pichini, S | 1 |
| Beauchemin, C; Hodgkins, PS; Lachaine, J; Sasane, R | 1 |
| Asherson, P; Hodgkins, P; McCarthy, S; Murray, ML; Wilton, L; Wong, IC | 2 |
| Hlavaty, L; Stein, MA; Weiss, M | 1 |
| Buitelaar, JK; Escobar, R; Harfterkamp, M; Hoekstra, PJ; Minderaa, RB; Pamulapati, S; Schacht, A; van de Loo-Neus, G; van der Gaag, RJ | 1 |
| Bender, S; Buse, J; Ehrlich, S; Münchau, A; Roessner, V; Schoenefeld, K | 1 |
| Almarsdóttir, AB; Baldursson, G; Halldórsson, M; Hernández-Diaz, S; Huybrechts, KF; Jónsdóttir, S; Ólafsson, Ö; Rothman, KJ; Valdimarsdóttir, UA; Zoëga, H | 1 |
| Gluud, C; Simonsen, E; Storebø, OJ; Winkel, P | 1 |
| Inoko, K; Kodaira, K; Osawa, M | 1 |
| Ahn, JH; Cho, JH; Kim, IH; Kim, SK; Kwon, SH; Lee, CH; Lee, TH; Park, JH; Park, OK; Won, MH; Yan, BC | 1 |
| Banaschewski, T; Garbe, E; Kraut, AA; Langner, I; Lindemann, C; Mikolajczyk, RT; Petermann, F; Petermann, U; Schad-Hansjosten, T; Schreyer-Mehlhop, I | 1 |
| Faraone, SV; Fredriksen, M; Haavik, J; Halmøy, A | 1 |
| Banaschewski, T; Dittmann, RW; Lehmann, M; Lehmkuhl, G; Schacht, A; Schneider-Fresenius, C; Ulberstad, F; Wehmeier, PM | 1 |
| Heinrich, J; Heinrich-Weltzien, R; Heitmueller, D; Herbarth, O; Hickel, R; Kohlboeck, G; Koletzko, S; Kühnisch, J; Neumann, C; Tiesler, C | 1 |
| Banaschewski, T; Dittmann, RW; Kipp, L; Schacht, A; Wehmeier, PM | 1 |
| Bédard, AC; Clerkin, SM; Fan, J; Halperin, JM; Ivanov, I; Newcorn, JH; Schulz, KP; Tang, CY | 1 |
| Anderson, A; Cantilena, L; Duncan, CC; Elkashef, A; Kahn, R; Li, SH | 1 |
| Bilbao, A; Farré, M; Garcia-Algar, O; Marchei, E; Pacifici, R; Papaseit, E; Pichini, S | 1 |
| Du, DT; Goldsmith, J; Hammad, TA; Nardinelli, C; Zhou, EH | 1 |
| Barrett, N; Brammer, MJ; Cubillo, A; Giampietro, V; Rubia, K; Simmons, A; Smith, AB | 1 |
| Alm, B; Dittmann, RW; Sabljic, D; Skopp, G; Sobanski, E; Strohbeck-Kühner, P; Wehmeier, PM | 1 |
| Bucci, DJ; Eggleston, RL; Robinson, AM | 1 |
| Corbisiero, S; Retz, W; Retz-Junginger, P; Rösler, M; Stieglitz, RD | 1 |
| Aggarwal, A; Jahan, S; Kulkarni, G | 1 |
| Bernauer, MJ; Farr, AM; Haynes, VS; Kelsey, D; Molife, C | 1 |
| Chen, KS; Erder, MH; Hodgkins, P; Lu, M; Signorovitch, JE; Sikirica, V; Wu, EQ; Xie, J | 1 |
| Biederman, J; Bush, G; Holmes, J; Makris, N; Mick, E; Seidman, LJ; Shin, LM; Surman, C | 1 |
| Pérez de los Cobos, J; Pérez, V; Siñol, N; Trujols, J | 1 |
| Gangadhar, BN; Rao, MG; Raveendranathan, D; Varambally, S; Venkatasubramanian, G | 1 |
| Bravaccio, C; Capuano, A; Granato, R; Grimaldi, G; Panei, P; Parretta, E; Pascotto, A; Rafaniello, C; Rinaldi, B; Rossi, F; Ruggiero, S; Sportiello, L | 1 |
| Cassidy, E; Dommett, EJ; Turner, M; Wilding, E | 1 |
| Faraone, SV; Li, H; Liu, L; Qian, Q; Wang, Y; Yang, L | 1 |
| Adler, LA; Deldar, A; Durell, TM; Fox, BK; Glaser, PE; McGough, JJ; Pigott, TA; Rubin, RL; Sarkis, EH; Williams, DW | 1 |
| Acharya, N; Bangs, ME; Hornbuckle, K; Jones, M; Landon, J; McAfee, AT; Wong, J | 1 |
| Banaschewski, T; Buitelaar, J; Coghill, D; Cortese, S; Danckaerts, M; Dittmann, RW; Graham, J; Holtmann, M; Sergeant, J; Taylor, E | 1 |
| Allen, AJ; Goto, T; Heinloth, AN; Keith Conners, C; Sandra Kooij, JJ; Tanaka, Y; Upadhyaya, HP; Williams, D | 1 |
| Alexander, GC; Conti, RM; Dorsey, ER; Dusetzina, SB; Garfield, CF; Higashi, AS; Huskamp, HA; Kornfield, R; Watson, S | 1 |
| Dwoskin, LP; Harvey, RC; Jordan, CJ; Kantak, KM; Moody, KR; Tassin, DH | 1 |
| Allen, AJ; Bickel, WK; Bymaster, FP; Calligaro, DO; Clarke, DO; Desaiah, D; Durell, TM; Emmerson, PJ; Kallman, MJ; Nisenbaum, ES; Schuh, KJ; Schuh, LM; Trzepacz, PT; Upadhyaya, HP | 1 |
| Biederman, J; Casat, C; Dittmann, R; Heiligenstein, JH; Kratochvil, CJ; Michelson, D; Milton, D; Newcorn, JH; Spencer, TJ; Wernicke, J | 1 |
| Holcomb, HH; Schweitzer, JB | 1 |
| Allen, AJ; Busner, J; Casat, C; Dunn, D; Harder, D; Kelsey, D; Kratochvil, C; Michelson, D; Newcorn, J; Sallee, FR; Sangal, RB; Saylor, K; Trapp, NJ; Wernicke, J; West, S | 1 |
| Bymaster, FP; Gehlert, DR; Heiligenstein, JH; Hemrick-Luecke, SK; Katner, JS; Morin, SM; Nelson, DL; Perry, KW; Threlkeld, PG | 1 |
| Biederman, J; Dittmann, R; Emslie, GJ; Faries, DE; Galil, N; Heiligenstein, JH; Kratochvil, CJ; Laws, HF; Schuh, KJ | 1 |
| Biederman, J; Conners, CK; Faries, DE; Heiligenstein, JH; Kratochvil, CJ; Potter, WZ; Spencer, T | 1 |
| Adler, L; Allen, AJ; Dietrich, A; Kelsey, D; Michelson, D; Milton, D; Reimherr, FW; Spencer, T; Wernicke, J; West, SA | 1 |
| Biederman, J; Faraone, SV; Spencer, TJ; Wilens, TE | 2 |
| Allen, AJ; Michelson, D | 1 |
| Kratochvil, CJ; Wernicke, JF | 1 |
| Chalon, SA; Desager, JP; Desante, KA; Frye, RF; Golnez, JL; Horsmans, Y; Long, AJ; Sauer, JM; Smith, BP; Thomasson, HR; Witcher, J | 1 |
| Carrey, N; Khan, SC; Kusumakar, V; MacMaster, FP; Sparkes, SJ | 1 |
| Stahl, SM | 1 |
| Daley, KC | 1 |
| Perry, CM; Simpson, D | 1 |
| Biederman, J; Heilgenstein, J; Long, A; Sauer, JM; Smith, B; Spencer, T; Wilens, T; Witcher, JW | 1 |
| Burke, WJ; Harrington, MJ; Kratochvil, CJ; Vaughan, BS | 1 |
| Brown, J; Faries, D; Gao, H; Girod, D; Heiligenstein, J; Kelsey, D; Lipetz, R; Michelson, D; Quintana, H; Wernicke, JF | 1 |
| Alessi, NE; Spalding, S | 1 |
| Bailey, KP | 1 |
| Maidment, ID | 1 |
| Lynch, T | 1 |
| Le Heuzey, MF | 2 |
| Wimett, L | 1 |
| Adler, L; Allen, AJ; Brown, WJ; Heiligenstein, J; Kelsey, D; Michelson, D; Milton, D; Ruff, D; Spencer, T; Wernicke, JF; West, SA | 1 |
| Plosker, GL; Simpson, D | 2 |
| Biederman, J; Spencer, T; Wilens, T | 1 |
| Eiland, LS; Guest, AL | 1 |
| Caballero, J; Nahata, MC | 1 |
| Hussar, DA | 1 |
| Artigas Pallares, J | 1 |
| Brown, TE | 1 |
| Garland, M; Kirkpatrick, P | 1 |
| Reeves, G; Schweitzer, J | 1 |
| Biederman, J; Buitelaar, JK; Danckaerts, M; Faries, DE; Gillberg, C; Michelson, D; Spencer, TJ; Zhang, S; Zuddas, A | 2 |
| Ciccone, PE; Creighton, CJ; Liu, J; Orsini, MJ; Ramabadran, K; Reitz, AB | 1 |
| Allen, AJ; Casat, CD; Coury, DL; Gonzales, J; Kelsey, DK; Malcolm, SK; Quintana, H; Saylor, KE; Schuh, KJ; Sumner, CR; Sutton, VK | 1 |
| Allen, AJ; Faries, DE; Kelsey, DK; Kratochvil, CJ; Perwien, AR; Sumner, CR | 1 |
| Michelson, D; Thomason, C | 1 |
| King, RA; Lee, TD; Lee, TS; Lombroso, PJ | 1 |
| Banaschewski, T; Dittmann, RW; Roessner, V; Rothenberger, A; Santosh, PJ | 1 |
| Velcea, G; Winsberg, BG | 1 |
| Christman, AK; Fermo, JD; Markowitz, JS | 1 |
| Hartman, K; Henderson, TA | 1 |
| Henderson, TA | 1 |
| Olfson, M | 1 |
| Becker, K; Bouvard, M; Buitelaar, JK; Danckaerts, M; Fagan, J; Fouche, DS; Gadoros, J; Gillberg, C; Harpin, V; Hazell, P; Johnson, M; Krikke-Workel, J; Lerman-Sagie, T; Michelson, D; Soutullo, CA; Wolanczyk, T; Zeiner, P; Zhang, S; Zuddas, A | 1 |
| Davids, E; Gastpar, M | 1 |
| Bergman, J; Gasior, M; Kallman, MJ; Paronis, CA | 1 |
| Feinberg, DT; McGough, JJ; Pataki, CS | 1 |
| Corman, SL; Culley, CM; Fedutes, BA | 1 |
| Shatkin, JP | 1 |
| Prasad, S | 1 |
| Barton, J | 1 |
| Hazell, P | 1 |
| Sangal, JM; Sangal, RB | 2 |
| Dodson, WW | 1 |
| Biederman, J; Michelson, D; Milton, DR; Newcorn, JH; Spencer, TJ | 1 |
| Cantrell, FL; Nestor, M | 1 |
| Adler, LA; Michelson, D; Milton, DR; Moore, RJ; Spencer, TJ | 1 |
| Banaschewski, T; Heise, CA; Himpel, S; Rothenberger, A | 1 |
| Schonwald, A | 1 |
| Busner, J; Casat, C; Dittmann, R; Harder, D; Heiligenstein, J; Kaplan, S; Wernicke, JF; West, S | 1 |
| Baldessarini, RJ; Moran-Gates, T; Tarazi, FI; Zhang, K | 1 |
| Allen, AJ; Feldman, PD; Ruff, DD | 1 |
| Greenfield, B; Hechman, L | 1 |
| Burke, WJ; Daughton, JM; Kratochvil, CJ; Mayfield-Jorgensen, ML; Vaughan, BS | 1 |
| Dworkin, N | 1 |
| Hamilton, J | 1 |
| Ring, BJ; Sauer, JM; Witcher, JW | 1 |
| Barton, J; Mooney, P; Prasad, S | 1 |
| Ledbetter, M | 1 |
| Allen, AJ; Gerbers, JA | 1 |
| Amler, RW; Brown, RT; Feldman, HM; Freeman, WS; Perrin, JM; Pierce, K; Stein, MT; Wolraich, ML | 1 |
| Brown, TE; Evans, SW; Gotlieb, EM; Knight, JR; Ross, EC; Shubiner, HH; Wender, EH; Wibbelsman, CJ; Wilens, T; Wolraich, ML | 1 |
| Allen, AJ; Dunn, D; Kelsey, D; Kratochvil, C; Stevens, L; Tamura, R; Tannock, R; Thomason, C; Velez-Borras, J; Weiss, M | 1 |
| Biederman, J; Kratochvil, CJ; Michelson, D; Newcorn, JH; Ruff, D; Spencer, TJ | 1 |
| Matza, LS; Rentz, AM; Revicki, DA; Secnik, K; Swensen, A | 1 |
| Gilbert, D; Mannix, S; Matza, LS; Rentz, AM; Revicki, DA; Sallee, FR; Secnik, K | 1 |
| Gilbert, DL; Lipps, TD; Ridel, KR; Sallee, FR; Wassermann, EM; Zhang, J | 1 |
| Adler, L; Hedges, DW; Marchant, BK; Reimherr, FW; Soni, P; Spencer, TJ; Strong, RE; West, SA | 1 |
| Bohnstedt, BN; Dunn, DW; Giauque, AL; Kronenberger, WG; Lafata, D; Rembusch, ME; Wood, EA | 1 |
| Arnold, LE; Biederman, J; Duesenberg, D; Emslie, GJ; Gao, H; Kratochvil, CJ; Michelson, D; Newcorn, JH; Quintana, H; Sarkis, EH; Wagner, KD | 1 |
| Dougherty, M; McDonnell, MA | 1 |
| Battel, S; Dittmann, RW; Döpfner, M; Lehmkuhl, G; Sevecke, K | 1 |
| Pritchard, D | 2 |
| Adler, L; Biederman, J; Faraone, SV; Michelson, D; Reimherr, F; Seidman, L; Spencer, T | 1 |
| Waxmonsky, JG | 1 |
| Davis, ME; Johnston, JA; Pohl, GM; Sterling, KL; Sun, PJ; Van Brunt, DL; Ye, W | 1 |
| Owens, JA; Sangal, J; Sangal, RB | 1 |
| Prince, JB | 1 |
| Wooltorton, E | 1 |
| Kemner, J; Starr, HL | 1 |
| Biederman, J; Clark, TM; Kollins, SH; Mays, DA; McCracken, JT; McGough, JJ; Posner, KL; Spencer, TJ; Tulloch, SJ; Wigal, SB; Wigal, TL; Zhang, Y | 1 |
| Chang, K; Hah, M | 1 |
| Allen, AJ; Coffey, BJ; Dunn, DW; Dure, LS; Erenberg, G; Feldman, PD; Gilbert, DL; Kelsey, DK; Kurlan, RM; Layton, LL; Lewis, DW; Linder, SL; Milton, DR; Mintz, MI; Ricardi, RK; Sallee, FR; Spencer, TJ; Winner, PK | 1 |
| Karande, S | 1 |
| Bebarta, VS; Gonzalez, MG; Kostic, MA | 1 |
| Garside, D; Riemer, EC; Ropero-Miller, JD | 1 |
| Arnsten, AF; Biederman, J; Culpepper, L; Doyle, AE; Faraone, SV; Safren, SA; Spencer, TJ; Weiss, MD; Wilens, TE | 1 |
| Gao, H; Kratochvil, C; Newcorn, JH; Wilens, TE | 1 |
| Miller, MC | 1 |
| Barton, J; Buitelaar, JK; Danckaerts, M; Friedrichs, E; Gillberg, C; Hazell, PL; Hellemans, H; Johnson, M; Kalverdijk, LJ; Masi, G; Michelson, D; Revol, O; Sebastian, JS; Zhang, S; Zuddas, A | 1 |
| Arcieri, R; Knellwolf, AL; Panei, P; Vella, S | 1 |
| Hamrin, V; Rains, A; Scahill, L | 1 |
| Myhr, K | 2 |
| Robertson, MM | 1 |
| Barton, J; Benn, D; Danckaerts, M; Hazell, P; Johnson, M; Ladikos, A; Michelson, D; Wolańczyk, T; Yoran-Hegesh, R; Zeiner, P; Zhang, S; Zuddas, A | 1 |
| Allen, C; Pitcock, J | 1 |
| Lechner, E; Schonwald, A | 1 |
| Johnston, JA; O'Hara, NN; Pohl, GM; Van Brunt, DL; Ye, W | 1 |
| Adler, LA; Biederman, J; Faraone, SV; Glatt, SJ; Michelson, D; Reimherr, FW; Spencer, TJ | 1 |
| Biederman, J; Mays, DA; McGough, JJ; Spencer, TJ; Wigal, SB | 1 |
| Corners, CK; Crismon, ML; Emslie, GJ; Hughes, CW; Jensen, PS; Lopez, M; McCRACKEN, JT; Pliszka, SR; Swanson, JM | 1 |
| Greenfield, B; Slatkoff, J | 1 |
| Bettinger, TL; Crismon, ML; Gibson, AP; Patel, NC | 1 |
| Badreldin, N; Gilbert, DL; Lipps, TD; Merhar, S; Ridel, KR; Sallee, FR; Wang, Z; Wassermann, EM; White, C; Zhang, J | 1 |
| Benarroch, F; Gross-Tsur, V; Jaworowski, S | 1 |
| Asseburg, C; Drummond, M; Golder, S; Griffin, S; Hodges, Z; King, S; Richardson, G; Riemsma, R; Taylor, E; Weatherly, H | 1 |
| Biederman, J; Gao, H; Rogers, AK; Spencer, TJ | 1 |
| Johnston, JA; Pohl, G; Sumner, CR; Van Brunt, DL; Ye, W | 1 |
| Feldman, PD; Gao, H; Kratochvil, CJ; Levine, LR; Newcorn, JH; Rogers, AK; Thomason, CK; Wilens, TE | 1 |
| Baker, KD; Feldman, PD; Gao, H; Gelowitz, DL; Greenhill, LL; Kratochvil, CJ; Wilens, TE | 1 |
| Unni, JC | 1 |
| Desarkar, P; Sinha, VK | 1 |
| Culpepper, L | 1 |
| Kashani, J; Lovecchio, F | 1 |
| Acharya, N; Allen, AJ; Bangs, ME; Dellva, MA; Polzer, J; Tauscher-Wisniewski, S; Watson, SB; Wilens, TE; Zhang, S | 1 |
| Aman, MG; Arnold, LE; Cook, AM; Hall, KL; Ramadan, Y; Thompson, S; Witwer, AN | 1 |
| Brown, RT; Faries, DE; Kratochvil, CJ; Perwien, A; Vaughan, BS | 1 |
| Blondeau, C; Dellu-Hagedorn, F | 1 |
| Maynard, M; McDougle, CJ; Posey, DJ; Stigler, KA; Wiegand, RE; Wilkerson, J | 1 |
| Buitelaar, JK; Hoekstra, PJ; Kalverdijk, LJ; Minderaa, RB; Steenhuis, MP; Troost, PW; Tuynman-Qua, HG | 1 |
| Biederman, J; Feldman, PD; Gao, H; Milton, DR; Newcorn, JH; Spencer, TJ; Witte, MM | 1 |
| Allen, AJ; Kratochvil, CJ; Michelson, D; Moore, RJ; Newcorn, JH; Ruff, DD | 1 |
| Adler, LA; Allen, AJ; Dietrich, AP; Kelsey, DK; Moore, RJ; Reimherr, FW; Sangal, RB; Saylor, KE; Secnik, K; Sutton, VK | 1 |
| Bates, G; Rajesh, AS; Wright, JG | 1 |
| Connolly, M; Dunn, DW; Gonzalez-Heydrich, J; Jan, JE; Kratochvil, CJ; Plioplys, S; Wambera, K; Weiss, M | 1 |
| Horner, WE; Johnson, DE; Rollema, H; Schmidt, AW | 1 |
| Brown, RT; Faries, DE; Kratochvil, CJ; Perwien, AR; Spencer, T; Vaughan, BS | 1 |
| Gardner, D; Jerome, L; Kutcher, SP | 1 |
| Anderson, DL; Barkley, RA; Kruesi, M | 1 |
| McCracken, J; Michelson, D; Read, HA; Ruff, DD; Witcher, J; Zhang, S | 1 |
| Allen, AJ; Kelsey, D; Owens, J; Sangal, RB; Schuh, K; Sutton, V | 1 |
| Duh, PD; Macken, E | 1 |
| Harpin, V; Jamdar, S; Poole, L; Prasad, S; Puvanendran, K; Zeitlin, H | 1 |
| Buermeyer, C; Busner, J; Faries, D; Kaplan, S; Kratochvil, CJ; Perwien, A; Saylor, K; Swindle, R; Vaughan, B | 1 |
| Bond, GR; Garro, AC; Gilbert, DL | 1 |
| Dewan, M; Faraone, SV; Kunwar, A | 1 |
| Schlamp, D | 1 |
| Feldman, PD; Gao, H; Greenhill, LL; Newcorn, JH | 1 |
| Singh, T | 1 |
| Biggins, P; Greenhill, LL; Kollins, SH; Kotler, LA; Kratochvil, CJ; March, JS; Mayfield-Jorgensen, ML; Murray, DW; Paykina, N; Ravi, H; Stoner, J; Vaughan, BS | 1 |
| Chamberlain, SR; Robbins, TW; Sahakian, BJ | 1 |
| Chen, RY; Cheng, JY; Ko, JS; Ng, EM | 1 |
| Brandyberry, J; Gilbert, DL; Lipps, TD; Natarajan, N; Sallee, FR; Wang, Z; Wassermann, EM; Zhang, J | 1 |
| Allen, AJ; Ball, S; Bangs, ME; Dunn, D; Edison, T; Holdridge, KC; Jin, L; Wernicke, JF; Zhang, S | 1 |
| Faraone, SV; Hodgkins, P; Wigal, SB | 1 |
| Avigan, M; Brinker, A; Burgess, M; Mosholder, A; Schech, SD | 1 |
| Chamberlain, SR; Clark, L; Del Campo, N; Dowson, J; Müller, U; Robbins, TW; Sahakian, BJ | 1 |
| Jamdar, S; Sathyamoorthy, BT | 1 |
| Katragadda, S; Schubiner, H | 1 |
| Allen, AJ; Bangs, ME; Cherlin, EA; Duesenberg, DA; Feldman, PD; Kelsey, DK; Quintana, H; Ramsey, JL | 1 |
| Buitelaar, JK; Feldman, PD; Trzepacz, PT; Williams, DW; Witcher, JW; Wrishko, RE | 1 |
| Allen, AJ; Busner, J; Dickson, R; Kratochvil, CJ; Luber, S; Michelson, D; Moore, RJ; Newcorn, JH; Ramsey, J; Ruff, DD; Saylor, KE; Turgay, A; Vaughan, B; Weiss, MD | 1 |
| Bakken, R; Donnelly, C; Geller, D; Kelsey, D; Lopez, F; Newcorn, J; Paczkowski, M; Rubin, R; Sumner, C; Sutton, V | 1 |
| Young, JL | 1 |
| Adler, LA | 1 |
| Lehmkuhl, G | 1 |
| McCarthy, J | 1 |
| Allen, AJ; Bangs, ME; Bartky, EJ; Busner, J; Carlson, C; Duesenberg, DA; Emslie, GJ; Harshawat, P; Kaplan, SL; Quintana, H; Ramsey, JL; Spencer, TJ; Sumner, CR | 1 |
| Allen, AJ; Chou, MC; Chou, WJ; Gau, SS; Huang, YS; Lee, P; Shang, CY; Soong, WT; Tseng, WL | 1 |
| Garcia-Bournissen, F; Humphreys, C; Ito, S; Koren, G | 1 |
| Brod, M; Faries, DE; Johnston, JA; Malley, KG; Matza, LS | 1 |
| Birnbaum, HG; Ivanova, JI; Mallet, D; Wu, EQ; Yang, E; Zhang, HF | 1 |
| Goodman, DW | 1 |
| Asheim, H; Furu, K; Johansen, K; Nilsen, KB | 1 |
| Rostain, AL | 1 |
| Bangerl, W; Friedrich, M; Kienbacher, C; Pellegrini, E; Scheidinger, H; Vesely, C; Wiesegger, G | 1 |
| Bevins, RA; Linkugel, JD; Reichel, CM | 1 |
| Gualtieri, CT; Johnson, LG | 1 |
| Allen, AJ; Budman, CL; Coffey, BJ; Dunn, DW; Feldman, PD; Geller, DA; Gilbert, DL; Kelsey, DK; Kurlan, RM; Leonard, HL; Lewis, DW; Linder, SL; McCracken, JT; Milton, DR; Mintz, M; Ricardi, RK; Sallee, FR; Spencer, TJ; Winner, PK | 1 |
| DeVane, CL; Donovan, JL; Gibson, BB; Jiang, Y; Markowitz, JS; Wang, JS; Zhu, HJ | 1 |
| Allen, AJ; Bailey, CE; Casat, CD; Dunn, DW; Feldman, PD; Furr, AJ; Geller, DA; Jain, R; Kratochvil, CJ; Lipetz, RS; Newcorn, JH; Ruff, DD; Sangal, RB; Saylor, KE; Spencer, TJ | 1 |
| Adler, LA; Biederman, J; Faraone, SV; Glatt, SJ; Marchant, BK; Michelson, D; Reimherr, FW; Spencer, TJ | 1 |
| Fu, R; McDonagh, MS; Peterson, K | 1 |
| Egger, HL; Emslie, GJ; Gleason, MM; Greenhill, LL; Kowatch, RA; Lieberman, AF; Luby, JL; Owens, J; Scahill, LD; Scheeringa, MS; Stafford, B; Wise, B; Zeanah, CH | 1 |
| Gaillez, C; Perrin, E; Sorbara, F | 1 |
| Gerhard, T; Johnson, M; Liu, H; Saidi, A; Shuster, J; Winterstein, AG; Zito, J | 1 |
| Bukstein, OG; Crismon, ML; Manos, MJ; Tom-Revzon, C | 1 |
| Barton, R | 1 |
| Prasad, S; Steer, C | 1 |
| Bálint, S; Bitter, I; Czobor, P; Mészáros, A; Simon, V | 1 |
| Acharya, N; Allen, AJ; Bangs, ME; Desaiah, D; Polzer, J; Tauscher-Wisniewski, S; Trzepacz, PT; Zhang, S | 1 |
| Axelson, AA; Bakken, RJ; Kelsey, DK; Kramer, HP; Malcolm, SK; Paczkowski, M; Sumner, CR; Williams, DW | 1 |
| Schlander, M | 2 |
| Adler, LA; Faraone, SV; Marchant, BK; Reimherr, FW; Robison, RJ; West, SA | 1 |
| Clement, HW; Gründer, G; Paulzen, M | 1 |
| Bangs, ME; Coghill, DR; Danckaerts, M; Hazell, P; Hoare, P; Levine, L; Moore, RJ; Wehmeier, PM; Williams, DW | 1 |
| Coghill, D; Graham, J | 1 |
| Allen, AJ; Anderson, SG; Durell, TM; Kelsey, D; Pumariega, A; Rothe, EM; Tamayo, JM; Vélez-Borrás, J; Williams, D | 1 |
| De Vries, TJ; Griffioen-Roose, S; Schiepers, OJ; Schoffelmeer, AN; Trezza, V; Van Leeuwen, N; Vanderschuren, LJ | 1 |
| Dittmann, RW; Lehmann, M; Lehmkuhl, G; Minarzyk, A; Schacht, A; Sevecke, K; Wehmeier, PM | 1 |
| Buermeyer, C; Faries, D; Khan, S; Saylor, K; Schuh, K; Sutton, V | 1 |
| Manos, MJ | 1 |
| Lei, GF; Liu, LL; Sun, RP; Wang, GJ; Wang, YW; Yang, J | 1 |
| Harpin, VA | 1 |
| Allen, AJ; Bangs, ME; Desaiah, D; Jin, L; Read, HA; Regev, A; Wernicke, JF; Zhang, S | 1 |
| Kratochvil, CJ; Vaughan, BS; Wetzel, MW | 1 |
| Adler, LA; Ahrbecker, LM; Brady, KT; Levine, LR; Michelson, D; Moore, RJ; Ramsey, JL; Renard, D; Schuh, LM; Trzepacz, PT; Weiss, MD; Wilens, TE | 1 |
| Patel, NC; Sears, J | 1 |
| Harris, DK; Párraga, HC; Párraga, MI | 1 |
| Adler, LA; Michelson, D; Moore, RJ; Spencer, TJ; Williams, DW | 1 |
| Heal, DJ; Kulkarni, RS; Rowley, HL; Smith, SL | 1 |
| Biederman, J; Faraone, SV; Harding, M; Hatch, M; Jones, J; Prince, J; Seidman, L; Spencer, T; Wilens, T | 1 |
| Biederman, J; Faraone, SV; Spencer, T; Wilens, TE | 1 |
| Baker, N; Bohac, D; Burke, WJ; Harrington, M; Kratochvil, CJ; May, D | 1 |
| Biederman, J; Faraone, SV; Faries, D; Heiligenstein, J; Prince, J; Rea, J; Spencer, T; Wilens, T; Witcher, J; Zervas, S | 1 |
| Faries, D; Kelsey, D; Kendrick, K; Michelson, D; Sallee, FR; Spencer, T; Wernicke, J | 1 |
| Preti, A | 1 |
260 review(s) available for atomoxetine hydrochloride and ADDH
| Article | Year |
|---|---|
Headache in ADHD as comorbidity and a side effect of medications: a systematic review and meta-analysis.
Topics: Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Comorbidity; Drug-Related Side Effects and Adverse Reactions; Guanfacine; Headache; Humans; Methylphenidate; Randomized Controlled Trials as Topic | 2022 |
Association between central nervous system stimulants used to treat attention deficit hyperactivity disorder (ADHD) and Raynaud's phenomenon: A scoping review.
Topics: Adolescent; Adult; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Humans; Methylphenidate; Raynaud Disease | 2021 |
How Are Attention-deficit Hyperactivity and Internet Gaming Disorders Related in Children and Youth?
Topics: Adolescent; Atomoxetine Hydrochloride; Attention; Attention Deficit Disorder with Hyperactivity; Child; Humans; Internet; Internet Addiction Disorder; Video Games | 2021 |
Current Pharmacological Treatments for ADHD.
Topics: Adolescent; Adult; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Drug-Related Side Effects and Adverse Reactions; Humans; Methylphenidate; Quality of Life | 2022 |
A systematic review of the use of atomoxetine for management of comorbid anxiety disorders in children and adolescents with attention-deficit hyperactivity disorder.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Anxiety; Anxiety Disorders; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Humans; Propylamines; Treatment Outcome | 2022 |
Nonstimulant Treatments for ADHD.
Topics: Adrenergic alpha-2 Receptor Agonists; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Clonidine; Guanfacine; Humans | 2022 |
Pharmacologic Treatment of Comorbid Attention-Deficit/Hyperactivity Disorder and Tourette and Tic Disorders.
Topics: Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Comorbidity; Humans; Tic Disorders; Tics | 2022 |
Do Treatments for Adult ADHD Improve Emotional Behavior? A Systematic Review and Analysis.
Topics: Adult; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Humans; Lisdexamfetamine Dimesylate; Methylphenidate; Treatment Outcome | 2022 |
Treating ADHD and Comorbid Anxiety in Children: A Guide for Clinical Practice.
Topics: Adolescent; Anxiety; Anxiety Disorders; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Comorbidity; Humans | 2023 |
Treatments for child and adolescent attention deficit hyperactivity disorder in low and middle-income countries: A narrative review.
Topics: Adolescent; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Child, Preschool; Clonidine; Developing Countries; Humans; Methylphenidate | 2022 |
Therapeutic Approaches for ADHD by Developmental Stage and Clinical Presentation.
Topics: Adolescent; Adult; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Guanfacine; Humans; Methylphenidate | 2022 |
Meta-analysis on the efficacy of the norepinephrine reuptake inhibitors reboxetine and atomoxetine for the treatment of schizophrenia and attention deficit hyperactivity disorder.
Topics: Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Humans; Norepinephrine; Reboxetine; Schizophrenia; Treatment Outcome | 2023 |
Personalizing atomoxetine dosing in children with ADHD: what can we learn from current supporting evidence.
Topics: Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Drug Interactions; Humans; Pharmacogenetics; Polymorphism, Genetic | 2023 |
[A precision medication study of atomoxetine in children with attention deficit hyperactivity disorder:
Topics: Adrenergic Uptake Inhibitors; Adult; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Cytochrome P-450 CYP2D6; Drug Monitoring; Genetic Testing; Humans; Propylamines; Treatment Outcome | 2023 |
Do ADHD Treatments Improve Executive Behavior Beyond Core ADHD Symptoms in Adults? Evidence From Systematic Analysis of Clinical Trials.
Topics: Adult; Amphetamine; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Executive Function; Humans; Lisdexamfetamine Dimesylate | 2023 |
[Pharmacotherapy and psychotherapy of children with attention deficit hyperactivity disorder].
Topics: Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Humans; Propylamines; Psychotherapy | 2023 |
Polyunsaturated fatty acids (PUFA) for attention deficit hyperactivity disorder (ADHD) in children and adolescents.
Topics: Adolescent; Amphetamine; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Fatty Acids, Omega-3; Fatty Acids, Unsaturated; Humans; Methylphenidate; Quality of Life | 2023 |
Nonstimulant Medications for Attention-Deficit/Hyperactivity Disorder (ADHD) in Adults: Systematic Review and Meta-analysis.
Topics: Adult; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Guanfacine; Humans; Randomized Controlled Trials as Topic; Viloxazine | 2023 |
Association between sleep pattern and pharmacological treatment in children with attention deficit disorder with hyperactivity: a systematic review.
Topics: Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Humans; Methylphenidate; Sleep | 2023 |
Relationship Between Treatment Duration and Efficacy of Pharmacological Treatment for ADHD: A Meta-Analysis and Meta-Regression of 87 Randomized Controlled Clinical Trials.
Topics: Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Duration of Therapy; Humans; Methylphenidate; Randomized Controlled Trials as Topic; Treatment Outcome | 2021 |
[Attention deficit hyperactivity disorder in childhood and adolescence : Current state of research].
Topics: Adolescent; Adult; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Child, Preschool; Germany; Humans; Methylphenidate | 2020 |
Clinical guidance on pharmacotherapy for the treatment of attention-deficit hyperactivity disorder (ADHD) for people with intellectual disability.
Topics: Adolescent; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Clonidine; Cognition; Dextroamphetamine; Humans; Intellectual Disability; Methylphenidate; Practice Guidelines as Topic; Quality of Life; Randomized Controlled Trials as Topic; Treatment Outcome | 2020 |
Adult attention deficit/hyperactivity disorder in the ambulatory care setting.
Topics: Adrenergic Uptake Inhibitors; Adult; Ambulatory Care; Amphetamines; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Cognitive Behavioral Therapy; Comorbidity; Diagnosis, Differential; Diagnostic Errors; Humans; Patient Education as Topic; Quality of Life | 2020 |
Practitioner Review: Pharmacological treatment of attention-deficit/hyperactivity disorder symptoms in children and youth with autism spectrum disorder: a systematic review and meta-analysis.
Topics: Adolescent; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Autism Spectrum Disorder; Central Nervous System Stimulants; Child; Guanfacine; Humans; Methylphenidate | 2021 |
Probable Genitourinary Adverse Events Associated With Atomoxetine in an Adult Male: A Case Report.
Topics: Adult; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Male; Propylamines; Treatment Outcome | 2021 |
Pharmacologic Treatment of Attention Deficit-Hyperactivity Disorder.
Topics: Adolescent; Adult; Amphetamines; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Child, Preschool; Growth; Guanfacine; Heart Rate; Humans; Hypertension; Methylphenidate; Patient Dropouts; Polymers; Practice Guidelines as Topic; Treatment Outcome | 2020 |
The female side of pharmacotherapy for ADHD-A systematic literature review.
Topics: Adolescent; Adult; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Child, Preschool; Databases, Factual; Drug Prescriptions; Female; Humans; Male; Men; Methylphenidate; Sex Characteristics; Young Adult | 2020 |
Pharmacologic treatment of attention deficit hyperactivity disorder in adults: A systematic review and network meta-analysis.
Topics: Adult; Amphetamine; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Bayes Theorem; Bupropion; Central Nervous System Stimulants; Dextroamphetamine; Drug-Related Side Effects and Adverse Reactions; Female; Guanfacine; Humans; Lisdexamfetamine Dimesylate; Male; Methylphenidate; Modafinil; Network Meta-Analysis; Quality of Life; Randomized Controlled Trials as Topic | 2020 |
Current and future nonstimulants in the treatment of pediatric ADHD: monoamine reuptake inhibitors, receptor modulators, and multimodal agents.
Topics: Adolescent; Adult; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Clonidine; Guanfacine; Humans; United States | 2022 |
Systematic Review: Medication Effects on Brain Intrinsic Functional Connectivity in Patients With Attention-Deficit/Hyperactivity Disorder.
Topics: Adult; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Brain; Central Nervous System Stimulants; Child; Female; Humans; Magnetic Resonance Imaging; Methylphenidate; Reproducibility of Results | 2021 |
Pharmacotherapy of attention deficit/hyperactivity disorder in individuals with autism spectrum disorder: A systematic review of the literature.
Topics: Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Autism Spectrum Disorder; Child; Guanfacine; Humans; Intellectual Disability; Methylphenidate; Treatment Outcome | 2021 |
Clinical practice guideline on pharmacological and psychological management of adult patients with attention deficit and hyperactivity disorder and comorbid substance use.
Topics: Adult; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Cocaine; Comorbidity; Humans; Methylphenidate; Substance-Related Disorders | 2022 |
Evidence-based pharmacological treatment options for ADHD in children and adolescents.
Topics: Adolescent; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Cross-Sectional Studies; Humans; Methylphenidate | 2022 |
A Practical, Evidence-informed Approach to Managing Stimulant-Refractory Attention Deficit Hyperactivity Disorder (ADHD).
Topics: Adrenergic alpha-2 Receptor Agonists; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Clonidine; Dextroamphetamine; Drug Resistance; Empirical Research; Humans; Methylphenidate; Randomized Controlled Trials as Topic | 2021 |
Editorial: Accumulating Evidence for the Benefit of Micronutrients for Children With Attention-Deficit/Hyperactivity Disorder.
Topics: Adolescent; Amphetamines; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Humans; Methylphenidate; Micronutrients | 2022 |
Safety of Treatments for ADHD in Adults: Pairwise and Network Meta-Analyses.
Topics: Adrenergic Uptake Inhibitors; Adult; Amphetamine; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Databases, Factual; Humans; Methylphenidate; Network Meta-Analysis; Odds Ratio; Sleep Initiation and Maintenance Disorders; Treatment Outcome; Wakefulness | 2019 |
Cross-species studies of cognition relevant to drug discovery: a translational approach.
Topics: Adrenergic Uptake Inhibitors; Animals; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Cognition; Depression; Drug Discovery; Humans; Obsessive-Compulsive Disorder; Reaction Time; Selective Serotonin Reuptake Inhibitors; Translational Research, Biomedical | 2017 |
Discontinuation of pharmacological treatment of children and adolescents with attention deficit hyperactivity disorder: meta-analysis of 63 studies enrolling 11,788 patients.
Topics: Adolescent; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Female; Humans; Male; Methylphenidate; Treatment Outcome; Withholding Treatment | 2017 |
Effects of stimulants and atomoxetine on emotional lability in adults: A systematic review and meta-analysis.
Topics: Adult; Affective Symptoms; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Emotions; Female; Humans; Methylphenidate; Middle Aged; Mood Disorders; Young Adult | 2017 |
Pharmacotherapy of emotional dysregulation in adults with ADHD: A systematic review and meta-analysis.
Topics: Amphetamines; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Emotions; Humans; Methylphenidate | 2018 |
Autism spectrum disorder: Consensus guidelines on assessment, treatment and research from the British Association for Psychopharmacology.
Topics: Animals; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Autism Spectrum Disorder; Brain; Consensus; Guanfacine; Humans; Melatonin; Methylphenidate; Psychopharmacology; Sleep Wake Disorders | 2018 |
Clinical trials in autism spectrum disorder: evidence, challenges and future directions.
Topics: Adrenergic alpha-Agonists; Adrenergic Uptake Inhibitors; Aggression; Antipsychotic Agents; Aripiprazole; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Autism Spectrum Disorder; Central Nervous System Depressants; Central Nervous System Stimulants; Clinical Trials as Topic; Evidence-Based Medicine; Humans; Hypoglycemic Agents; Irritable Mood; Melatonin; Metformin; Methylphenidate; Obesity; Outcome Assessment, Health Care; Precision Medicine; Risperidone; Sleep; Sleep Wake Disorders | 2018 |
Effective Use of Animal Models for Therapeutic Development in Psychiatric and Substance Use Disorders.
Topics: Adrenergic Uptake Inhibitors; Animals; Antidepressive Agents; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Depressive Disorder; Drug Discovery; Humans; Ketamine; Mental Disorders; Models, Animal; Nicotinic Agonists; Tobacco Use Disorder; Varenicline | 2018 |
Adverse drug events related to mood and emotion in paediatric patients treated for ADHD: A meta-analysis.
Topics: Affect; Affective Symptoms; Anxiety; Anxiety Disorders; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Male; Mood Disorders; Personality Disorders | 2018 |
Are ADHD medications under or over prescribed worldwide?: Protocol for a systematic review and meta-analysis.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Adult; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Child, Preschool; Humans; Practice Patterns, Physicians'; Prevalence; Systematic Reviews as Topic; Young Adult | 2018 |
Pharmacological treatment for attention deficit hyperactivity disorder (ADHD) in children with comorbid tic disorders.
Topics: Adolescent; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Child, Preschool; Clonidine; Desipramine; Dextroamphetamine; Female; Guanfacine; Humans; Male; Methylphenidate; Randomized Controlled Trials as Topic; Selegiline; Tic Disorders | 2018 |
Update on Common Psychiatric Medications for Children.
Topics: Adolescent; Adrenergic alpha-2 Receptor Agonists; Adrenergic Uptake Inhibitors; Anxiety; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Depression; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Selective Serotonin Reuptake Inhibitors | 2018 |
The Effect of Methylphenidate and Atomoxetine on Heart Rate and Systolic Blood Pressure in Young People and Adults with Attention-Deficit Hyperactivity Disorder (ADHD): Systematic Review, Meta-Analysis, and Meta-Regression.
Topics: Adolescent; Adult; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Blood Pressure; Central Nervous System Stimulants; Child; Heart Rate; Humans; Methylphenidate | 2018 |
Management of Attention-Deficit Disorder and Attention-Deficit/Hyperactivity Disorder Drug Intoxication in Dogs and Cats: An Update.
Topics: Adrenergic Uptake Inhibitors; Amphetamines; Animals; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Cat Diseases; Cats; Dog Diseases; Dogs; Humans; Prognosis | 2018 |
Light up ADHD: II. Neuropharmacological effects measured by near infrared spectroscopy: is there a biomarker?
Topics: Aging; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Biomarkers; Humans; Methylphenidate; Oxyhemoglobins; Prefrontal Cortex; Spectroscopy, Near-Infrared | 2019 |
Pharmacological treatment of attention-deficit hyperactivity disorder comorbid with an anxiety disorder: a systematic review.
Topics: Adolescent; Adult; Anxiety Disorders; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Agents; Child; Comorbidity; Desipramine; Double-Blind Method; Female; Fluvoxamine; Humans; Male; Methylphenidate; Randomized Controlled Trials as Topic; Treatment Outcome | 2019 |
Atomoxetine for attention deficit hyperactivity disorder in children and adolescents with autism: A systematic review and meta-analysis.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Autism Spectrum Disorder; Child; Female; Humans; Male; Treatment Outcome | 2019 |
Clinical Pharmacogenetics Implementation Consortium Guideline for Cytochrome P450 (CYP)2D6 Genotype and Atomoxetine Therapy.
Topics: Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Cytochrome P-450 CYP2D6; Dose-Response Relationship, Drug; Genetic Testing; Genotype; Humans; Pharmacogenetics | 2019 |
Using Cell Cultures for the Investigation of Treatments for Attention Deficit Hyperactivity Disorder: A Systematic Review.
Topics: Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Cell Culture Techniques; Cells, Cultured; Central Nervous System Stimulants; Child; Humans; Methylphenidate; Neurons | 2019 |
[Adult attention deficit hyperactivity disorder (ADHD) with comorbid addictive disorder. Therapeutic challenges using the example of a survey of clinical practice].
Topics: Adult; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Humans; Methylphenidate; Substance-Related Disorders; Surveys and Questionnaires | 2019 |
Toward quality care in ADHD: defining the goals of treatment.
Topics: Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Dextroamphetamine; Goals; Guanfacine; Humans; Lisdexamfetamine Dimesylate; Methylphenidate; Propylamines; Quality of Health Care; Treatment Outcome | 2015 |
Systematic review of atomoxetine data in childhood and adolescent attention-deficit hyperactivity disorder 2009-2011: focus on clinical efficacy and safety.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Humans; Methylphenidate; Propylamines; Treatment Outcome | 2014 |
Pharmacology and pharmacogenetics of pediatric ADHD with associated aggression: a review.
Topics: Adolescent; Adrenergic alpha-Agonists; Adrenergic Uptake Inhibitors; Aggression; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Humans; Impulsive Behavior; Pharmacogenetics; Precision Medicine; Propylamines; Psychotropic Drugs; Treatment Outcome | 2013 |
[Bases for the selection of pharmacological treatment in attention deficit hyperactivity disorder].
Topics: Adolescent; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Drug Prescriptions; Humans; Methylphenidate; Practice Guidelines as Topic; Propylamines | 2013 |
Systematic review and meta-analysis of pharmacological treatment of the symptoms of attention-deficit/hyperactivity disorder in children with pervasive developmental disorders.
Topics: Adolescent; Atomoxetine Hydrochloride; Attention; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Child Development Disorders, Pervasive; Child, Preschool; Double-Blind Method; Female; Humans; Methylphenidate; Propylamines; Randomized Controlled Trials as Topic | 2013 |
A systematic review of combination therapy with stimulants and atomoxetine for attention-deficit/hyperactivity disorder, including patient characteristics, treatment strategies, effectiveness, and tolerability.
Topics: Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Drug Therapy, Combination; Humans; Propylamines; Treatment Outcome | 2013 |
A meta-analysis of the consistency of atomoxetine treatment effects in pediatric patients with attention-deficit/hyperactivity disorder from 15 clinical trials across four geographic regions.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Double-Blind Method; Female; Geography; Humans; Male; Propylamines; Psychiatric Status Rating Scales; Randomized Controlled Trials as Topic; Treatment Outcome | 2013 |
Attention deficit hyperactivity disorder in the European adult population: prevalence, disease awareness, and treatment guidelines.
Topics: Adrenergic Uptake Inhibitors; Adult; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Europe; Female; Humans; Male; Methylphenidate; Practice Guidelines as Topic; Prevalence; Propylamines; Randomized Controlled Trials as Topic; Retrospective Studies | 2013 |
Atomoxetine for attention deficit hyperactivity disorder in the adulthood: a meta-analysis and meta-regression.
Topics: Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Data Interpretation, Statistical; Humans; Patient Dropouts; Propylamines; Randomized Controlled Trials as Topic; Treatment Outcome | 2013 |
[The practice and problem of therapeutic agents for AD/HD].
Topics: Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Humans; Japan; Methylphenidate; Propylamines; Treatment Outcome | 2010 |
[Autism and attention deficit hyperactivity disorder: pharmacological intervention].
Topics: Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Brain; Central Nervous System Stimulants; Child; Child Development Disorders, Pervasive; Clonidine; Dopamine Uptake Inhibitors; Drug Evaluation; Guanfacine; Humans; Methylphenidate; Neuroimaging; Propylamines; Psychotropic Drugs; Randomized Controlled Trials as Topic; Treatment Outcome | 2013 |
Prognostic factors of improvement in health-related quality of life in atomoxetine-treated children and adolescents with attention-deficit/hyperactivity disorder, based on a pooled analysis.
Topics: Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Clinical Trials as Topic; Double-Blind Method; Educational Status; Female; Humans; Logistic Models; Male; Prognosis; Propylamines; Quality of Life; Risk Reduction Behavior; Treatment Outcome | 2014 |
Current pharmacotherapy of attention deficit hyperactivity disorder.
Topics: Amphetamines; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Central Nervous System Stimulants; Humans; Methylphenidate; Propylamines | 2013 |
Clinical practice: Adult attention deficit-hyperactivity disorder.
Topics: Adrenergic Uptake Inhibitors; Adult; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Cognitive Behavioral Therapy; Female; Humans; Practice Guidelines as Topic; Propylamines | 2013 |
A review of the pathophysiology, etiology, and treatment of attention-deficit hyperactivity disorder (ADHD).
Topics: Amphetamines; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Drug Interactions; Humans; Methylphenidate; Propylamines | 2014 |
Efficacy and safety of atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder: results from a comprehensive meta-analysis and metaregression.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Humans; Propylamines; Treatment Outcome | 2014 |
Systematic evidence synthesis of treatments for ADHD in children and adolescents: indirect treatment comparisons of lisdexamfetamine with methylphenidate and atomoxetine.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Dextroamphetamine; Dopamine Uptake Inhibitors; Europe; Humans; Lisdexamfetamine Dimesylate; Methylphenidate; Models, Statistical; Propylamines; Treatment Outcome | 2014 |
Pharmacological and psychosocial treatments for adolescents with ADHD: an updated systematic review of the literature.
Topics: Adolescent; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Central Nervous System Stimulants; Combined Modality Therapy; Humans; Methylphenidate; Propylamines; Treatment Outcome | 2014 |
[Cardiovascular risk assessment for the use of ADHD drugs in children].
Topics: Adolescent; Adrenergic Uptake Inhibitors; Algorithms; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Death, Sudden, Cardiac; Electrocardiography; Heart Diseases; Humans; Medical History Taking; Practice Guidelines as Topic; Propylamines; Risk Assessment; Risk Factors | 2014 |
A review of atomoxetine effects in young people with developmental disabilities.
Topics: Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child Development Disorders, Pervasive; Developmental Disabilities; Humans; Propylamines | 2014 |
Safety of medicines used for ADHD in children: a review of published prospective clinical trials.
Topics: Adolescent; Amphetamines; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Humans; Methylphenidate; Propylamines; Prospective Studies; Treatment Outcome | 2014 |
Sofinicline: a novel nicotinic acetylcholine receptor agonist in the treatment of attention-deficit/hyperactivity disorder.
Topics: Animals; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Azabicyclo Compounds; Humans; Nicotinic Agonists; Propylamines; Pyridines; Receptors, Nicotinic | 2014 |
Priapism associated with the use of stimulant medications and atomoxetine for attention-deficit/hyperactivity disorder in children.
Topics: Adrenergic Uptake Inhibitors; Amphetamines; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Humans; Male; Methylphenidate; Priapism; Propylamines | 2014 |
Meta-analysis of suicide-related behavior or ideation in child, adolescent, and adult patients treated with atomoxetine.
Topics: Adolescent; Adult; Aged; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Clinical Trials as Topic; Female; Humans; Male; Middle Aged; Norepinephrine Plasma Membrane Transport Proteins; Propylamines; Suicidal Ideation; Suicide, Attempted; Young Adult | 2014 |
Efficacy of atomoxetine in adults with attention deficit hyperactivity disorder: an integrated analysis of the complete database of multicenter placebo-controlled trials.
Topics: Adrenergic Uptake Inhibitors; Adult; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Databases, Pharmaceutical; Double-Blind Method; Female; Humans; Male; Multicenter Studies as Topic; Propylamines; Psychiatric Status Rating Scales; Randomized Controlled Trials as Topic; Treatment Outcome | 2014 |
Cardiovascular effects of methylphenidate, amphetamines and atomoxetine in the treatment of attention-deficit hyperactivity disorder: an update.
Topics: Amphetamines; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Blood Pressure; Central Nervous System Stimulants; Death, Sudden, Cardiac; Heart Rate; Humans; Methylphenidate; Propylamines | 2014 |
Brain abnormalities in attention-deficit hyperactivity disorder: a review.
Topics: Adolescent; Adult; Atomoxetine Hydrochloride; Attention Deficit and Disruptive Behavior Disorders; Attention Deficit Disorder with Hyperactivity; Bipolar Disorder; Brain; Brain Mapping; Central Nervous System Stimulants; Child; Clinical Trials as Topic; Conduct Disorder; Diagnosis, Differential; Humans; Magnetic Resonance Imaging; Methylphenidate; Nerve Net; Neuroimaging; Neuroprotective Agents; Positron-Emission Tomography; White Matter | 2014 |
[ADHD in children and adults].
Topics: Adrenergic Uptake Inhibitors; Adult; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Child, Preschool; Humans; Patient Education as Topic; Propylamines | 2014 |
[Atomoxetine for treatment of children and adolescents with ADHD].
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Humans | 2014 |
Attention-deficit/hyperactivity disorder treatment: what are the long-term cardiovascular risks?
Topics: Adult; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Blood Pressure; Cardiovascular Diseases; Central Nervous System Stimulants; Child; Humans; Time Factors | 2015 |
The efficacy of atomoxetine for the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a comprehensive review of over a decade of clinical research.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Comorbidity; Humans; Propylamines; Randomized Controlled Trials as Topic | 2015 |
Comparative efficacy and acceptability of atomoxetine, lisdexamfetamine, bupropion and methylphenidate in treatment of attention deficit hyperactivity disorder in children and adolescents: a meta-analysis with focus on bupropion.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Bupropion; Central Nervous System Stimulants; Child; Comparative Effectiveness Research; Dextroamphetamine; Double-Blind Method; Female; Humans; Lisdexamfetamine Dimesylate; Male; Methylphenidate; Patient Acceptance of Health Care; Propylamines; Randomized Controlled Trials as Topic; Treatment Outcome | 2015 |
The pharmacological management of oppositional behaviour, conduct problems, and aggression in children and adolescents with attention-deficit hyperactivity disorder, oppositional defiant disorder, and conduct disorder: a systematic review and meta-analysi
Topics: Adolescent; Adrenergic alpha-2 Receptor Agonists; Adrenergic Uptake Inhibitors; Aggression; Atomoxetine Hydrochloride; Attention Deficit and Disruptive Behavior Disorders; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Conduct Disorder; Humans | 2015 |
Atomoxetine pharmacogenetics: associations with pharmacokinetics, treatment response and tolerability.
Topics: Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Cytochrome P-450 CYP2D6; Genotype; Humans; Pharmacogenetics; Treatment Outcome | 2015 |
Atomoxetine treatment in adults with attention-deficit/hyperactivity disorder.
Topics: Adrenergic Uptake Inhibitors; Adult; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Behavioral Symptoms; Executive Function; Humans; Psychiatric Status Rating Scales; Treatment Outcome | 2015 |
Atomoxetine in patients with ADHD: A clinical and pharmacological review of the onset, trajectory, duration of response and implications for patients.
Topics: Adrenergic Uptake Inhibitors; Animals; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Half-Life; Humans | 2015 |
The use of stimulants and atomoxetine in adults with comorbid ADHD and bipolar disorder.
Topics: Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Bipolar Disorder; Central Nervous System Stimulants; Comorbidity; Humans; Substance-Related Disorders; Treatment Outcome | 2015 |
Long-Term Pharmacotherapy of Adults With Attention Deficit Hyperactivity Disorder: A Literature Review and Clinical Study.
Topics: Adrenergic Uptake Inhibitors; Adult; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Databases, Factual; Humans; Methylphenidate; Randomized Controlled Trials as Topic; Time Factors; Treatment Outcome | 2016 |
Are there any potentially dangerous pharmacological effects of combining ADHD medication with alcohol and drugs of abuse? A systematic review of the literature.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Alcohol Drinking; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Dextroamphetamine; Drug Interactions; Humans; Illicit Drugs; Lisdexamfetamine Dimesylate; Methylphenidate; Substance-Related Disorders | 2015 |
Guanfacine Extended Release: A New Pharmacological Treatment Option in Europe.
Topics: Adolescent; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Delayed-Action Preparations; Europe; Guanfacine; Humans; Treatment Outcome | 2016 |
Atomoxetine: A Review of Its Pharmacokinetics and Pharmacogenomics Relative to Drug Disposition.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Adult; Age Factors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Cytochrome P-450 CYP2D6; Humans; Pharmacogenetics; Polymorphism, Genetic | 2016 |
A network meta-analysis of atomoxetine and osmotic release oral system methylphenidate in the treatment of attention-deficit/hyperactivity disorder in adult patients.
Topics: Adrenergic Uptake Inhibitors; Adult; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Humans; Methylphenidate; Network Meta-Analysis | 2016 |
Treatment of Attention-Deficit/Hyperactivity Disorder in Adolescents: A Systematic Review.
Topics: Adolescent; Adrenergic alpha-2 Receptor Agonists; Amphetamines; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Clonidine; Delayed-Action Preparations; Guanfacine; Humans; Methylphenidate; Motivation; Psychotherapy; Randomized Controlled Trials as Topic; Social Skills | 2016 |
The Safety of Atomoxetine for the Treatment of Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Comprehensive Review of Over a Decade of Research.
Topics: Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention; Attention Deficit Disorder with Hyperactivity; Humans; Propylamines; Research | 2016 |
An Evaluation on the Efficacy and Safety of Treatments for Attention Deficit Hyperactivity Disorder in Children and Adolescents: a Comparison of Multiple Treatments.
Topics: Adolescent; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Clonidine; Dextroamphetamine; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Lisdexamfetamine Dimesylate; Male; Methylphenidate; Treatment Outcome | 2017 |
Current and Investigational Medication Delivery Systems for Treating Attention-Deficit/Hyperactivity Disorder.
Topics: Adrenergic Agents; Amphetamines; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Clinical Trials as Topic; Clonidine; Guanfacine; Humans; Methylphenidate; Treatment Outcome | 2016 |
The efficacy of atomoxetine in treating adult attention deficit hyperactivity disorder (ADHD): A meta-analysis of controlled trials.
Topics: Adrenergic Uptake Inhibitors; Adult; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Humans | 2016 |
Optimizing outcomes in ADHD treatment: from clinical targets to novel delivery systems.
Topics: Adrenergic alpha-2 Receptor Agonists; Adrenergic Uptake Inhibitors; Anxiety Disorders; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Bipolar Disorder; Central Nervous System Stimulants; Clonidine; Comorbidity; Delayed-Action Preparations; Depressive Disorder; Dextroamphetamine; Guanfacine; Humans; Methylphenidate | 2016 |
Comparative efficacy and safety of methylphenidate and atomoxetine for attention-deficit hyperactivity disorder in children and adolescents: Meta-analysis based on head-to-head trials.
Topics: Adolescent; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Female; Humans; Male; Methylphenidate; Treatment Outcome | 2017 |
Atomoxetine treatment for children and adolescents with Attention-Deficit/Hyperactivity Disorder (ADHD): a comprehensive meta-analysis of outcomes on parent-rated core symptomatology.
Topics: Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Humans; Treatment Outcome | 2017 |
Cardiovascular Effects of Stimulant and Non-Stimulant Medication for Children and Adolescents with ADHD: A Systematic Review and Meta-Analysis of Trials of Methylphenidate, Amphetamines and Atomoxetine.
Topics: Adolescent; Amphetamines; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Blood Pressure; Central Nervous System Stimulants; Child; Child, Preschool; Clinical Trials as Topic; Heart Rate; Humans; Infant; Methylphenidate; Psychotropic Drugs | 2017 |
Evolution of the treatment of attention-deficit/hyperactivity disorder in children: a review.
Topics: Amphetamines; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Dexmethylphenidate Hydrochloride; Humans; Methylphenidate; Norepinephrine Plasma Membrane Transport Proteins; Prodrugs; Propylamines | 2008 |
[Long-acting medications for the treatment of hyperkinetic disorders - a systematic review and European treatment guidelines. Part 2: a quantitative evaluation of long-acting medications].
Topics: Amphetamines; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Delayed-Action Preparations; Europe; Evidence-Based Medicine; Humans; Methylphenidate; Practice Guidelines as Topic; Propylamines; Quality of Life; Treatment Outcome | 2008 |
[Atomoxetine (strattera) in the treatment of attention deficit hyperactivity syndrome].
Topics: Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Humans; Propylamines; Treatment Outcome | 2008 |
[Attention deficit hyperactivity disorder: clinical heterogeneity and possibilities of therapy].
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Child, Preschool; Humans; Propylamines | 2008 |
[Principles of medical care for children with ADHD].
Topics: Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Diagnosis, Differential; Electric Stimulation; Electroencephalography; Humans; Propylamines | 2008 |
Dopamine vs noradrenaline: inverted-U effects and ADHD theories.
Topics: Adrenergic alpha-Agonists; Adrenergic Uptake Inhibitors; Alleles; Animals; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Catechol O-Methyltransferase; Dopamine; Guanfacine; Humans; Memory, Short-Term; Nerve Net; Norepinephrine; Polymorphism, Genetic; Prefrontal Cortex; Propylamines; Receptors, Adrenergic, alpha-2; Receptors, Dopamine D4; Space Perception; Thalamus | 2009 |
Update on atomoxetine in the treatment of attention-deficit/hyperactivity disorder.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Adult; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Controlled Clinical Trials as Topic; Dose-Response Relationship, Drug; Humans; Propylamines; Treatment Outcome; Young Adult | 2009 |
Review of ADHD pharmacotherapies: advantages, disadvantages, and clinical pearls.
Topics: Adolescent; Adrenergic alpha-Agonists; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Bupropion; Central Nervous System Stimulants; Child; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Administration Routes; Drug Costs; Humans; Propylamines; Treatment Outcome; United States; United States Food and Drug Administration | 2009 |
InforMatrix for attention deficit hyperactivity disorder.
Topics: Adrenergic Uptake Inhibitors; Animals; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Chemistry, Pharmaceutical; Clinical Trials as Topic; Humans; Methylphenidate; Netherlands; Propylamines | 2009 |
Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Drug Administration Schedule; Humans; Propylamines | 2009 |
ADHD in children and adolescents.
Topics: Adolescent; Atomoxetine Hydrochloride; Attention Deficit and Disruptive Behavior Disorders; Attention Deficit Disorder with Hyperactivity; Child; Dextroamphetamine; Diagnostic and Statistical Manual of Mental Disorders; Humans; Methylphenidate | 2008 |
Attention-deficit-hyperactivity disorder: an update.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Adult; Amphetamine; Antidepressive Agents, Second-Generation; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Bupropion; Case-Control Studies; Central Nervous System Stimulants; Child; Conduct Disorder; Follow-Up Studies; Humans; Juvenile Delinquency; Longitudinal Studies; Methylphenidate; Patient Compliance; Prescriptions; Prevalence; Propylamines; Substance-Related Disorders; Time Factors; Treatment Outcome; United States | 2009 |
Current issues around the pharmacotherapy of ADHD in children and adults.
Topics: Adult; Age Factors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Humans; Propylamines; Treatment Outcome | 2009 |
Assessing the value of atomoxetine in treating children and adolescents with ADHD in the UK.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Cost-Benefit Analysis; Humans; Practice Guidelines as Topic; Propylamines; Quality of Life; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; United Kingdom | 2009 |
Clinical considerations for the diagnosis and treatment of ADHD in the managed care setting.
Topics: Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Dextroamphetamine; Diagnostic and Statistical Manual of Mental Disorders; Dopamine Uptake Inhibitors; Humans; Managed Care Programs; Methylphenidate; Propylamines | 2009 |
The role of pharmacotherapy and managed care pharmacy interventions in the treatment of ADHD.
Topics: Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Dextroamphetamine; Humans; Managed Care Programs; Medication Adherence; Methylphenidate; Propylamines | 2009 |
Meta-analysis: treatment of attention-deficit/hyperactivity disorder in children with comorbid tic disorders.
Topics: Adrenergic alpha-Agonists; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Comorbidity; Contraindications; Dose-Response Relationship, Drug; Double-Blind Method; Humans; Methylphenidate; Propylamines; Psychotropic Drugs; Randomized Controlled Trials as Topic; Tic Disorders; Tourette Syndrome | 2009 |
Use of atomoxetine in patients with attention-deficit hyperactivity disorder and co-morbid conditions.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Clinical Trials as Topic; Comorbidity; Humans; Propylamines | 2009 |
Atomoxetine treatment for ADHD: younger adults compared with older adults.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Adult; Age Factors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Female; Humans; Male; Middle Aged; Propylamines; Treatment Outcome | 2010 |
[Attention Deficit Hyperactivity Disorder (ADHD) and road traffic - special considerations for the treatment of adolescents with ADHD].
Topics: Accidents, Traffic; Adolescent; Adrenergic Uptake Inhibitors; Adult; Amphetamines; Atomoxetine Hydrochloride; Attention; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Female; Germany; Humans; Male; Methylphenidate; Propylamines; Substance Abuse Detection; Young Adult | 2009 |
The neuropharmacology of ADHD drugs in vivo: insights on efficacy and safety.
Topics: Adrenergic Uptake Inhibitors; Amphetamine; Animals; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Brain; Catecholamines; Central Nervous System Stimulants; Dopamine Agents; Humans; Methylphenidate; Propylamines; Stereoisomerism; Substance-Related Disorders | 2009 |
Treating attention-deficit/hyperactivity disorder beyond symptom control alone in children and adolescents: a review of the potential benefits of long-acting stimulants.
Topics: Adolescent; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Delayed-Action Preparations; Humans; Methylphenidate; Personality Development; Propylamines; Quality of Life; Social Perception; Treatment Outcome | 2010 |
Characteristics of placebo responders in pediatric clinical trials of attention-deficit/hyperactivity disorder.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Anxiety Disorders; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Comorbidity; Depressive Disorder, Major; Double-Blind Method; Female; Humans; Male; Multicenter Studies as Topic; Personality Assessment; Placebo Effect; Propylamines; Randomized Controlled Trials as Topic; Research Design | 2009 |
Spotlight on atomoxetine in attention-deficit hyperactivity disorder in children and adolescents.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Clinical Trials as Topic; Economics, Pharmaceutical; Humans; Propylamines | 2010 |
A comparison of the efficacy of medications for adult attention-deficit/hyperactivity disorder using meta-analysis of effect sizes.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Adult; Age Factors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Bupropion; Central Nervous System Stimulants; Diagnostic and Statistical Manual of Mental Disorders; Drug Administration Schedule; Female; Humans; Male; Medication Adherence; Placebos; Propylamines; Psychiatric Status Rating Scales; Randomized Controlled Trials as Topic; Regression Analysis; Research Design; Search Engine; Treatment Outcome | 2010 |
Progress and promise of attention-deficit hyperactivity disorder pharmacogenetics.
Topics: Amphetamine; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Catechol O-Methyltransferase; Central Nervous System Stimulants; Dopamine Plasma Membrane Transport Proteins; Humans; Inactivation, Metabolic; Methylphenidate; Norepinephrine Plasma Membrane Transport Proteins; Propylamines; Receptors, Adrenergic, alpha-2; Receptors, Dopamine D4; Receptors, Dopamine D5; Synaptosomal-Associated Protein 25 | 2010 |
Principles of medical care for children with attention deficit hyperactivity disorder.
Topics: Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child, Preschool; Diagnosis, Differential; Electric Stimulation; Electroencephalography; Humans; Propylamines | 2010 |
Pharmacologic mood destabilization: case vignettes.
Topics: Adult; Affect; Anticonvulsants; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Bipolar Disorder; Central Nervous System Stimulants; Depressive Disorder; Dose-Response Relationship, Drug; Evidence-Based Medicine; Female; Humans; Lamotrigine; Male; Middle Aged; Phenylpropanolamine; Propylamines; Rhinitis, Allergic, Seasonal; Triazines | 2009 |
A current update on ADHD pharmacogenomics.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Catechol O-Methyltransferase; Central Nervous System Stimulants; Child; Dopamine Plasma Membrane Transport Proteins; Humans; Methylphenidate; Pharmacogenetics; Propylamines; Receptors, Adrenergic, alpha-2; Receptors, Dopamine D4 | 2010 |
Pharmacogenetic approach for a better drug treatment in children.
Topics: Adolescent; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Clinical Trials as Topic; Dopamine Plasma Membrane Transport Proteins; Humans; Methylphenidate; Pharmacogenetics; Polymorphism, Genetic; Propylamines; Receptors, Dopamine D4; Selective Serotonin Reuptake Inhibitors; Treatment Outcome | 2010 |
Quality of life and attention-deficit/hyperactivity disorder core symptoms: a pooled analysis of 5 non-US atomoxetine clinical trials.
Topics: Adolescent; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Canada; Child; Clinical Trials as Topic; Europe; Female; Follow-Up Studies; Humans; Male; Propylamines; Quality of Life; Randomized Controlled Trials as Topic; Severity of Illness Index; Treatment Outcome | 2010 |
Attention deficit hyperactivity disorder in adults.
Topics: Adrenergic Uptake Inhibitors; Adult; Age Factors; Amphetamines; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Delayed-Action Preparations; Diagnosis, Differential; Drug Administration Schedule; Humans; Medication Adherence; Methylphenidate; Propylamines; Treatment Outcome | 2010 |
Cardiovascular effects of methylphenidate, amphetamines and atomoxetine in the treatment of attention-deficit hyperactivity disorder.
Topics: Adrenergic Uptake Inhibitors; Amphetamines; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Blood Pressure; Central Nervous System Stimulants; Electrocardiography; Heart Rate; Humans; Methylphenidate; Propylamines | 2010 |
Core ADHD symptom improvement with atomoxetine versus methylphenidate: a direct comparison meta-analysis.
Topics: Adolescent; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Female; Humans; Male; Methylphenidate; Propylamines; Randomized Controlled Trials as Topic; Treatment Outcome | 2011 |
Understanding attention-deficit/hyperactivity disorder from childhood to adulthood.
Topics: Adrenergic alpha-Agonists; Adrenergic Uptake Inhibitors; Anxiety Disorders; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Brain; Central Nervous System Stimulants; Humans; Magnetic Resonance Imaging; Mood Disorders; Propylamines; Psychotherapy; Remedial Teaching; Substance-Related Disorders | 2010 |
Review of pharmacotherapy options for the treatment of attention-deficit/hyperactivity disorder (ADHD) and ADHD-like symptoms in children and adolescents with developmental disorders.
Topics: Adolescent; Amphetamines; Antipsychotic Agents; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Child Development Disorders, Pervasive; Child, Preschool; Clinical Trials as Topic; Clonidine; Comorbidity; Developmental Disabilities; Drug Therapy, Combination; Female; Fetal Alcohol Spectrum Disorders; Humans; Intellectual Disability; Male; Methylphenidate; Pregnancy; Propylamines; Psychotropic Drugs | 2010 |
The neurobiological basis of ADHD.
Topics: Animals; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Basal Ganglia; Behavior Therapy; Brain; Central Nervous System Stimulants; Cerebellum; Dopamine; Dopamine Agents; Dopamine Uptake Inhibitors; Drug Therapy, Combination; Evidence-Based Medicine; Humans; Italy; Methylphenidate; Prefrontal Cortex; Propylamines; Risk Factors; Treatment Outcome | 2010 |
Advances in the treatment of attention-deficit/hyperactivity disorder: a guide for pediatric neurologists.
Topics: Adrenergic alpha-2 Receptor Agonists; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Dextroamphetamine; Guanfacine; Humans; Lisdexamfetamine Dimesylate; Methylphenidate; Propylamines | 2010 |
Pharmacotherapy for child and adolescent attention-deficit hyperactivity disorder.
Topics: Adolescent; Adrenergic alpha-2 Receptor Agonists; Adrenergic Uptake Inhibitors; Amphetamines; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Guanfacine; Humans; Methylphenidate; Propylamines | 2011 |
How oppositionality, inattention, and hyperactivity affect response to atomoxetine versus methylphenidate: a pooled meta-analysis.
Topics: Adolescent; Atomoxetine Hydrochloride; Attention Deficit and Disruptive Behavior Disorders; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Humans; Hyperkinesis; Methylphenidate; Propylamines; Treatment Outcome | 2012 |
Catecholamine influences on prefrontal cortical function: relevance to treatment of attention deficit/hyperactivity disorder and related disorders.
Topics: Adrenergic alpha-2 Receptor Agonists; Adrenergic Uptake Inhibitors; Animals; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Catecholamines; Central Nervous System Stimulants; Dopamine; Guanfacine; Humans; Models, Neurological; Norepinephrine; Prefrontal Cortex; Propylamines; Receptors, Catecholamine | 2011 |
[Towards an understanding of the molecular mechanisms underlying the pharmacological treatments of attention deficit hyperactivity disorder].
Topics: Amphetamines; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Corpus Striatum; Dopamine; Humans; Methylphenidate; Norepinephrine; Prefrontal Cortex; Propylamines | 2011 |
[Autism and ADHD across the life span. Differential diagnoses or comorbidity?].
Topics: Adrenergic Uptake Inhibitors; Antipsychotic Agents; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Brain; Central Nervous System Stimulants; Child; Child Development Disorders, Pervasive; Comorbidity; Diagnosis, Differential; Humans; Propylamines; Risperidone | 2011 |
Catecholamine influences on dorsolateral prefrontal cortical networks.
Topics: Adrenergic alpha-Agonists; Adrenergic Uptake Inhibitors; Animals; Arousal; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Catecholamines; Cognition; Guanfacine; Humans; Memory, Short-Term; Methylphenidate; Models, Neurological; Neural Pathways; Prefrontal Cortex; Propylamines; Synaptic Transmission | 2011 |
[Effectiveness and safety of methylphenidate and atomoxetine for attention deficit hyperactivity disorder: a systematic review].
Topics: Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Delayed-Action Preparations; Humans; Methylphenidate; Propylamines; Randomized Controlled Trials as Topic; Tablets | 2011 |
Cognitive enhancers for the treatment of ADHD.
Topics: Adult; Amphetamine; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Cholinergic Agents; Clonidine; Cognition; Executive Function; Guanfacine; Humans; Intelligence; Methylphenidate; Nootropic Agents; Propylamines; Reward; Social Behavior | 2011 |
[Stimulant and non-stimulant medication in current and future therapy for ADHD].
Topics: Adrenergic alpha-2 Receptor Agonists; Adult; Amphetamines; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Benzhydryl Compounds; Central Nervous System Stimulants; Child; Dextroamphetamine; Fatty Acids, Omega-3; Guanfacine; Histamine Agonists; Humans; Isoxazoles; Lisdexamfetamine Dimesylate; Memantine; Methylphenidate; Modafinil; Off-Label Use; Propylamines; Pyridines; Pyrrolidines; Receptors, AMPA | 2012 |
Long-term outcomes with medications for attention-deficit hyperactivity disorder: current status of knowledge.
Topics: Adrenergic alpha-2 Receptor Agonists; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Clonidine; Delayed-Action Preparations; Guanfacine; Humans; Propylamines; Treatment Outcome | 2011 |
ADHD in children and adolescents.
Topics: Adolescent; Atomoxetine Hydrochloride; Attention Deficit and Disruptive Behavior Disorders; Attention Deficit Disorder with Hyperactivity; Child; Clonidine; Diagnostic and Statistical Manual of Mental Disorders; Double-Blind Method; Humans; Methylphenidate; Schools | 2011 |
Efficacy and tolerability of pharmacotherapies for attention-deficit hyperactivity disorder in adults.
Topics: Adrenergic Uptake Inhibitors; Adult; Animals; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Bupropion; Central Nervous System Stimulants; Humans; Propylamines; Treatment Outcome | 2011 |
Comparative efficacy and acceptability of methylphenidate and atomoxetine in treatment of attention deficit hyperactivity disorder in children and adolescents: a meta-analysis.
Topics: Adolescent; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Humans; Methylphenidate; Propylamines; Treatment Outcome | 2011 |
Psychopharmacological treatment of ADHD symptoms in children with autism spectrum disorder.
Topics: Adrenergic alpha-2 Receptor Agonists; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Child Development Disorders, Pervasive; Clinical Trials as Topic; Humans; Propylamines | 2011 |
[Diagnosis and treatment of attention deficit hyperactivity disorder in adults].
Topics: Adult; Amphetamines; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Automobile Driving; Behavior Therapy; Bupropion; Central Nervous System Stimulants; Combined Modality Therapy; Comorbidity; Dextroamphetamine; Diagnostic Self Evaluation; Educational Status; Female; Humans; Interpersonal Relations; Interview, Psychological; Lisdexamfetamine Dimesylate; Male; Methylphenidate; Neuropsychological Tests; Occupations; Propylamines; Quality of Life; Severity of Illness Index; Symptom Assessment | 2012 |
Management of attention-deficit disorder and attention-deficit/hyperactivity disorder drug intoxication in dogs and cats.
Topics: Adrenergic Uptake Inhibitors; Amphetamines; Animals; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Cat Diseases; Cats; Central Nervous System Stimulants; Dog Diseases; Dogs; Humans; Poison Control Centers; Propylamines | 2012 |
Metabolic, toxicological, and safety considerations for drugs used to treat ADHD.
Topics: Amphetamines; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Clinical Trials as Topic; Clonidine; Comorbidity; Drug Combinations; Drug-Related Side Effects and Adverse Reactions; Guanfacine; Humans; Methylphenidate; Propylamines | 2012 |
Atomoxetine for treating ADHD symptoms in autism: a systematic review.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Autistic Disorder; Child; Child, Preschool; Comorbidity; Humans; Propylamines | 2013 |
ADHD treatments, sleep, and sleep problems: complex associations.
Topics: Adrenergic alpha-2 Receptor Agonists; Adrenergic Uptake Inhibitors; Antipsychotic Agents; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Humans; Propylamines; Sleep; Sleep Wake Disorders | 2012 |
Pharmacological treatment of tic disorders and Tourette Syndrome.
Topics: Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Dopamine Antagonists; Humans; Pimozide; Propylamines; Risperidone; Tiapride Hydrochloride; Tic Disorders; Tourette Syndrome | 2013 |
Long-term efficacy and safety of treatment with stimulants and atomoxetine in adult ADHD: a review of controlled and naturalistic studies.
Topics: Adrenergic Uptake Inhibitors; Adult; Amphetamine; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Cross-Sectional Studies; Humans; Longitudinal Studies; Methylphenidate; Propylamines; Randomized Controlled Trials as Topic | 2013 |
Emotional dysregulation in adult ADHD: What is the empirical evidence?
Topics: Adolescent; Adrenergic Uptake Inhibitors; Adult; Age Factors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Emotions; Evidence-Based Medicine; Humans; Mood Disorders; Propylamines; Social Behavior | 2012 |
Pharmacological and clinical dilemmas of prescribing in co-morbid adult attention-deficit/hyperactivity disorder and addiction.
Topics: Adrenergic Uptake Inhibitors; Adult; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Combined Modality Therapy; Diagnosis, Dual (Psychiatry); Humans; Methylphenidate; Practice Patterns, Physicians'; Propylamines; Psychotherapy; Substance-Related Disorders | 2014 |
Practitioner review: current best practice in the management of adverse events during treatment with ADHD medications in children and adolescents.
Topics: Adolescent; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Blood Pressure; Body Size; Cardiovascular Diseases; Central Nervous System Stimulants; Child; Clonidine; Dextroamphetamine; Growth Disorders; Guanfacine; Heart Rate; Humans; Lisdexamfetamine Dimesylate; Methylphenidate; Propylamines; Psychoses, Substance-Induced; Seizures; Sleep Wake Disorders; Substance-Related Disorders; Suicide Prevention; Tic Disorders; Treatment Outcome | 2013 |
A review of the abuse potential assessment of atomoxetine: a nonstimulant medication for attention-deficit/hyperactivity disorder.
Topics: Adrenergic Uptake Inhibitors; Animals; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Behavior, Addictive; Drug-Seeking Behavior; Humans; Norepinephrine Plasma Membrane Transport Proteins; Propylamines; Protein Binding; Receptors, Neurotransmitter; Substance-Related Disorders | 2013 |
Drugs under investigation for attention-deficit hyperactivity disorder.
Topics: Animals; Antidepressive Agents; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Benzhydryl Compounds; Central Nervous System Stimulants; Clinical Trials as Topic; Cyclobutanes; Donepezil; Histamine Agonists; Humans; Indans; Modafinil; Nootropic Agents; Piperidines; Propylamines | 2002 |
Overview and neurobiology of attention-deficit/hyperactivity disorder.
Topics: Adult; Age Factors; Antidepressive Agents; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Brain; Child; Diagnosis, Differential; Diseases in Twins; Female; Global Health; Humans; Magnetic Resonance Imaging; Prefrontal Cortex; Pregnancy; Prevalence; Propylamines; Risk Factors | 2002 |
Novel treatments for attention-deficit/hyperactivity disorder in children.
Topics: Adolescent; Age Factors; Amphetamine; Antidepressive Agents, Tricyclic; Antihypertensive Agents; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Bupropion; Central Nervous System Stimulants; Child; Dextroamphetamine; Drug Administration Schedule; Humans; Meta-Analysis as Topic; Monoamine Oxidase Inhibitors; Propylamines; Psychiatric Status Rating Scales; Research Design; Selective Serotonin Reuptake Inhibitors | 2002 |
Safety profile of atomoxetine in the treatment of children and adolescents with ADHD.
Topics: Adolescent; Age Factors; Antidepressive Agents; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Blood Pressure; Body Weight; Child; Clinical Trials as Topic; Cytochrome P-450 CYP2D6; Electrocardiography; Feeding and Eating Disorders; Headache; Humans; Placebos; Propylamines; Pulse; Treatment Outcome | 2002 |
Non-stimulant treatment of attention-deficit/hyperactivity disorder.
Topics: Adrenergic alpha-Agonists; Antidepressive Agents; Antidepressive Agents, Tricyclic; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Benzhydryl Compounds; Bupropion; Child; Clinical Trials as Topic; Humans; Modafinil; Practice Guidelines as Topic; Propylamines; Treatment Outcome | 2003 |
Atomoxetine.
Topics: Adolescent; Animals; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Biological Availability; Body Weight; Child; Drug Administration Schedule; Half-Life; Humans; Intestinal Absorption; Propylamines; Randomized Controlled Trials as Topic; Tissue Distribution | 2003 |
Atomoxetine: a selective noradrenaline reuptake inhibitor for the treatment of attention-deficit/hyperactivity disorder.
Topics: Absorption; Adolescent; Adult; Area Under Curve; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Clinical Trials as Topic; Half-Life; Humans; Propylamines; Treatment Outcome | 2003 |
Cardiovascular effects of atomoxetine in children, adolescents, and adults.
Topics: Adolescent; Adult; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Blood Pressure; Child; Double-Blind Method; Electrocardiography; Female; Heart Conduction System; Hemodynamics; Humans; Male; Propylamines; Randomized Controlled Trials as Topic | 2003 |
Pharmacological treatments for ADHD and the novel agent atomoxetine.
Topics: Adult; Antidepressive Agents; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Multicenter Studies as Topic; Propylamines; Randomized Controlled Trials as Topic; Treatment Outcome; United States | 2003 |
The use of antidepressants to treat attention deficit hyperactivity disorder in adults.
Topics: Adult; Antidepressive Agents; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Bupropion; Clinical Trials as Topic; Cyclohexanols; Humans; Propylamines; Venlafaxine Hydrochloride | 2003 |
[Medical treatments of hyperactive child].
Topics: Antidepressive Agents; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Central Nervous System Stimulants; Child; Combined Modality Therapy; Humans; Methylphenidate; Propylamines | 2004 |
Atomoxetine: a review of its use in adults with attention deficit hyperactivity disorder.
Topics: Adrenergic Uptake Inhibitors; Animals; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Clinical Trials as Topic; Humans; Norepinephrine; Propylamines; Treatment Outcome | 2004 |
Evidence-based pharmacotherapy for attention-deficit hyperactivity disorder.
Topics: Adrenergic alpha-Agonists; Adrenergic Uptake Inhibitors; Adult; Antidepressive Agents; Antidepressive Agents, Second-Generation; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Bupropion; Central Nervous System Stimulants; Child; Clonidine; Delayed-Action Preparations; Evidence-Based Medicine; Guanfacine; Humans; Methylphenidate; Propylamines | 2004 |
Atomoxetine treatment of attention-deficit/hyperactivity disorder.
Topics: Administration, Oral; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Capsules; Drug Interactions; Humans; Propylamines | 2004 |
Atomoxetine hydrochloride for the treatment of attention-deficit/hyperactivity disorder.
Topics: Adolescent; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Clinical Trials as Topic; Drug Interactions; Female; Humans; Male; Propylamines | 2003 |
Impact of ADHD and its treatment on substance abuse in adults.
Topics: Adult; Antidepressive Agents, Second-Generation; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Bupropion; Central Nervous System Stimulants; Combined Modality Therapy; Humans; Propylamines; Psychotherapy; Risk Factors; Self Medication; Substance-Related Disorders | 2004 |
Spotlight on atomoxetine in adults with attention-deficit hyperactivity disorder.
Topics: Administration, Oral; Adrenergic Uptake Inhibitors; Adult; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Dose-Response Relationship, Drug; Drug Evaluation; Drug Tolerance; Humans; Propylamines; Treatment Outcome | 2004 |
Pharmacological management of attention-deficit hyperactivity disorder.
Topics: Adrenergic alpha-Agonists; Amphetamines; Antidepressive Agents; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Bupropion; Central Nervous System Stimulants; Child; Clonidine; Guanfacine; Humans; Methylphenidate; Propylamines | 2004 |
Improvement in health-related quality of life in children with ADHD: an analysis of placebo controlled studies of atomoxetine.
Topics: Adolescent; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Female; Humans; Male; Propylamines; Quality of Life; Randomized Controlled Trials as Topic; Surveys and Questionnaires; Treatment Outcome | 2004 |
Atomoxetine--treatment of attention deficit hyperactivity disorder: beyond stimulants.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Clinical Trials as Topic; Drug Interactions; Humans; Propylamines; Receptors, Adrenergic; Treatment Outcome | 2004 |
Non-stimulant medications in the treatment of ADHD.
Topics: Antidepressive Agents, Tricyclic; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Drug Interactions; Drug Tolerance; Humans; Norepinephrine; Propylamines | 2004 |
Atomoxetine, a novel treatment for attention-deficit-hyperactivity disorder.
Topics: Adolescent; Adult; Animals; Area Under Curve; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Female; Half-Life; Humans; Intestinal Absorption; Male; Pregnancy; Propylamines; Randomized Controlled Trials as Topic; Severity of Illness Index; Tissue Distribution; Treatment Outcome | 2004 |
New options in the pharmacological management of attention-deficit/hyperactivity disorder.
Topics: Adolescent; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Humans; Mental Disorders; Propylamines; United States | 2004 |
[Atomoxetine for the treatment of attention-deficit/hyperactivity disorder].
Topics: Adolescent; Adrenergic Uptake Inhibitors; Adult; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Clinical Trials as Topic; Device Approval; Female; Humans; Male; Propylamines; Randomized Controlled Trials as Topic; Research Design; United States; United States Food and Drug Administration | 2004 |
New drugs for the treatment of attention-deficit/hyperactivity disorder.
Topics: Amphetamines; Antidepressive Agents; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Humans; Methylphenidate; Propylamines | 2004 |
Atomoxetine: the first nonstimulant for the management of attention-deficit/hyperactivity disorder.
Topics: Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Clinical Trials as Topic; Humans; Propylamines | 2004 |
A new paradigm for developing drugs in children: atomoxetine as a model.
Topics: Age Factors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Drug Design; Humans; Propylamines | 2005 |
Atomoxetine: a new pharmacotherapeutic approach in the management of attention deficit/hyperactivity disorder.
Topics: Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Double-Blind Method; Humans; Propylamines; Randomized Controlled Trials as Topic | 2005 |
Pharmacotherapy of adult ADHD.
Topics: Adolescent; Adult; Age Factors; Amphetamine; Antidepressive Agents; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Central Nervous System Stimulants; Child; Combined Modality Therapy; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Male; Methylphenidate; Propylamines; Treatment Outcome | 2005 |
The safety of non-stimulant agents for the treatment of attention-deficit hyperactivity disorder.
Topics: Adrenergic alpha-Agonists; Adult; Antidepressive Agents, Tricyclic; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Bupropion; Child; Clonidine; Desipramine; Guanfacine; Humans; Imipramine; Nortriptyline; Propylamines | 2005 |
Update: attention deficit/hyperactivity disorder in the primary care office.
Topics: Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Dental Caries; Diagnosis, Differential; Diet; Dietary Supplements; Enuresis; Ferritins; Gene Expression; Humans; Monitoring, Physiologic; Primary Health Care; Propylamines; Treatment Outcome | 2005 |
Treatment of attention deficit hyperactivity disorder in adults.
Topics: Antidepressive Agents; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Clinical Trials as Topic; Cognitive Behavioral Therapy; Drug Therapy; Drug Therapy, Combination; Expert Testimony; Humans; Nicotine; Propylamines; Substance-Related Disorders | 2005 |
Atomoxetine in the treatment of attention deficit hyperactivity disorder.
Topics: Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Humans; Mental Disorders; Propylamines | 2004 |
Clinical pharmacokinetics of atomoxetine.
Topics: Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Chemical Phenomena; Chemistry, Physical; Child; Drug Interactions; Humans; Propylamines | 2005 |
Treatment of attention-deficit/hyperactivity disorder: overview of the evidence.
Topics: Adolescent; Antidepressive Agents, Tricyclic; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Caregivers; Central Nervous System Stimulants; Child; Combined Modality Therapy; Dextroamphetamine; Evidence-Based Medicine; Family; Female; Humans; Male; Methylphenidate; Norepinephrine Plasma Membrane Transport Proteins; Pemoline; Practice Guidelines as Topic; Propylamines; Randomized Controlled Trials as Topic; Stress, Psychological; Symporters | 2005 |
Attention-deficit/hyperactivity disorder among adolescents: a review of the diagnosis, treatment, and clinical implications.
Topics: Adolescent; Antidepressive Agents; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Automobile Driving; Case Management; Central Nervous System Stimulants; Child; Clonidine; Comorbidity; Continuity of Patient Care; Family Health; Female; Forecasting; Health Services Accessibility; Humans; Insurance Coverage; Intellectual Disability; Male; Mental Disorders; Patient Compliance; Propylamines; Puberty; Risk; Substance-Related Disorders | 2005 |
Righting a troubled course. Diagnosing and treating ADHD in adults.
Topics: Adult; Age Factors; Amphetamine; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Comorbidity; Humans; Methylphenidate; Nurse Practitioners; Nursing Assessment; Practice Guidelines as Topic; Primary Health Care; Propylamines | 2005 |
[The effectiveness of atomoxetine in children, adolescents, and adults with ADHD. A systematic overview].
Topics: Adolescent; Adrenergic Uptake Inhibitors; Adult; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Clinical Trials as Topic; Humans; Methylphenidate; Norepinephrine Plasma Membrane Transport Proteins; Propylamines; United States; United States Food and Drug Administration | 2006 |
Attention deficit hyperactivity disorder in children.
Topics: Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Clonidine; Combined Modality Therapy; Dextroamphetamine; Humans; Methylphenidate; Propylamines; Psychotherapy | 2005 |
Nonstimulant therapies for attention-deficit hyperactivity disorder (ADHD) in children and adults.
Topics: Adrenergic Uptake Inhibitors; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Benzhydryl Compounds; Bupropion; Child; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Modafinil; Propylamines; Psychotherapy; Psychotropic Drugs | 2005 |
Pharmacotherapy of attention-deficit hyperactivity disorder in children and adolescents: update on new stimulant preparations, atomoxetine, and novel treatments.
Topics: Adolescent; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Delayed-Action Preparations; Humans; Methylphenidate; Norepinephrine; Propylamines | 2006 |
Attention deficit hyperactivity disorder--a review for family physicians.
Topics: Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Central Nervous System Stimulants; Child; Combined Modality Therapy; Comorbidity; Early Diagnosis; Family Practice; Humans; Methylphenidate; Propylamines | 2005 |
Managing adverse reactions to psychotropic medications.
Topics: Adolescent; Anticonvulsants; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Death, Sudden; Depressive Disorder; Humans; Poisoning; Propylamines; Psychotropic Drugs; Suicide, Attempted; Valproic Acid | 2005 |
Do children and adolescents with ADHD respond differently to atomoxetine?
Topics: Adolescent; Age Factors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Female; Humans; Male; Propylamines; Randomized Controlled Trials as Topic; Safety | 2006 |
Attention deficit hyperactivity disorder, tics and Tourette's syndrome: the relationship and treatment implications. A commentary.
Topics: Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Humans; Methylphenidate; Propylamines; Tics; Tourette Syndrome | 2006 |
Close up on atomoxetine: a nonstimulant choice for treating ADHD.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Adult; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Body Weight; Central Nervous System Stimulants; Chemical and Drug Induced Liver Injury; Child; Choice Behavior; Drug Administration Schedule; Drug Interactions; Drug Labeling; Humans; Nursing Assessment; Patient Selection; Practice Guidelines as Topic; Propylamines; Risk Factors; Suicide; Treatment Outcome | 2006 |
Attention deficit/hyperactivity disorder: complexities and controversies.
Topics: Administration, Cutaneous; Amphetamines; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Behavior; Central Nervous System Stimulants; Child; Dose-Response Relationship, Drug; Humans; Methylphenidate; Propylamines; Risk Factors | 2006 |
Long-acting medications for the hyperkinetic disorders. A systematic review and European treatment guideline.
Topics: Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Delayed-Action Preparations; Europe; Humans; Propylamines | 2006 |
Pharmacological treatment of attention-deficit/hyperactivity disorder in adults.
Topics: Adrenergic Uptake Inhibitors; Adult; Antidepressive Agents, Tricyclic; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Desipramine; Drug Administration Schedule; Drug Therapy, Combination; Humans; Methylphenidate; Propylamines; Randomized Controlled Trials as Topic | 2006 |
Atomoxetine versus stimulants for treatment of attention deficit/hyperactivity disorder.
Topics: Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Clinical Trials as Topic; Humans; Propylamines; Substance-Related Disorders | 2006 |
A systematic review and economic model of the effectiveness and cost-effectiveness of methylphenidate, dexamfetamine and atomoxetine for the treatment of attention deficit hyperactivity disorder in children and adolescents.
Topics: Adolescent; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Child, Preschool; Cost-Benefit Analysis; Dextroamphetamine; Humans; Methylphenidate; Models, Economic; Propylamines; Treatment Outcome | 2006 |
Long-term atomoxetine treatment in adolescents with attention-deficit/hyperactivity disorder.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Clinical Trials as Topic; Databases as Topic; Dose-Response Relationship, Drug; Female; Humans; Male; Propylamines; Psychiatric Status Rating Scales; Treatment Outcome | 2006 |
Effects of long-term atomoxetine treatment for young children with attention-deficit/hyperactivity disorder.
Topics: Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Female; Humans; Male; Propylamines; Time Factors | 2006 |
Atomoxetine.
Topics: Administration, Oral; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Humans; Methylphenidate; Propylamines | 2006 |
Mechanism of action of agents used in attention-deficit/hyperactivity disorder.
Topics: Adrenergic alpha-Agonists; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Bupropion; Central Nervous System Stimulants; Child; Clonidine; Guanfacine; Humans; Nicotinic Antagonists; Pharmacogenetics; Propylamines | 2006 |
Primary care treatment of attention-deficit/hyperactivity disorder.
Topics: Adult; Age Factors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Attitude to Health; Bupropion; Central Nervous System Stimulants; Child; Combined Modality Therapy; Comorbidity; Family Health; Humans; Parents; Physicians, Family; Primary Health Care; Professional-Family Relations; Propylamines; Psychiatric Status Rating Scales; Psychotherapy; Teaching | 2006 |
Attention deficit hyperactivity disorder in children.
Topics: Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Clonidine; Combined Modality Therapy; Dextroamphetamine; Humans; Methylphenidate; Propylamines; Psychotherapy | 2006 |
Meta-analysis of aggression or hostility events in randomized, controlled clinical trials of atomoxetine for ADHD.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Aged; Aggression; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Databases as Topic; Double-Blind Method; Female; Hostility; Humans; Male; Methylphenidate; Middle Aged; Odds Ratio; Proportional Hazards Models; Propylamines | 2007 |
Drugs for treatment of ADHD.
Topics: Adrenergic Uptake Inhibitors; Adult; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Dosage Forms; Drug Interactions; Humans; Propylamines | 2006 |
Effect of comorbid symptoms of oppositional defiant disorder on responses to atomoxetine in children with ADHD: a meta-analysis of controlled clinical trial data.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit and Disruptive Behavior Disorders; Attention Deficit Disorder with Hyperactivity; Child; Comorbidity; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Personality Assessment; Propylamines; Quality of Life; Randomized Controlled Trials as Topic; Statistics as Topic | 2007 |
Pharmacologic treatment of attention-deficit/hyperactivity disorder: efficacy, safety and mechanisms of action.
Topics: Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Decision Trees; Humans; Neurotransmitter Agents; Propylamines | 2007 |
Treating common psychiatric disorders associated with attention-deficit/hyperactivity disorder.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Antidepressive Agents, Second-Generation; Anxiety Disorders; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Bupropion; Child; Comorbidity; Depressive Disorder, Major; Humans; Mental Disorders; Prevalence; Propylamines | 2007 |
[My child is so restless].
Topics: Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Biofeedback, Psychology; Central Nervous System Stimulants; Child; Counseling; Diagnosis, Differential; Humans; Methylphenidate; Propylamines; Time Factors | 2007 |
Update on drugs for hyperactivity in childhood.
Topics: Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Delayed-Action Preparations; Dextroamphetamine; Drug Costs; Humans; Methylphenidate; Propylamines; Treatment Outcome | 2007 |
Efficacy and safety of atomoxetine for attention-deficit/hyperactivity disorder in children and adolescents-meta-analysis and meta-regression analysis.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Female; Humans; Male; Propylamines; Quality of Life; Randomized Controlled Trials as Topic; Regression Analysis; Sex Factors; Treatment Outcome | 2007 |
Management of attention-deficit/hyperactivity disorder.
Topics: Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Complementary Therapies; Diet; Forecasting; Humans; Patient Care Planning; Practice Guidelines as Topic; Propylamines; Psychotherapy; School Health Services; Treatment Outcome | 2007 |
ADHD in children, adolescents, and adults.
Topics: Adolescent; Adult; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Behavioral Medicine; Central Nervous System Stimulants; Child; Comorbidity; Family Practice; Humans; Methylphenidate; Pediatrics; Primary Health Care; Propylamines; Risk Factors | 2007 |
Non-stimulant trials of adult ADHD.
Topics: Adult; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Clinical Trials as Topic; Drug Approval; Humans; Propylamines; Psychotropic Drugs | 2007 |
[Attention deficit hyperactivity disorders in children and adolescents: diagnostic and therapeutic guidelines].
Topics: Adolescent; Adrenergic Uptake Inhibitors; Amphetamines; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Cognitive Behavioral Therapy; Combined Modality Therapy; Diagnosis, Differential; Humans; Practice Guidelines as Topic; Propylamines; Psychotropic Drugs; Surveys and Questionnaires; Time Factors | 2007 |
Children with autism spectrum disorders and intellectual disability.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Autistic Disorder; Central Nervous System Stimulants; Child; Humans; Intellectual Disability; Methylphenidate; Prevalence; Propylamines | 2007 |
Exposure to attention deficit hyperactivity disorder medications during pregnancy.
Topics: Abnormalities, Drug-Induced; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Congenital Abnormalities; Decision Making; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Infant, Newborn; Methylphenidate; Pregnancy; Pregnancy Complications; Propylamines; Risk Assessment | 2007 |
The consequences of attention-deficit/hyperactivity disorder in adults.
Topics: Achievement; Adult; Age Factors; Amphetamine; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Cognitive Behavioral Therapy; Combined Modality Therapy; Comorbidity; Disease Progression; Female; Health Care Costs; Humans; Impulsive Behavior; Male; Mental Disorders; Methylphenidate; Propylamines; Quality of Life; Sex Distribution; Social Adjustment; Substance-Related Disorders | 2007 |
[Pharmacotherapy of attention-deficit/hyperactivity disorder (ADHD) and comorbid disorders].
Topics: Adrenergic Uptake Inhibitors; Antipsychotic Agents; Anxiety Disorders; Atomoxetine Hydrochloride; Attention Deficit and Disruptive Behavior Disorders; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Comorbidity; Contraindications; Cross-Sectional Studies; Drug Therapy, Combination; Humans; Mood Disorders; Nortriptyline; Practice Guidelines as Topic; Propylamines; Randomized Controlled Trials as Topic; Tic Disorders | 2007 |
Comparative benefits and harms of competing medications for adults with attention-deficit hyperactivity disorder: a systematic review and indirect comparison meta-analysis.
Topics: Adrenergic Uptake Inhibitors; Adult; Adverse Drug Reaction Reporting Systems; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Bupropion; Central Nervous System Stimulants; Controlled Clinical Trials as Topic; Delayed-Action Preparations; Dopamine Uptake Inhibitors; Humans; Propylamines; Psychotropic Drugs; Treatment Outcome | 2008 |
Psychopharmacological treatment for very young children: contexts and guidelines.
Topics: Algorithms; Amphetamines; Antidepressive Agents; Antipsychotic Agents; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child Psychiatry; Child, Preschool; Drug Prescriptions; Humans; Mental Disorders; Methylphenidate; Propylamines; Psychopharmacology; Risperidone | 2007 |
Changes and challenges: managing ADHD in a fast-paced world.
Topics: Algorithms; Antihypertensive Agents; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Benzhydryl Compounds; Central Nervous System Stimulants; Child; Comorbidity; Drug Delivery Systems; Family; Guanfacine; Humans; Modafinil; Patient Compliance; Prodrugs; Propylamines; Quality of Life; Randomized Controlled Trials as Topic; Substance-Related Disorders; Treatment Outcome | 2007 |
Use of medication in children with psychiatric disorders.
Topics: Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Child Psychiatry; Drug Prescriptions; Drug Utilization; Fluoxetine; Fluvoxamine; Health Policy; Humans; Melatonin; Mental Disorders; Methylphenidate; Needs Assessment; Patient Selection; Practice Guidelines as Topic; Practice Patterns, Physicians'; Propylamines; Psychotropic Drugs; Risperidone; Sertraline; United Kingdom | 2007 |
Switching from neurostimulant therapy to atomoxetine in children and adolescents with attention-deficit hyperactivity disorder : clinical approaches and review of current available evidence.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Humans; Practice Guidelines as Topic; Propylamines; Treatment Outcome | 2008 |
[Pharmacotherapy of adult Attention Deficit/Hyperactivity Disorder (ADHD): a systematic review].
Topics: Adrenergic Uptake Inhibitors; Adult; Antidepressive Agents, Second-Generation; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Bupropion; Controlled Clinical Trials as Topic; Dopamine Uptake Inhibitors; Double-Blind Method; Female; Humans; Male; Propylamines | 2007 |
Meta-analysis of suicide-related behavior events in patients treated with atomoxetine.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Adverse Drug Reaction Reporting Systems; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Controlled Clinical Trials as Topic; Cross-Sectional Studies; Double-Blind Method; Female; Humans; Male; Propylamines; Suicide, Attempted | 2008 |
Adverse effects of pharmacotherapies for attention-deficit hyperactivity disorder: epidemiology, prevention and management.
Topics: Antidepressive Agents; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Cardiovascular Diseases; Central Nervous System Stimulants; Clinical Trials as Topic; Growth Disorders; Humans; Mental Disorders; Nervous System Diseases; Propylamines | 2008 |
Has NICE got it right? An international perspective considering the case of Technology Appraisal No. 98 by the National Institute for Health and Clinical Excellence (NICE).
Topics: Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Cost-Benefit Analysis; Dextroamphetamine; Germany; Humans; Internationality; Methylphenidate; Propylamines; Quality-Adjusted Life Years; Technology Assessment, Biomedical; United States | 2008 |
Understanding the risk of using medications for attention deficit hyperactivity disorder with respect to physical growth and cardiovascular function.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Appetite; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Blood Pressure; Body Height; Central Nervous System Stimulants; Child; Child, Preschool; Controlled Clinical Trials as Topic; Death, Sudden, Cardiac; Electrocardiography; Heart Rate; Humans; Long-Term Care; Methylphenidate; Propylamines; Risk Factors | 2008 |
Pharmacologic treatment of ADHD: road conditions in driving patients to successful outcomes.
Topics: Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Clinical Trials as Topic; Dextroamphetamine; Humans; Lisdexamfetamine Dimesylate; Practice Patterns, Physicians'; Prodrugs; Propylamines; Treatment Outcome | 2008 |
Medication options when treating children and adolescents with ADHD: interpreting the NICE guidance 2006.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Child, Preschool; Dextroamphetamine; Humans; Methylphenidate; Practice Guidelines as Topic; Propylamines | 2008 |
Beyond the 'typical' patient: treating attention-deficit/hyperactivity disorder in preschoolers and adults.
Topics: Adult; Age Factors; Age of Onset; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child, Preschool; Cognitive Behavioral Therapy; Comorbidity; Humans; Mental Disorders; Methylphenidate; Propylamines; Psychology | 2008 |
New perspectives from microdialysis studies in freely-moving, spontaneously hypertensive rats on the pharmacology of drugs for the treatment of ADHD.
Topics: Amphetamine; Animals; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Disease Models, Animal; Dopamine; Humans; Methylphenidate; Microdialysis; Norepinephrine; Propylamines; Rats; Rats, Inbred SHR; Rats, Inbred WKY | 2008 |
[What's new about hyperactivity disorder in children?].
Topics: Adrenergic Uptake Inhibitors; Age Factors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Child, Preschool; Cognitive Behavioral Therapy; Combined Modality Therapy; Delayed-Action Preparations; Drug Combinations; Ferrous Compounds; France; Humans; Methylphenidate; Mucins; Propylamines; Psychotherapy; Speech Therapy; Time Factors | 2008 |
Adults with attention-deficit/hyperactivity disorder: a controversial diagnosis.
Topics: Adolescent; Adult; Age Factors; Antidepressive Agents; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Clinical Trials as Topic; Comorbidity; Desipramine; Humans; Mental Disorders; Methylphenidate; Propylamines; Reproducibility of Results; Retrospective Studies; Severity of Illness Index; Syndrome | 1998 |
New treatments and approaches for attention deficit hyperactivity disorder.
Topics: Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Clinical Trials as Topic; Drug Therapy; Humans; Propylamines | 2001 |
Tomoxetine (Eli Lilly & Co).
Topics: Animals; Antidepressive Agents; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Depression; Drug Industry; Drugs, Investigational; Humans; Propylamines; Structure-Activity Relationship; Treatment Outcome | 2002 |
209 trial(s) available for atomoxetine hydrochloride and ADDH
| Article | Year |
|---|---|
Coenzyme Q10 in the Treatment of Attention Deficit Hyperactivity Disorder in Children: A Randomized Controlled Trial.
Topics: Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Double-Blind Method; Humans; Propylamines; Treatment Outcome; Ubiquinone | 2022 |
Atomoxetine in comorbid ADHD/PTSD: A randomized, placebo controlled, pilot, and feasibility study.
Topics: Adrenergic Uptake Inhibitors; Adult; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Cross-Over Studies; Double-Blind Method; Feasibility Studies; Humans; Propylamines; Quality of Life; Stress Disorders, Post-Traumatic; Treatment Outcome | 2022 |
Single-dose effects of methylphenidate and atomoxetine on functional connectivity during an n-back task in boys with ADHD.
Topics: Adolescent; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Brain; Central Nervous System Stimulants; Child; Frontal Lobe; Humans; Magnetic Resonance Imaging; Male; Methylphenidate | 2023 |
Assessment of probiotic strain Lactobacillus acidophilus LB supplementation as adjunctive management of attention-deficit hyperactivity disorder in children and adolescents: a randomized controlled clinical trial.
Topics: Adolescent; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Dietary Supplements; Humans; Lactobacillus; Lactobacillus acidophilus; Probiotics; Treatment Outcome | 2023 |
Role of the norepinephrine transporter polymorphisms in atomoxetine treatment: From response to side effects in children with ADHD.
Topics: Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Humans; Norepinephrine Plasma Membrane Transport Proteins; Polymorphism, Single Nucleotide; Treatment Outcome | 2022 |
Adverse Events of Atomoxetine in a Double-Blind Placebo-Controlled Study in Children with Autism.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Appetite; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Autism Spectrum Disorder; Child; Child, Preschool; Double-Blind Method; Fatigue; Female; Humans; Male; Parents | 2017 |
Striatal Activation Predicts Differential Therapeutic Responses to Methylphenidate and Atomoxetine.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Caudate Nucleus; Central Nervous System Stimulants; Child; Female; Humans; Inhibition, Psychological; Magnetic Resonance Imaging; Male; Methylphenidate; Motor Cortex | 2017 |
Neural correlates of atomoxetine improving inhibitory control and visual processing in Drug-naïve adults with attention-deficit/hyperactivity disorder.
Topics: Adrenergic Uptake Inhibitors; Adult; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Brain; Brain Mapping; Double-Blind Method; Female; Humans; Inhibition, Psychological; Magnetic Resonance Imaging; Male; Motor Activity; Neuropsychological Tests; Psychiatric Status Rating Scales; Psychotropic Drugs; Treatment Outcome; Visual Perception | 2017 |
A Signature of Attention-Elicited Electrocortical Activity Distinguishes Response From Non-Response to the Non-Stimulant Atomoxetine in Children and Adolescents With ADHD.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention; Attention Deficit Disorder with Hyperactivity; Biomarkers; Brain Mapping; Central Nervous System Stimulants; Child; Cross-Over Studies; Double-Blind Method; Electroencephalography; Evoked Potentials; Female; Humans; Male; Sensitivity and Specificity | 2019 |
Atomoxetine, Parent Training, and Their Effects on Sleep in Youth with Autism Spectrum Disorder and Attention-Deficit/Hyperactivity Disorder.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Autism Spectrum Disorder; Child; Child, Preschool; Female; Humans; Male; Parents; Sleep; Surveys and Questionnaires; Treatment Outcome | 2018 |
Mindfulness vs psychoeducation in adult ADHD: a randomized controlled trial.
Topics: Adrenergic Uptake Inhibitors; Adult; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Female; Follow-Up Studies; Humans; Male; Middle Aged; Mindfulness; Patient Education as Topic; Psychiatric Status Rating Scales; Self Report; Severity of Illness Index; Sex Characteristics; Treatment Outcome | 2018 |
QTc prolongation after ADHD medication.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Arrhythmias, Cardiac; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Dose-Response Relationship, Drug; Female; Heart Rate; Humans; Male; Methylphenidate; Slovakia | 2018 |
Efficacy of Hippotherapy Versus Pharmacotherapy in Attention-Deficit/Hyperactivity Disorder: A Randomized Clinical Trial.
Topics: Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Child Behavior; Electroencephalography; Equine-Assisted Therapy; Female; Humans; Male; Methylphenidate | 2018 |
Response inhibition and emotional cognition improved by atomoxetine in children and adolescents with ADHD: The ACTION randomized controlled trial.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Anxiety Disorders; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Cognition Disorders; Cohort Studies; Cross-Over Studies; Double-Blind Method; Female; Humans; Inhibition, Psychological; Male; Psychiatric Status Rating Scales; Treatment Outcome | 2018 |
A 1.5-Year Follow-Up of Parent Training and Atomoxetine for Attention-Deficit/Hyperactivity Disorder Symptoms and Noncompliant/Disruptive Behavior in Autism.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Autism Spectrum Disorder; Child; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Parents; Problem Behavior; Psychiatric Status Rating Scales; Surveys and Questionnaires; Treatment Outcome | 2018 |
Comparative Efficacy of Methylphenidate and Atomoxetine on Emotional and Behavioral Problems in Youths with Attention-Deficit/Hyperactivity Disorder.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Emotions; Female; Humans; Male; Methylphenidate; Problem Behavior; Surveys and Questionnaires | 2019 |
Changes in serum miRNA-let-7 level in children with attention deficit hyperactivity disorder treated by repetitive transcranial magnetic stimulation or atomoxetine: An exploratory trial.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Biomarkers; Child; Double-Blind Method; Female; Humans; Male; MicroRNAs; Transcranial Magnetic Stimulation; Treatment Outcome | 2019 |
Methylphenidate and atomoxetine normalise fronto-parietal underactivation during sustained attention in ADHD adolescents.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention; Attention Deficit Disorder with Hyperactivity; Brain; Central Nervous System Stimulants; Child; Cross-Over Studies; Double-Blind Method; Functional Neuroimaging; Humans; Magnetic Resonance Imaging; Male; Methylphenidate; Neural Pathways; Neuropsychological Tests | 2019 |
An Open-Label, Randomized Trial of Methylphenidate and Atomoxetine Treatment in Adults With ADHD.
Topics: Adolescent; Adult; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Male; Medication Adherence; Methylphenidate; Middle Aged; Psychiatric Status Rating Scales; Quality of Life; Treatment Outcome; Young Adult | 2017 |
Long-term treatment with atomoxetine for attention-deficit/hyperactivity disorder symptoms in children and adolescents with autism spectrum disorder: an open-label extension study.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Child Development Disorders, Pervasive; Double-Blind Method; Female; Humans; Male; Propylamines; Psychiatric Status Rating Scales; Time Factors | 2013 |
Drug-specific laterality effects on frontal lobe activation of atomoxetine and methylphenidate in attention deficit hyperactivity disorder boys during working memory.
Topics: Adolescent; Analysis of Variance; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Basal Ganglia; Brain Mapping; Child; Cross-Over Studies; Double-Blind Method; Frontal Lobe; Functional Laterality; Humans; Magnetic Resonance Imaging; Male; Memory, Short-Term; Methylphenidate; Neuropsychological Tests; Neurotransmitter Uptake Inhibitors; Placebos; Prefrontal Cortex; Propylamines | 2014 |
A head-to-head randomized clinical trial of methylphenidate and atomoxetine treatment for executive function in adults with attention-deficit hyperactivity disorder.
Topics: Adrenergic Uptake Inhibitors; Adult; Atomoxetine Hydrochloride; Attention; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Chi-Square Distribution; Dopamine Uptake Inhibitors; Executive Function; Female; Humans; Linear Models; Male; Memory, Short-Term; Methylphenidate; Neuropsychological Tests; Propylamines; Taiwan; Time Factors; Treatment Outcome; Visual Perception | 2013 |
Fast vs. slow switching from stimulants to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Female; Humans; Male; Propylamines; Psychiatric Status Rating Scales; Time Factors; Treatment Failure; Treatment Outcome | 2013 |
Neurofunctional effects of methylphenidate and atomoxetine in boys with attention-deficit/hyperactivity disorder during time discrimination.
Topics: Adolescent; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Brain; Brain Mapping; Cross-Over Studies; Discrimination, Psychological; Double-Blind Method; Humans; Magnetic Resonance Imaging; Male; Methylphenidate; Prefrontal Cortex; Propylamines; Time Factors | 2013 |
Open-label, dose-titration tolerability study of atomoxetine hydrochloride in Korean, Chinese, and Taiwanese adults with attention-deficit/hyperactivity disorder.
Topics: Administration, Oral; Adrenergic Uptake Inhibitors; Adult; Aged; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; China; Drug Administration Schedule; Female; Humans; Male; Medication Adherence; Middle Aged; Propylamines; Republic of Korea; Taiwan; Treatment Outcome | 2014 |
Combination use of atomoxetine hydrochloride and olanzapine in the treatment of attention-deficit/hyperactivity disorder with comorbid disruptive behavior disorder in children and adolescents 10-18 years of age.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Aggression; Antipsychotic Agents; Atomoxetine Hydrochloride; Attention Deficit and Disruptive Behavior Disorders; Attention Deficit Disorder with Hyperactivity; Benzodiazepines; Child; Drug Therapy, Combination; Female; Humans; Male; Olanzapine; Propylamines; Time Factors; Treatment Outcome; Weight Gain | 2013 |
Efficacy and safety of lisdexamfetamine dimesylate and atomoxetine in the treatment of attention-deficit/hyperactivity disorder: a head-to-head, randomized, double-blind, phase IIIb study.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Blood Pressure; Child; Dextroamphetamine; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Lisdexamfetamine Dimesylate; Male; Propylamines; Treatment Outcome | 2013 |
Long-term quality-of-life and functioning comparison of atomoxetine versus other standard treatment in pediatric attention-deficit/hyperactivity disorder.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Male; Methylphenidate; Propylamines; Quality of Life; Time Factors; Treatment Outcome | 2013 |
A randomized, double-blind comparison of atomoxetine and placebo on response inhibition and interference control in children and adolescents with autism spectrum disorder and comorbid attention-deficit/hyperactivity disorder symptoms.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Child Development Disorders, Pervasive; Double-Blind Method; Female; Humans; Male; Propylamines; Treatment Outcome | 2013 |
A randomized placebo-controlled trial of electroencephalographic (EEG) neurofeedback in children with attention-deficit/hyperactivity disorder.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Age Factors; Arousal; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Cerebral Cortex; Child; Combined Modality Therapy; Double-Blind Method; Female; Humans; Male; Netherlands; Neurofeedback; Personality Assessment; Propylamines; Signal Processing, Computer-Assisted | 2013 |
Changes in the serum levels of brain-derived neurotrophic factor in adults with attention deficit hyperactivity disorder after treatment with atomoxetine.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Adult; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Brain-Derived Neurotrophic Factor; Female; Humans; Male; Middle Aged; Propylamines; Psychiatric Status Rating Scales; Treatment Outcome; Young Adult | 2014 |
Efficacy and Safety of Atomoxetine Hydrochloride in Asian Adults With ADHD.
Topics: Adrenergic Uptake Inhibitors; Adult; Asian People; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Double-Blind Method; Drug Administration Schedule; Drug Substitution; Executive Function; Female; Humans; Japan; Male; Quality of Life; Republic of Korea; Taiwan; Treatment Outcome | 2017 |
Atomoxetine improved attention in children and adolescents with attention-deficit/hyperactivity disorder and dyslexia in a 16 week, acute, randomized, double-blind trial.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Cognition; Double-Blind Method; Dyslexia; Female; Humans; Male; Memory, Short-Term; Propylamines; Psychiatric Status Rating Scales; Self Concept; Severity of Illness Index; Time Factors; Treatment Outcome | 2013 |
Long-term safety and tolerability of atomoxetine in Japanese adults with attention deficit hyperactivity disorder.
Topics: Adrenergic Uptake Inhibitors; Adult; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Female; Humans; Japan; Male; Propylamines; Time Factors; Treatment Outcome | 2014 |
Atomoxetine tolerability in pediatric and adult patients receiving different dosing strategies.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Adult; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Monitoring; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Kaplan-Meier Estimate; Male; Medication Adherence; Middle Aged; Outcome Assessment, Health Care; Propylamines; Time Factors | 2013 |
Neurophysiologic predictors of response to atomoxetine in young adults with attention deficit hyperactivity disorder: a pilot project.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Adult; Analysis of Variance; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Brain Waves; Double-Blind Method; Electroencephalography; Female; Humans; Male; Pilot Projects; Propylamines; Psychiatric Status Rating Scales; Treatment Outcome; Young Adult | 2014 |
Improved prefrontal activity in AD/HD children treated with atomoxetine: a NIRS study.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Child, Preschool; Female; Hemodynamics; Humans; Male; Prefrontal Cortex; Propylamines; Spectroscopy, Near-Infrared | 2015 |
Differential impact of methylphenidate and atomoxetine on sustained attention in youth with attention-deficit/hyperactivity disorder.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Cross-Over Studies; Double-Blind Method; Executive Function; Female; Humans; Inhibition, Psychological; Male; Methylphenidate; Propylamines; Psychomotor Performance; Treatment Outcome | 2015 |
Executive function in adults with attention-deficit/hyperactivity disorder during treatment with atomoxetine in a randomized, placebo-controlled, withdrawal study.
Topics: Adrenergic Uptake Inhibitors; Adult; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Double-Blind Method; Executive Function; Female; Humans; Male; Propylamines; Substance Withdrawal Syndrome; Treatment Outcome; Young Adult | 2014 |
Comparative short term efficacy and tolerability of methylphenidate and atomoxetine in attention deficit hyperactivity disorder.
Topics: Adolescent; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Child Behavior; Female; Humans; Male; Methylphenidate; Propylamines | 2014 |
Treatment response and remission in a double-blind, randomized, head-to-head study of lisdexamfetamine dimesylate and atomoxetine in children and adolescents with attention-deficit hyperactivity disorder.
Topics: Adolescent; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Dextroamphetamine; Double-Blind Method; Drug Administration Schedule; Humans; Lisdexamfetamine Dimesylate; Propylamines; Remission Induction; Severity of Illness Index; Treatment Outcome | 2014 |
Atomoxetine effects on executive function as measured by the BRIEF--a in young adults with ADHD: a randomized, double-blind, placebo-controlled study.
Topics: Adrenergic Uptake Inhibitors; Adult; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Executive Function; Female; Humans; Male; Propylamines; Treatment Outcome; Young Adult | 2014 |
Atomoxetine for attention deficits following traumatic brain injury: results from a randomized controlled trial.
Topics: Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Brain Injuries; Cross-Over Studies; Double-Blind Method; Executive Function; Female; Glasgow Coma Scale; Humans; Male; Propylamines; Recovery of Function; Severity of Illness Index; Treatment Outcome | 2014 |
Reading outcomes of children and adolescents with attention-deficit/hyperactivity disorder and dyslexia following atomoxetine treatment.
Topics: Adolescent; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Dyslexia; Female; Humans; Male; Propylamines; Reading; Treatment Outcome | 2014 |
Efficacy and safety of atomoxetine hydrochloride in Korean adults with attention-deficit hyperactivity disorder.
Topics: Adrenergic Uptake Inhibitors; Adult; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Propylamines; Quality of Life; Republic of Korea; Treatment Outcome | 2014 |
Increased prefrontal hemodynamic change after atomoxetine administration in pediatric attention-deficit/hyperactivity disorder as measured by near-infrared spectroscopy.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Female; Hemodynamics; Humans; Male; Oxyhemoglobins; Prefrontal Cortex; Spectroscopy, Near-Infrared; Stroop Test | 2015 |
Differential response profiles in children and adolescents with attention-deficit/hyperactivity disorder: treatment with atomoxetine.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Double-Blind Method; Female; Humans; Male; Propylamines; Severity of Illness Index; Sex Distribution; Treatment Outcome | 2015 |
Acute neuropharmacological effects of atomoxetine on inhibitory control in ADHD children: a fNIRS study.
Topics: Adolescent; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Brain; Child; Cross-Over Studies; Double-Blind Method; Executive Function; Female; Humans; Male; Propylamines; Spectroscopy, Near-Infrared | 2014 |
Efficacy and safety of extended-release guanfacine hydrochloride in children and adolescents with attention-deficit/hyperactivity disorder: a randomized, controlled, phase III trial.
Topics: Adolescent; Adrenergic alpha-2 Receptor Agonists; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Delayed-Action Preparations; Dose-Response Relationship, Drug; Double-Blind Method; Female; Guanfacine; Humans; Male; Propylamines; Psychiatric Status Rating Scales | 2014 |
What Is a Clinically Relevant Improvement in Quality of Life in Adults With ADHD?
Topics: Adolescent; Adrenergic Uptake Inhibitors; Adult; Aged; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Double-Blind Method; Female; Humans; Male; Middle Aged; Quality of Life; Treatment Outcome; Young Adult | 2019 |
CYP2D6 predicted metabolizer status and safety in adult patients with attention-deficit hyperactivity disorder participating in a large placebo-controlled atomoxetine maintenance of response clinical trial.
Topics: Adrenergic Uptake Inhibitors; Adult; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Cytochrome P-450 CYP2D6; Female; Genotype; Humans; Male; Phenotype; Young Adult | 2015 |
Functional outcomes from a head-to-head, randomized, double-blind trial of lisdexamfetamine dimesylate and atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder and an inadequate response to methylphenidate.
Topics: Adolescent; Atomoxetine Hydrochloride; Attention; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Lisdexamfetamine Dimesylate; Male; Methylphenidate; Treatment Outcome | 2016 |
Pharmacotherapy of the Preschool ADHD Treatment Study (PATS) Children Growing Up.
Topics: Antipsychotic Agents; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Child, Preschool; Comorbidity; Female; Follow-Up Studies; Humans; Logistic Models; Male; Methylphenidate; Prospective Studies; Psychiatric Status Rating Scales; Treatment Outcome | 2015 |
Effects of Atomoxetine and Osmotic Release Oral System-Methylphenidate on Executive Functions in Patients with Combined Type Attention-Deficit/Hyperactivity Disorder.
Topics: Administration, Oral; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Cognition; Executive Function; Female; Humans; Male; Methylphenidate; Neuropsychological Tests; Osmosis; Prospective Studies; Psychiatric Status Rating Scales; Treatment Outcome | 2015 |
An Open-Label, Randomized Trial of Methylphenidate and Atomoxetine Treatment in Children with Attention-Deficit/Hyperactivity Disorder.
Topics: Adolescent; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Female; Humans; Male; Medication Adherence; Methylphenidate; Psychiatric Status Rating Scales; Treatment Outcome | 2015 |
Safety of Methylphenidate and Atomoxetine in Children with Attention-Deficit/Hyperactivity Disorder (ADHD): Data from the Italian National ADHD Registry.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Comorbidity; Female; Humans; Incidence; Italy; Male; Methylphenidate; Psychiatric Status Rating Scales; Psychotropic Drugs; Registries; Severity of Illness Index | 2015 |
Time-to-onset and -resolution of adverse events before/after atomoxetine discontinuation in adult patients with ADHD.
Topics: Adrenergic Uptake Inhibitors; Adult; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Blood Pressure; Cardiovascular Diseases; Dose-Response Relationship, Drug; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; Erectile Dysfunction; Female; Heart Rate; Humans; Male; Time Factors; Treatment Outcome; Withholding Treatment | 2015 |
Atomoxetine Treatment Strengthens an Anti-Correlated Relationship between Functional Brain Networks in Medication-Naïve Adults with Attention-Deficit Hyperactivity Disorder: A Randomized Double-Blind Placebo-Controlled Clinical Trial.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Adult; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Brain; Brain Mapping; Case-Control Studies; Double-Blind Method; Female; Follow-Up Studies; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neural Pathways; Neuropsychological Tests; Psychotropic Drugs; Rest; Treatment Outcome; Young Adult | 2015 |
Variants of Dopamine Beta Hydroxylase Gene Moderate Atomoxetine Response in Children with Attention-Deficit/Hyperactivity Disorder.
Topics: Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Dopamine beta-Hydroxylase; Female; Genotype; Haplotypes; Humans; Linkage Disequilibrium; Male; Polymorphism, Single Nucleotide; Prospective Studies; Treatment Outcome | 2015 |
Atomoxetine, Parent Training, and Their Combination in Children With Autism Spectrum Disorder and Attention-Deficit/Hyperactivity Disorder.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Autism Spectrum Disorder; Behavior Rating Scale; Child; Child, Preschool; Double-Blind Method; Female; Humans; Male; Parents; Psychiatric Status Rating Scales; Severity of Illness Index; Surveys and Questionnaires; Treatment Outcome; United States | 2015 |
Anxiety reduction on atomoxetine and methylphenidate medication in children with ADHD.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Anxiety; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Child, Preschool; Dopamine Uptake Inhibitors; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Methylphenidate; Retrospective Studies; Treatment Outcome | 2016 |
Reliability and Validity of the Daily Parent Rating of Evening and Morning Behavior Scale, Revised.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Behavior Rating Scale; Child; Child Behavior Disorders; Child, Preschool; Double-Blind Method; Female; Humans; Male; Parents; Reproducibility of Results; Schools; Time Factors | 2018 |
Osmotic Release Oral System Methylphenidate Versus Atomoxetine for the Treatment of Attention-Deficit/Hyperactivity Disorder in Chinese Youth: 8-Week Comparative Efficacy and 1-Year Follow-Up.
Topics: Administration, Oral; Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Drug Liberation; Female; Follow-Up Studies; Humans; Male; Medication Adherence; Methylphenidate; Osmosis; Time Factors; Treatment Outcome | 2016 |
Caregiver Satisfaction with a Multisite Trial of Atomoxetine and Parent Training for Attention-Deficit/Hyperactivity Disorder and Behavioral Noncompliance in Children with Autism Spectrum Disorder.
Topics: Adolescent; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Autism Spectrum Disorder; Caregivers; Child; Combined Modality Therapy; Female; Humans; Male; Parents; Personal Satisfaction; Surveys and Questionnaires; Treatment Outcome | 2016 |
Atomoxetine could improve intra-individual variability in drug-naïve adults with attention-deficit/hyperactivity disorder comparably with methylphenidate: A head-to-head randomized clinical trial.
Topics: Adrenergic Uptake Inhibitors; Adult; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Female; Humans; Male; Methylphenidate; Reaction Time | 2016 |
Post Hoc Analysis of Potential Predictors of Response to Atomoxetine for the Treatment of Adults with Attention-Deficit/Hyperactivity Disorder using an Integrated Database.
Topics: Adolescent; Adult; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Drug Resistance; Female; Humans; Male; Middle Aged; Psychiatric Status Rating Scales; Sensitivity and Specificity; Time Factors; Treatment Outcome; Young Adult | 2016 |
Effect of Atomoxetine Treatment on Reading and Phonological Skills in Children with Dyslexia or Attention-Deficit/Hyperactivity Disorder and Comorbid Dyslexia in a Randomized, Placebo-Controlled Trial.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Double-Blind Method; Dyslexia; Female; Humans; Male; Reading; Treatment Outcome | 2017 |
Is emotion recognition the only problem in ADHD? effects of pharmacotherapy on face and emotion recognition in children with ADHD.
Topics: Adolescent; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Case-Control Studies; Central Nervous System Stimulants; Child; Emotions; Facial Expression; Female; Humans; Male; Methylphenidate; Recognition, Psychology; Sex Factors | 2016 |
Atomoxetine and Parent Training for Children With Autism and Attention-Deficit/Hyperactivity Disorder: A 24-Week Extension Study.
Topics: Adolescent; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Autism Spectrum Disorder; Child; Child, Preschool; Combined Modality Therapy; Double-Blind Method; Female; Humans; Male; Parents; Psychiatric Status Rating Scales; Surveys and Questionnaires; Treatment Outcome | 2016 |
Atomoxetine-Related Change in Sluggish Cognitive Tempo Is Partially Independent of Change in Attention-Deficit/Hyperactivity Disorder Inattentive Symptoms.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Cognition; Double-Blind Method; Dyslexia; Female; Humans; Male; Regression Analysis; Severity of Illness Index; Treatment Outcome | 2017 |
Effectiveness of atomoxetine and methylphenidate for problematic online gaming in adolescents with attention deficit hyperactivity disorder.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Behavior, Addictive; Central Nervous System Stimulants; Humans; Impulsive Behavior; Internet; Male; Methylphenidate; Psychiatric Status Rating Scales; Severity of Illness Index; Single-Blind Method; Treatment Outcome; Video Games | 2016 |
Assessment of effects of atomoxetine in adult patients with ADHD: consistency among three geographic regions in a response maintenance study.
Topics: Adrenergic Uptake Inhibitors; Adult; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Canada; Double-Blind Method; Europe; Humans; Latin America; Treatment Outcome; United States; Young Adult | 2017 |
[The treatment of attention deficit hyperactivity disorder with comorbid tic hyperkinesis].
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention; Attention Deficit Disorder with Hyperactivity; Child; Child, Preschool; Dose-Response Relationship, Drug; Electroencephalography; Follow-Up Studies; Humans; Propylamines; Tic Disorders; Treatment Outcome | 2008 |
[Atomoxetine and piracetam in the treatment of attention deficit hyperactivity disorder in children].
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Drug Administration Schedule; Female; Humans; Male; Nootropic Agents; Piracetam; Propylamines | 2008 |
Once-daily atomoxetine for adult attention-deficit/hyperactivity disorder: a 6-month, double-blind trial.
Topics: Adrenergic Uptake Inhibitors; Adult; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Propylamines; Treatment Outcome; United States; Young Adult | 2009 |
Efficacy and safety of atomoxetine as add-on to psychoeducation in the treatment of attention deficit/hyperactivity disorder: a randomized, double-blind, placebo-controlled study in stimulant-naïve Swedish children and adolescents.
Topics: Adolescent; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Double-Blind Method; Female; Humans; Male; Mental Health; Patient Education as Topic; Propylamines; Quality of Life; Surveys and Questionnaires; Sweden | 2009 |
Comparison of symptomatic versus functional changes in children and adolescents with ADHD during randomized, double-blind treatment with psychostimulants, atomoxetine, or placebo.
Topics: Adolescent; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Diagnostic and Statistical Manual of Mental Disorders; Double-Blind Method; Female; Humans; Male; Placebo Effect; Propylamines; Severity of Illness Index; Treatment Outcome | 2009 |
Atomoxetine's effect on societal costs in Sweden.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Costs and Cost Analysis; Female; Health Care Costs; Humans; Male; Mental Health Services; Prevalence; Propylamines; Sweden | 2010 |
Atomoxetine in children with attention-deficit hyperactivity disorder with prior stimulant therapy: a prospective open-label study.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Analysis of Variance; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Chi-Square Distribution; Child; Diagnostic and Statistical Manual of Mental Disorders; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Intention to Treat Analysis; Male; Patient Satisfaction; Patient Selection; Propylamines; Prospective Studies; Treatment Outcome | 2009 |
A haplotype of the norepinephrine transporter (Net) gene Slc6a2 is associated with clinical response to atomoxetine in attention-deficit hyperactivity disorder (ADHD).
Topics: Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Cohort Studies; Cytochrome P-450 CYP2D6; Double-Blind Method; Female; Haplotypes; Humans; Male; Norepinephrine Plasma Membrane Transport Proteins; Odds Ratio; Polymorphism, Single Nucleotide; Propylamines; Sequence Analysis, DNA; Severity of Illness Index; Treatment Outcome | 2009 |
Once-daily atomoxetine for treating pediatric attention-deficit/hyperactivity disorder: comparison of morning and evening dosing.
Topics: Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Propylamines; Time Factors; Treatment Outcome | 2009 |
Open-label trial of atomoxetine hydrochloride in adults with ADHD.
Topics: Adrenergic Uptake Inhibitors; Adult; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Drug Administration Schedule; Female; Humans; Intention to Treat Analysis; Longitudinal Studies; Male; Middle Aged; Patient Selection; Propylamines; Time; Treatment Outcome | 2010 |
Atomoxetine improves patient and family coping in attention deficit/hyperactivity disorder: a randomized, double-blind, placebo-controlled study in Swedish children and adolescents.
Topics: Achievement; Adaptation, Psychological; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit and Disruptive Behavior Disorders; Attention Deficit Disorder with Hyperactivity; Caregivers; Child; Child Rearing; Combined Modality Therapy; Cost of Illness; Double-Blind Method; Education; Family Conflict; Female; Harm Reduction; Humans; Male; Parenting; Propylamines; Quality of Life; Self Concept; Sweden | 2009 |
Evaluation of patients' and parents' quality of life in a randomized placebo-controlled atomoxetine study in attention-deficit/hyperactivity disorder.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Analysis of Variance; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Double-Blind Method; Female; Humans; Male; Parents; Patient Satisfaction; Propylamines; Psychiatric Status Rating Scales; Psychometrics; Quality of Life; Severity of Illness Index | 2009 |
Atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder: a 6-week, randomized, placebo-controlled, double-blind trial in Russia.
Topics: Abdominal Pain; Adolescent; Adrenergic Uptake Inhibitors; Analysis of Variance; Anorexia; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Double-Blind Method; Female; Humans; Nausea; Parents; Propylamines; Psychiatric Status Rating Scales; Russia; Sleep; Treatment Outcome; Weight Loss | 2010 |
A randomized, double-blind, placebo-controlled study of atomoxetine in Japanese children and adolescents with attention-deficit/hyperactivity disorder.
Topics: Adolescent; Age Factors; Asian People; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Propylamines | 2009 |
Atomoxetine hydrochloride in the treatment of children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: A placebo-controlled Italian study.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit and Disruptive Behavior Disorders; Attention Deficit Disorder with Hyperactivity; Child; Child, Preschool; Diagnostic and Statistical Manual of Mental Disorders; Double-Blind Method; Female; Humans; Italy; Male; Propylamines; Psychiatric Status Rating Scales; Treatment Outcome | 2009 |
Evaluation of atomoxetine for first-line treatment of newly diagnosed, treatment-naïve children and adolescents with attention deficit/hyperactivity disorder.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Age of Onset; Algorithms; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Double-Blind Method; Female; Humans; Male; Placebos; Propylamines | 2009 |
Validation of the adult ADHD investigator symptom rating scale (AISRS).
Topics: Adolescent; Adrenergic Uptake Inhibitors; Adult; Atomoxetine Hydrochloride; Attention; Attention Deficit Disorder with Hyperactivity; Factor Analysis, Statistical; Humans; Impulsive Behavior; Middle Aged; Propylamines; Psychiatric Status Rating Scales; Reproducibility of Results; Severity of Illness Index; Treatment Outcome | 2010 |
Improvement of executive functions in boys with attention deficit hyperactivity disorder: an open-label follow-up study with once-daily atomoxetine.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Executive Function; Follow-Up Studies; Humans; Male; Propylamines; Psychomotor Performance; Severity of Illness Index; Treatment Outcome | 2010 |
An open study of adjunct OROS-methylphenidate in children and adolescents who are atomoxetine partial responders: I. Effectiveness.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Delayed-Action Preparations; Drug Therapy, Combination; Female; Humans; Male; Methylphenidate; Propylamines; Severity of Illness Index; Treatment Outcome | 2009 |
An open study of adjunct OROS-methylphenidate in children who are atomoxetine partial responders: II. Tolerability and pharmacokinetics.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Blood Pressure; Central Nervous System Stimulants; Child; Delayed-Action Preparations; Drug Therapy, Combination; Electrocardiography; Female; Heart Rate; Humans; Liver Function Tests; Male; Methylphenidate; Propylamines | 2009 |
Atomoxetine as an adjunct therapy in the treatment of co-morbid attention-deficit/hyperactivity disorder in children and adolescents with bipolar I or II disorder.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Antimanic Agents; Antipsychotic Agents; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Bipolar Disorder; Child; Female; Humans; Male; Propylamines; Prospective Studies; Psychiatric Status Rating Scales; Severity of Illness Index | 2009 |
Effect of atomoxetine on executive function impairments in adults with ADHD.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Adult; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Double-Blind Method; Executive Function; Female; Humans; Male; Middle Aged; Propylamines; Treatment Outcome | 2011 |
Differential effects of atomoxetine on executive functioning and lexical decision in attention-deficit/hyperactivity disorder and reading disorder.
Topics: Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Cross-Over Studies; Decision Making; Dose-Response Relationship, Drug; Dyslexia; Executive Function; Humans; Inhibition, Psychological; Memory; Neuropsychological Tests; Propylamines; Reading; Treatment Outcome | 2009 |
Atomoxetine and neuropsychological function in children with attention-deficit/hyperactivity disorder: results of a pilot study.
Topics: Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention; Attention Deficit Disorder with Hyperactivity; Child; Executive Function; Female; Humans; Learning; Male; Memory; Neuropsychological Tests; Pilot Projects; Propylamines; Psychiatric Status Rating Scales; Severity of Illness Index; Treatment Outcome | 2009 |
Atomoxetine treatment in adolescents with attention-deficit/hyperactivity disorder.
Topics: Adaptation, Psychological; Adolescent; Adolescent Behavior; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Dose-Response Relationship, Drug; Drug Administration Schedule; Educational Status; Female; Humans; Male; Propylamines; Psychiatric Status Rating Scales; Severity of Illness Index; Treatment Outcome | 2009 |
Safety and tolerability of atomoxetine over 3 to 4 years in children and adolescents with ADHD.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Aggression; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Child, Preschool; Double-Blind Method; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Hostility; Humans; Male; Propylamines; Psychiatric Status Rating Scales; Treatment Outcome; Vital Signs | 2009 |
Atomoxetine in the treatment of adults with subthreshold and/or late onset attention-deficit hyperactivity disorder-not otherwise specified (ADHD-NOS): a prospective open-label 6-week study.
Topics: Adrenergic Uptake Inhibitors; Adult; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Male; Middle Aged; Pilot Projects; Propylamines; Prospective Studies; Severity of Illness Index; Treatment Outcome; Young Adult | 2010 |
Relationship between atomoxetine plasma concentration, treatment response and tolerability in attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder.
Topics: Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit and Disruptive Behavior Disorders; Attention Deficit Disorder with Hyperactivity; Child; Dose-Response Relationship, Drug; Female; Humans; Male; Propylamines | 2009 |
Self-esteem in adolescent patients with attention-deficit/hyperactivity disorder during open-label atomoxetine treatment: psychometric evaluation of the Rosenberg Self-Esteem Scale and clinical findings.
Topics: Adolescent; Adolescent Behavior; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Factor Analysis, Statistical; Female; Humans; Male; Personality Assessment; Principal Component Analysis; Propylamines; Psychometrics; Reproducibility of Results; Self Concept; Self Report; Severity of Illness Index | 2009 |
EEG-vigilance and response to stimulants in paediatric patients with attention deficit/hyperactivity disorder.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Analysis of Variance; Arousal; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Case-Control Studies; Child; Electroencephalography; Humans; Male; Neuropsychological Tests; Propylamines; Reaction Time; Time Factors | 2010 |
Randomized, controlled trial of atomoxetine for attention-deficit/hyperactivity disorder in adolescents with substance use disorder.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Checklist; Cognitive Behavioral Therapy; Combined Modality Therapy; Comorbidity; Diagnostic and Statistical Manual of Mental Disorders; Double-Blind Method; Female; Humans; Interview, Psychological; Male; Motivation; Propylamines; Substance-Related Disorders | 2010 |
Post hoc analysis: early changes in ADHD-RS items predict longer term response to atomoxetine in pediatric patients.
Topics: Administration, Oral; Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Outpatients; Pediatrics; Propylamines; Psychological Tests; Reproducibility of Results; Severity of Illness Index; Time Factors; Treatment Outcome | 2010 |
Changes of urine dihydroxyphenylglycol to norepinephrine ratio in children with attention-deficit hyperactivity disorder (ADHD) treated with atomoxetine.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Double-Blind Method; Female; Humans; Male; Methoxyhydroxyphenylglycol; Norepinephrine; Pilot Projects; Propylamines; Treatment Outcome | 2011 |
Effects of atomoxetine on self-reported high-risk behaviors and health-related quality of life in adolescents with ADHD.
Topics: Adolescent; Adolescent Behavior; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Health Status; Humans; Male; Propylamines; Quality of Life; Risk-Taking; Self Concept | 2010 |
Effects of atomoxetine with and without behavior therapy on the school and home functioning of children with attention-deficit/hyperactivity disorder.
Topics: Activities of Daily Living; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Child; Combined Modality Therapy; Female; Humans; Male; Propylamines; Psychiatric Status Rating Scales; Schools; Social Adjustment; Treatment Outcome | 2010 |
Does placebo response differ between objective and subjective measures in children with attention-deficit/hyperactivity disorder?
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Delayed-Action Preparations; Dose-Response Relationship, Drug; Female; Humans; Male; Methylphenidate; Neuropsychological Tests; Placebo Effect; Propylamines; Severity of Illness Index | 2010 |
Atomoxetine for attention deficit hyperactivity disorder in mental retardation.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Child, Preschool; Dose-Response Relationship, Drug; Female; Humans; Male; Mental Disorders; Propylamines; Prospective Studies; Psychiatric Status Rating Scales; Young Adult | 2010 |
Effect of atomoxetine on quality of life and family burden: results from a randomized, placebo-controlled, double-blind study in children and adolescents with ADHD and comorbid oppositional defiant or conduct disorder.
Topics: Adaptation, Psychological; Adolescent; Adolescent Behavior; Adrenergic Uptake Inhibitors; Analysis of Variance; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Child Welfare; Conduct Disorder; Confidence Intervals; Double-Blind Method; Family Relations; Female; Humans; Male; Propylamines; Psychometrics; Self Concept; Stress, Psychological; Students, Medical; Surveys and Questionnaires | 2011 |
Safety and efficacy of ABT-089 in pediatric attention-deficit/hyperactivity disorder: results from two randomized placebo-controlled clinical trials.
Topics: Adrenergic Uptake Inhibitors; Adult; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Double-Blind Method; Drug Monitoring; Female; Humans; Male; Nicotinic Agonists; Propylamines; Psychiatric Status Rating Scales; Pyridines; Pyrrolidines; Treatment Outcome | 2011 |
Atomoxetine and methylphenidate treatment in children with ADHD: the efficacy, tolerability and effects on executive functions.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Executive Function; Female; Humans; Male; Methylphenidate; Neuropsychological Tests; Propylamines; Treatment Outcome | 2011 |
An open-label, dose-titration tolerability study of atomoxetine hydrochloride in Japanese adults with attention-deficit/hyperactivity disorder.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Adult; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Dose-Response Relationship, Drug; Female; Humans; Japan; Male; Middle Aged; Propylamines; Psychiatric Status Rating Scales; Treatment Outcome; Young Adult | 2011 |
A comparison of atomoxetine administered as once versus twice daily dosing on the school and home functioning of children with attention-deficit/hyperactivity disorder.
Topics: Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Child; Combined Modality Therapy; Drug Administration Schedule; Female; Humans; Male; Parents; Propylamines; Schools; Treatment Outcome | 2011 |
A randomized controlled trial investigation of a non-stimulant in attention deficit hyperactivity disorder (ACTION): rationale and design.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Affect; Anxiety; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Australia; Child; Cognition; Comorbidity; Cross-Over Studies; Double-Blind Method; Humans; Logistic Models; Neuropsychological Tests; Propylamines; Psychiatric Status Rating Scales; Research Design; Surveys and Questionnaires; Time Factors; Treatment Outcome | 2011 |
A double-blind, placebo-controlled study of atomoxetine in young children with ADHD.
Topics: Age Factors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Child, Preschool; Combined Modality Therapy; Dose-Response Relationship, Drug; Double-Blind Method; Education; Female; Humans; Male; Off-Label Use; Personality Assessment; Propylamines; Psychometrics | 2011 |
Minor differences in ADHD-related difficulties between boys and girls treated with atomoxetine for attention-deficit/hyperactivity disorder.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Dose-Response Relationship, Drug; Female; Humans; Male; Parents; Physicians; Propylamines; Quality of Life; Self Report; Severity of Illness Index; Sex Characteristics | 2010 |
Improvement in global psychopathology increases quality of life during treatment of ADHD with atomoxetine or stimulants.
Topics: Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Female; Follow-Up Studies; Humans; Male; Propylamines; Psychiatric Status Rating Scales; Quality of Life; Statistics, Nonparametric | 2011 |
Long-term open-label response to atomoxetine in adult ADHD: influence of sex, emotional dysregulation, and double-blind response to atomoxetine.
Topics: Adrenergic Uptake Inhibitors; Adult; Affective Symptoms; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Double-Blind Method; Female; Humans; Male; Propylamines; Psychiatric Status Rating Scales; Sex Characteristics; Time Factors | 2011 |
Atomoxetine versus placebo in children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: a double-blind, randomized, multicenter trial in Germany.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention; Attention Deficit and Disruptive Behavior Disorders; Attention Deficit Disorder with Hyperactivity; Child; Comorbidity; Conduct Disorder; Disease Progression; Double-Blind Method; Female; Germany; Humans; Male; Placebos; Propylamines; Treatment Outcome | 2011 |
One-year prospective follow-up of pharmacological treatment in children with attention-deficit/hyperactivity disorder.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Cohort Studies; Follow-Up Studies; Humans; Male; Methylphenidate; Propylamines; Prospective Studies | 2011 |
Adjunctive atomoxetine to SSRIs or SNRIs in the treatment of adult ADHD patients with comorbid partially responsive generalized anxiety (GA): an open-label study.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Adult; Anxiety Disorders; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Blood Pressure; Body Weight; Drug Resistance; Drug Therapy, Combination; Female; Heart Rate; Humans; Male; Middle Aged; Propylamines; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors | 2011 |
Effect of atomoxetine on Tanner stage sexual development in children and adolescents with attention deficit/hyperactivity disorder: 18-month results from a double-blind, placebo-controlled trial.
Topics: Adolescent; Adolescent Development; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Australia; Child; Diagnostic and Statistical Manual of Mental Disorders; Double-Blind Method; Europe; Female; Humans; Israel; Male; Propylamines; Sexual Development; South Africa; Treatment Outcome | 2011 |
Comparative study of OROS-MPH and atomoxetine on executive function improvement in ADHD: a randomized controlled trial.
Topics: Administration, Oral; Adolescent; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Delayed-Action Preparations; Executive Function; Female; Humans; Male; Memory, Short-Term; Methylphenidate; Neuropsychological Tests; Propylamines; Treatment Outcome | 2012 |
Correlates of alcohol use in adults with ADHD and comorbid alcohol use disorders: exploratory analysis of a placebo-controlled trial of atomoxetine.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Adult; Aged; Alcohol Drinking; Alcohol-Induced Disorders; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Depressants; Double-Blind Method; Ethanol; Female; Humans; Middle Aged; Propylamines; Time Factors | 2011 |
Neuropsychological outcomes across the day in children with attention-deficit/hyperactivity disorder treated with atomoxetine: results from a placebo-controlled study using a computer-based continuous performance test combined with an infra-red motion-tra
Topics: Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Diagnosis, Computer-Assisted; Double-Blind Method; Female; Humans; Male; Placebos; Propylamines | 2011 |
Academic outcomes in Asian children aged 8-11 years with attention-deficit/hyperactivity disorder treated with atomoxetine hydrochloride.
Topics: Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; China; Educational Status; Female; Humans; Male; Propylamines; Republic of Korea; Taiwan; Treatment Outcome | 2011 |
A randomized, waiting list-controlled 12-week trial of atomoxetine in adults with ADHD.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Adult; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Female; Humans; Male; Middle Aged; Patient Satisfaction; Propylamines; Quality of Life; Self Concept; Treatment Outcome; Waiting Lists; Young Adult | 2012 |
An 8-week, randomized controlled trial of atomoxetine, atomoxetine plus buspirone, or placebo in adults with ADHD.
Topics: Adult; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Buspirone; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Norepinephrine; Propylamines; Treatment Outcome | 2012 |
Efficacy of atomoxetine for the treatment of ADHD symptoms in patients with pervasive developmental disorders: a prospective, open-label study.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Child Development Disorders, Pervasive; Child, Preschool; Comorbidity; Humans; Male; Neuropsychological Tests; Pilot Projects; Propylamines; Prospective Studies; Time Factors; Treatment Outcome | 2013 |
Randomized clinical study of a histamine H3 receptor antagonist for the treatment of adults with attention-deficit hyperactivity disorder.
Topics: Administration, Oral; Adolescent; Adrenergic Uptake Inhibitors; Adult; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Benzamides; Central Nervous System Stimulants; Delayed-Action Preparations; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Histamine H3 Antagonists; Humans; Male; Methylphenidate; Middle Aged; Piperazines; Propylamines; Treatment Outcome; Wakefulness; Young Adult | 2012 |
Does stimulant pretreatment modify atomoxetine effects on core symptoms of ADHD in children assessed by quantitative measurement technology?
Topics: Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Diagnosis, Computer-Assisted; Double-Blind Method; Female; Humans; Male; Propylamines; Severity of Illness Index; Treatment Outcome | 2014 |
A randomized double-blind study of atomoxetine versus placebo for attention-deficit/hyperactivity disorder symptoms in children with autism spectrum disorder.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Child Development Disorders, Pervasive; Comorbidity; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Personality Assessment; Propylamines; Psychometrics | 2012 |
Social-skills and parental training plus standard treatment versus standard treatment for children with ADHD--the randomised SOSTRA trial.
Topics: Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Dextroamphetamine; Dopamine Uptake Inhibitors; Female; Humans; Male; Methylphenidate; Parents; Propylamines; Social Behavior | 2012 |
Does atomoxetine improve executive function, inhibitory control, and hyperactivity? Results from a placebo-controlled trial using quantitative measurement technology.
Topics: Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Diagnosis, Computer-Assisted; Dose-Response Relationship, Drug; Double-Blind Method; Executive Function; Female; Humans; Male; Propylamines; Psychiatric Status Rating Scales; Reaction Time; Severity of Illness Index; Treatment Outcome | 2012 |
Common and unique therapeutic mechanisms of stimulant and nonstimulant treatments for attention-deficit/hyperactivity disorder.
Topics: Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Brain; Brain Mapping; Central Nervous System Stimulants; Child; Female; Frontal Lobe; Gyrus Cinguli; Humans; Image Interpretation, Computer-Assisted; Image Processing, Computer-Assisted; Imaging, Three-Dimensional; Inhibition, Psychological; Magnetic Resonance Imaging; Male; Methylphenidate; Motor Cortex; Neural Pathways; Neuropsychological Tests; Parietal Lobe; Propylamines; Psychomotor Performance; Treatment Outcome | 2012 |
Safety of atomoxetine in combination with intravenous cocaine in cocaine-experienced participants.
Topics: Adrenergic Uptake Inhibitors; Adult; Affect; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Blood Pressure; Cocaine; Cocaine-Related Disorders; Cognition; Comorbidity; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Interactions; Electrocardiography; Heart Rate; Humans; Male; Middle Aged; Motivation; Neuropsychological Tests; Opiate Substitution Treatment; Propylamines; Substance Abuse, Intravenous; Young Adult | 2012 |
Shared and drug-specific effects of atomoxetine and methylphenidate on inhibitory brain dysfunction in medication-naive ADHD boys.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Analysis of Variance; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Brain; Case-Control Studies; Catecholamines; Central Nervous System Stimulants; Child; Cross-Over Studies; Data Interpretation, Statistical; Double-Blind Method; Humans; Image Processing, Computer-Assisted; Inhibition, Psychological; Intelligence Tests; Magnetic Resonance Imaging; Male; Methylphenidate; Movement; Neuropsychological Tests; Prefrontal Cortex; Propylamines; Psychomotor Performance | 2014 |
Driving performance in adults with ADHD: results from a randomized, waiting list controlled trial with atomoxetine.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Adult; Atomoxetine Hydrochloride; Attention; Attention Deficit Disorder with Hyperactivity; Automobile Driving; Female; Humans; Male; Middle Aged; Propylamines; Reaction Time; Surveys and Questionnaires; Treatment Outcome; Waiting Lists | 2013 |
Cost effectiveness of guanfacine extended-release versus atomoxetine for the treatment of attention-deficit/hyperactivity disorder: application of a matching-adjusted indirect comparison.
Topics: Adolescent; Adrenergic alpha-2 Receptor Agonists; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Cost-Benefit Analysis; Delayed-Action Preparations; Female; Guanfacine; Humans; Male; Markov Chains; Propylamines; Quality-Adjusted Life Years; Treatment Outcome | 2012 |
Atomoxetine treatment of attention-deficit/hyperactivity disorder in young adults with assessment of functional outcomes: a randomized, double-blind, placebo-controlled clinical trial.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Adult; Analysis of Variance; Atomoxetine Hydrochloride; Attention; Attention Deficit Disorder with Hyperactivity; Double-Blind Method; Executive Function; Humans; Least-Squares Analysis; Predictive Value of Tests; Propylamines; Prospective Studies; Psychiatric Status Rating Scales; Puerto Rico; Quality of Life; Recovery of Function; Severity of Illness Index; Time Factors; Treatment Outcome; United States; Young Adult | 2013 |
Validity of conners' adult attention-deficit/hyperactivity disorder rating Scale-investigator rated: screening version in patients from within and outside of Europe.
Topics: Adolescent; Adult; Argentina; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Europe; Female; Humans; Male; Middle Aged; North America; Propylamines; Psychiatric Status Rating Scales; Reproducibility of Results; Russia | 2013 |
Atomoxetine and methylphenidate treatment in children with ADHD: a prospective, randomized, open-label trial.
Topics: Adolescent; Antidepressive Agents; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Female; Humans; Male; Methylphenidate; Propylamines; Prospective Studies | 2002 |
Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study.
Topics: Adolescent; Antidepressive Agents; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Drug Administration Schedule; Female; Humans; Male; Personality Assessment; Propylamines; Treatment Outcome | 2002 |
Efficacy of atomoxetine versus placebo in school-age girls with attention-deficit/hyperactivity disorder.
Topics: Adolescent; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Double-Blind Method; Female; Humans; Male; Propylamines; Sex Factors; Treatment Outcome | 2002 |
Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder.
Topics: Antidepressive Agents; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Double-Blind Method; Female; Humans; Male; Propylamines; Treatment Outcome | 2002 |
Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies.
Topics: Adult; Antidepressive Agents; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Double-Blind Method; Female; Humans; Male; Propylamines; Treatment Outcome | 2003 |
Atomoxetine pharmacokinetics in children and adolescents with attention deficit hyperactivity disorder.
Topics: Adolescent; Adult; Antidepressive Agents; Area Under Curve; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Cytochrome P-450 CYP2D6; Drug Administration Schedule; Female; Humans; Male; Propylamines; Treatment Outcome | 2003 |
Changes in symptoms and adverse events after discontinuation of atomoxetine in children and adults with attention deficit/hyperactivity disorder: a prospective, placebo-controlled assessment.
Topics: Adult; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Diagnostic and Statistical Manual of Mental Disorders; Drug Administration Schedule; Humans; Propylamines; Prospective Studies; Recurrence; Severity of Illness Index; Time Factors; Treatment Outcome; Withholding Treatment | 2004 |
Relapse prevention in pediatric patients with ADHD treated with atomoxetine: a randomized, double-blind, placebo-controlled study.
Topics: Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Double-Blind Method; Female; Humans; Male; Propylamines; Secondary Prevention | 2004 |
Once-daily atomoxetine treatment for children with attention-deficit/hyperactivity disorder, including an assessment of evening and morning behavior: a double-blind, placebo-controlled trial.
Topics: Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Double-Blind Method; Female; Humans; Male; Norepinephrine Plasma Membrane Transport Proteins; Propylamines; Surveys and Questionnaires; Symporters; Treatment Outcome | 2004 |
Atomoxetine and nonresponders to stimulants.
Topics: Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Diagnostic and Statistical Manual of Mental Disorders; Drug Administration Schedule; Drug Costs; Humans; Propylamines; Psychiatric Status Rating Scales; Treatment Outcome | 2004 |
A prospective, multicenter, open-label assessment of atomoxetine in non-North American children and adolescents with ADHD.
Topics: Adolescent; Adrenergic Agents; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Diagnostic and Statistical Manual of Mental Disorders; Female; Humans; Male; Propylamines; Prospective Studies; Severity of Illness Index | 2004 |
Attention-deficit/hyperactivity disorder: cognitive evoked potential (P300) amplitude predicts treatment response to atomoxetine.
Topics: Acoustic Stimulation; Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Auditory Cortex; Brain Mapping; Child; Electrodes; Electroencephalography; Event-Related Potentials, P300; Female; Humans; Male; Multivariate Analysis; Predictive Value of Tests; Propylamines | 2005 |
Pharmacotherapy of adult ADHD.
Topics: Adolescent; Adult; Age Factors; Amphetamine; Antidepressive Agents; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Central Nervous System Stimulants; Child; Combined Modality Therapy; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Male; Methylphenidate; Propylamines; Treatment Outcome | 2005 |
Atomoxetine treatment in children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder.
Topics: Adolescent; Atomoxetine Hydrochloride; Attention Deficit and Disruptive Behavior Disorders; Attention Deficit Disorder with Hyperactivity; Child; Diagnostic and Statistical Manual of Mental Disorders; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Norepinephrine; Propylamines | 2005 |
Long-term, open-label study of the safety and efficacy of atomoxetine in adults with attention-deficit/hyperactivity disorder: an interim analysis.
Topics: Adult; Age Factors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Blood Pressure; Body Weight; Erectile Dysfunction; Female; Headache; Heart Rate; Humans; Longitudinal Studies; Male; Patient Dropouts; Placebos; Propylamines; Psychiatric Status Rating Scales; Treatment Outcome; Xerostomia | 2005 |
Efficacy and safety of atomoxetine in childhood attention-deficit/hyperactivity disorder with comorbid oppositional defiant disorder.
Topics: Adolescent; Atomoxetine Hydrochloride; Attention Deficit and Disruptive Behavior Disorders; Attention Deficit Disorder with Hyperactivity; Child; Diagnostic and Statistical Manual of Mental Disorders; Double-Blind Method; Female; Humans; Male; Neuropsychological Tests; Norepinephrine; Propylamines; Single-Blind Method | 2004 |
A randomized, placebo-controlled study of once-daily atomoxetine in the school setting in children with ADHD.
Topics: Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Propylamines; Schools; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index | 2005 |
Comparison of the inhibitory and excitatory effects of ADHD medications methylphenidate and atomoxetine on motor cortex.
Topics: Adrenergic Uptake Inhibitors; Adult; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Cross-Over Studies; Double-Blind Method; Evoked Potentials, Motor; Female; Humans; Male; Meta-Analysis as Topic; Methylphenidate; Motor Cortex; Neural Inhibition; Propylamines; Time Factors; Transcranial Magnetic Stimulation | 2006 |
Emotional dysregulation in adult ADHD and response to atomoxetine.
Topics: Adrenergic Uptake Inhibitors; Adult; Affective Symptoms; Analysis of Variance; Anxiety Disorders; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Depressive Disorder; Double-Blind Method; Female; Humans; Male; Middle Aged; Mood Disorders; Norepinephrine; Propylamines | 2005 |
Investigator ratings of ADHD symptoms during a randomized, placebo-controlled trial of atomoxetine: a comparison of parents and teachers as informants.
Topics: Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Double-Blind Method; Faculty; Female; Humans; Male; Norepinephrine; Observer Variation; Parents; Propylamines; Psychiatric Status Rating Scales | 2005 |
Atomoxetine alone or combined with fluoxetine for treating ADHD with comorbid depressive or anxiety symptoms.
Topics: Adolescent; Anxiety; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Depressive Disorder; Double-Blind Method; Drug Therapy, Combination; Female; Fluoxetine; Humans; Male; Propylamines; Selective Serotonin Reuptake Inhibitors | 2005 |
Atomoxetine and stroop task performance in adult attention-deficit/hyperactivity disorder.
Topics: Adult; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Color Perception; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neuropsychological Tests; Propylamines | 2005 |
Multicenter, randomized, open-label study of OROS methylphenidate versus atomoxetine: treatment outcomes in African-American children with ADHD.
Topics: Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Delayed-Action Preparations; Female; Humans; Male; Methylphenidate; Propylamines; Treatment Outcome | 2005 |
A laboratory school comparison of mixed amphetamine salts extended release (Adderall XR) and atomoxetine (Strattera) in school-aged children with attention deficit/hyperactivity disorder.
Topics: Amphetamines; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Delayed-Action Preparations; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Norepinephrine; Propylamines; Treatment Outcome | 2005 |
Atomoxetine treatment in children and adolescents with ADHD and comorbid tic disorders.
Topics: Adolescent; Adrenergic Agonists; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Body Weight; Child; Comorbidity; Double-Blind Method; Female; Heart Rate; Humans; Male; Placebo Effect; Propylamines; Tachycardia; Tic Disorders; Treatment Outcome | 2005 |
Comorbid oppositional defiant disorder and the risk of relapse during 9 months of atomoxetine treatment for attention-deficit/hyperactivity disorder.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit and Disruptive Behavior Disorders; Attention Deficit Disorder with Hyperactivity; Child; Comorbidity; Double-Blind Method; Female; Humans; Male; Propylamines; Recurrence; Risk; Severity of Illness Index | 2006 |
Atomoxetine and adult attention-deficit/hyperactivity disorder: the effects of comorbidity.
Topics: Adrenergic Uptake Inhibitors; Adult; Age Factors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Comorbidity; Depressive Disorder; Diagnostic and Statistical Manual of Mental Disorders; Double-Blind Method; Female; Health Status; Humans; Male; Mental Disorders; Neuropsychological Tests; Norepinephrine Plasma Membrane Transport Proteins; Placebos; Propylamines; Psychiatric Status Rating Scales; Risk Factors; Stress Disorders, Post-Traumatic; Treatment Outcome | 2006 |
A post hoc subgroup analysis of an 18-day randomized controlled trial comparing the tolerability and efficacy of mixed amphetamine salts extended release and atomoxetine in school-age girls with attention-deficit/hyperactivity disorder.
Topics: Adrenergic Uptake Inhibitors; Amphetamines; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Delayed-Action Preparations; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Propylamines; Psychiatric Status Rating Scales; Treatment Outcome | 2006 |
Dopamine transporter genotype influences the physiological response to medication in ADHD.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Cross-Over Studies; Dopamine Plasma Membrane Transport Proteins; Double-Blind Method; Female; Genotype; Humans; Male; Methylphenidate; Motor Cortex; Neural Inhibition; Pharmacogenetics; Phenotype; Propylamines; Tourette Syndrome; Treatment Outcome | 2006 |
Comparison of parent and teacher reports of attention-deficit/hyperactivity disorder symptoms from two placebo-controlled studies of atomoxetine in children.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Double-Blind Method; Female; Humans; Male; Neuropsychological Tests; Parents; Personality Assessment; Propylamines; Teaching; Time Factors; Treatment Outcome | 2006 |
Attention-deficit/hyperactivity disorder: use of cognitive evoked potential (P300) to predict treatment response.
Topics: Acoustic Stimulation; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Brain Mapping; Cerebral Cortex; Child; Cross-Over Studies; Double-Blind Method; Electroencephalography; Event-Related Potentials, P300; Female; Functional Laterality; Humans; Male; Methylphenidate; Predictive Value of Tests; Propylamines; Reference Values; ROC Curve | 2006 |
A randomized, double-blind study of continuation treatment for attention-deficit/hyperactivity disorder after 1 year.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Propylamines; Secondary Prevention; Treatment Outcome | 2007 |
Meta-analysis of aggression or hostility events in randomized, controlled clinical trials of atomoxetine for ADHD.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Aged; Aggression; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Databases as Topic; Double-Blind Method; Female; Hostility; Humans; Male; Methylphenidate; Middle Aged; Odds Ratio; Proportional Hazards Models; Propylamines | 2007 |
Atomoxetine for hyperactivity in autism spectrum disorders: placebo-controlled crossover pilot trial.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Autistic Disorder; Child; Cross-Over Studies; Double-Blind Method; Female; Humans; Male; Pilot Projects; Propylamines | 2006 |
Atomoxetine in the management of children with ADHD: effects on quality of life and school functioning.
Topics: Adrenergic Uptake Inhibitors; Analysis of Variance; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Double-Blind Method; Efficiency; Faculty; Female; Humans; Male; Parents; Propylamines; Psychiatric Status Rating Scales; Psychomotor Performance; Quality of Life; Schools; Surveys and Questionnaires; Treatment Outcome; United States | 2006 |
Low-dose atomoxetine for maintenance treatment of attention-deficit/hyperactivity disorder.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Double-Blind Method; Female; Humans; Male; Propylamines | 2006 |
Quality of life assessment in adult patients with attention-deficit/hyperactivity disorder treated with atomoxetine.
Topics: Adrenergic Uptake Inhibitors; Adult; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Double-Blind Method; Female; Humans; Male; Propylamines; Psychiatric Status Rating Scales; Quality of Life; Treatment Outcome; United States | 2006 |
Atomoxetine treatment in children and adolescents with attention-deficit hyperactivity disorder: what are the long-term health-related quality-of-life outcomes?
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Female; Follow-Up Studies; Humans; Long-Term Care; Male; Neuropsychological Tests; Propylamines; Quality of Life; Surveys and Questionnaires; Treatment Outcome | 2006 |
A pilot study of the effects of atomoxetine on driving performance in adults with ADHD.
Topics: Adrenergic Uptake Inhibitors; Adult; Atomoxetine Hydrochloride; Attention; Attention Deficit Disorder with Hyperactivity; Automobile Driving; Computer Simulation; Female; Humans; Male; Middle Aged; Pilot Projects; Propylamines; Psychomotor Performance; User-Computer Interface | 2007 |
Effects of atomoxetine and methylphenidate on sleep in children with ADHD.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Electrophysiology; Female; Humans; Male; Methylphenidate; Propylamines; Sleep, REM | 2006 |
A multi-centre, randomised, open-label study of atomoxetine compared with standard current therapy in UK children and adolescents with attention-deficit/hyperactivity disorder (ADHD).
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Clonidine; Drug Therapy, Combination; Female; Headache; Humans; Male; Methylphenidate; Nausea; Propylamines; Prospective Studies; Severity of Illness Index; Treatment Outcome | 2007 |
Emotional expression during attention-deficit/hyperactivity disorders treatment: initial assessment of treatment effects.
Topics: Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Cross-Sectional Studies; Double-Blind Method; Drug Administration Schedule; Emotions; Female; Humans; Male; Personality Assessment; Propylamines | 2007 |
Effect of two different methods of initiating atomoxetine on the adverse event profile of atomoxetine.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Diagnostic and Statistical Manual of Mental Disorders; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Propylamines; Severity of Illness Index | 2007 |
A pilot study of atomoxetine in young children with attention-deficit/hyperactivity disorder.
Topics: Adrenergic Uptake Inhibitors; Age Factors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Child, Preschool; Feasibility Studies; Female; Humans; Male; Pilot Projects; Propylamines; Severity of Illness Index; Treatment Outcome | 2007 |
Forecasting three-month outcomes in a laboratory school comparison of mixed amphetamine salts extended release (Adderall XR) and atomoxetine (Strattera) in school-aged children With ADHD.
Topics: Adrenergic Uptake Inhibitors; Amphetamines; Atomoxetine Hydrochloride; Attention; Attention Deficit and Disruptive Behavior Disorders; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; Forecasting; Humans; Male; Problem Solving; Propylamines; Treatment Outcome; United States | 2007 |
Atomoxetine improved response inhibition in adults with attention deficit/hyperactivity disorder.
Topics: Administration, Oral; Adrenergic Uptake Inhibitors; Adult; Analysis of Variance; Atomoxetine Hydrochloride; Attention; Attention Deficit Disorder with Hyperactivity; Case-Control Studies; Cognition; Cross-Over Studies; Double-Blind Method; Female; Humans; Inhibition, Psychological; Male; Memory, Short-Term; Neuropsychological Tests; Propylamines; Reaction Time; Time Factors | 2007 |
Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Amphetamine; Analysis of Variance; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Blood Pressure; Central Nervous System Stimulants; Child; Drug Administration Schedule; Drug Therapy, Combination; Electrocardiography; Female; Heart Rate; Humans; Male; Methylphenidate; Pilot Projects; Propylamines; Severity of Illness Index; Treatment Outcome | 2007 |
CYP2D6 metabolizer status and atomoxetine dosing in children and adolescents with ADHD.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Cytochrome P-450 CYP2D6; Dose-Response Relationship, Drug; Drug Evaluation; Female; Humans; Male; Propylamines; Time Factors | 2008 |
High-dose atomoxetine treatment of ADHD in youths with limited response to standard doses.
Topics: Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Propylamines | 2007 |
Atomoxetine treatment for pediatric patients with attention-deficit/hyperactivity disorder with comorbid anxiety disorder.
Topics: Adrenergic Uptake Inhibitors; Anxiety Disorders; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Comorbidity; Diagnostic and Statistical Manual of Mental Disorders; Double-Blind Method; Female; Humans; Male; Propylamines | 2007 |
Efficacy and safety of atomoxetine in adolescents with attention-deficit/hyperactivity disorder and major depression.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Bipolar Disorder; Child; Depressive Disorder, Major; Double-Blind Method; Female; Humans; Male; Nausea; Propylamines; Psychiatric Status Rating Scales; Severity of Illness Index | 2007 |
A randomized, double-blind, placebo-controlled clinical trial on once-daily atomoxetine in Taiwanese children and adolescents with attention-deficit/hyperactivity disorder.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Appetite; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Double-Blind Method; Drug Administration Schedule; Faculty; Female; Humans; Male; Nausea; Parents; Propylamines; Psychiatric Status Rating Scales; Severity of Illness Index; Taiwan; Treatment Outcome | 2007 |
Responsiveness of the Adult Attention-Deficit/Hyperactivity Disorder Quality of Life Scale (AAQoL).
Topics: Adult; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Female; Humans; Male; Middle Aged; Outcome Assessment, Health Care; Propylamines; Psychometrics; Quality of Life; Sensitivity and Specificity; Sickness Impact Profile; Surveys and Questionnaires; United States | 2007 |
Medications do not necessarily normalize cognition in ADHD patients.
Topics: Adrenergic Uptake Inhibitors; Amphetamine; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Cognition; Cross-Sectional Studies; Female; Humans; Male; Methylphenidate; Neuropsychological Tests; Propylamines | 2008 |
Atomoxetine treatment of ADHD in children with comorbid Tourette syndrome.
Topics: Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Comorbidity; Double-Blind Method; Female; Humans; Male; Propylamines; Severity of Illness Index; Tourette Syndrome | 2008 |
The reliability and validity of self- and investigator ratings of ADHD in adults.
Topics: Adrenergic Uptake Inhibitors; Adult; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Diagnostic and Statistical Manual of Mental Disorders; Double-Blind Method; Female; Humans; Male; Propylamines; Reproducibility of Results; Self-Assessment; Severity of Illness Index; Surveys and Questionnaires | 2008 |
[Atomoxetine (Strattera), an alternative in the treatment of attention-deficit/hyperactivity disorder (ADHD) in children].
Topics: Adolescent; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Double-Blind Method; Female; Humans; Male; Propylamines | 2007 |
Atomoxetine for the treatment of attention-deficit/hyperactivity disorder and oppositional defiant disorder.
Topics: Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit and Disruptive Behavior Disorders; Attention Deficit Disorder with Hyperactivity; Child; Double-Blind Method; Female; Humans; Male; Multivariate Analysis; Propylamines; Treatment Outcome | 2008 |
Effectiveness of atomoxetine and quality of life in children with attention-deficit/hyperactivity disorder as perceived by patients, parents, and physicians in an open-label study.
Topics: Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Female; Humans; Male; Parents; Patient Satisfaction; Physicians; Propylamines; Psychiatric Status Rating Scales; Psychometrics; Quality of Life; Severity of Illness Index; Time Factors | 2007 |
Both atomoxetine and stimulants improve quality of life in an ADHD population treated in a community clinic.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Appetite Depressants; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Child, Preschool; Female; Humans; Male; Propylamines; Psychiatric Status Rating Scales; Quality of Life; Treatment Outcome | 2008 |
Hepatic events associated with atomoxetine treatment for attention-deficit hyperactivity disorder.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Adult; Adverse Drug Reaction Reporting Systems; Alanine Transaminase; Aspartate Aminotransferases; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Chemical and Drug Induced Liver Injury; Child; Female; Humans; Liver Function Tests; Male; Propylamines | 2008 |
Atomoxetine treatment of adults with ADHD and comorbid alcohol use disorders.
Topics: Adrenergic Uptake Inhibitors; Adult; Alcohol Drinking; Alcohol-Related Disorders; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Comorbidity; Diagnostic and Statistical Manual of Mental Disorders; Double-Blind Method; Female; Humans; Male; Placebos; Propylamines; Psychiatric Status Rating Scales; Treatment Outcome | 2008 |
Long-term, open-label safety and efficacy of atomoxetine in adults with ADHD: final report of a 4-year study.
Topics: Adrenergic Uptake Inhibitors; Adult; Amphetamine; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Diagnostic and Statistical Manual of Mental Disorders; Double-Blind Method; Humans; Longitudinal Studies; Methylphenidate; Patient Dropouts; Placebos; Propylamines; Psychiatric Status Rating Scales; Safety; Severity of Illness Index; Treatment Outcome | 2008 |
Effectiveness and tolerability of tomoxetine in adults with attention deficit hyperactivity disorder.
Topics: Adult; Ambulatory Care; Antidepressive Agents; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Cross-Over Studies; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Placebos; Propylamines; Psychiatric Status Rating Scales; Treatment Outcome | 1998 |
An open-label trial of tomoxetine in pediatric attention deficit hyperactivity disorder.
Topics: Adolescent; Antidepressive Agents; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Dose-Response Relationship, Drug; Humans; Male; Propylamines; Psychiatric Status Rating Scales | 2001 |
An open-label, dose-ranging study of atomoxetine in children with attention deficit hyperactivity disorder.
Topics: Adolescent; Antidepressive Agents; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Dose-Response Relationship, Drug; Drug Administration Schedule; Electrocardiography; Female; Hemodynamics; Humans; Male; Patient Compliance; Propylamines; Prospective Studies; Psychological Tests; Severity of Illness Index | 2001 |
Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study.
Topics: Adolescent; Age Factors; Algorithms; Analysis of Variance; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Depression; Dose-Response Relationship, Drug; Drugs, Investigational; Female; Humans; Male; Propylamines | 2001 |
428 other study(ies) available for atomoxetine hydrochloride and ADDH
| Article | Year |
|---|---|
[Influence of pantogam and atomoxetine on attention stability and distribution of dopamine D2 and GABAB receptors in the attention deficit mouse model].
Topics: Animals; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Dopamine; gamma-Aminobutyric Acid; Mice; Pantothenic Acid | 2021 |
Effects of two kinds of noradrenergic ADHD medicines on sign-tracking and goal-tracking in male rats.
Topics: Animals; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Goals; Guanfacine; Male; Norepinephrine; Rats; Rats, Sprague-Dawley | 2022 |
A parallel-group study of near-infrared spectroscopy-neurofeedback in children with attention deficit hyperactivity disorder.
Topics: Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Humans; Neurofeedback; Spectroscopy, Near-Infrared; Treatment Outcome | 2022 |
Effects of Atomoxetine Hydrochloride on Regulation of Lifespan in Drosophila Model.
Topics: Animals; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Drosophila; Drosophila melanogaster; Female; Longevity; Male | 2022 |
Brainmarker-I Differentially Predicts Remission to Various Attention-Deficit/Hyperactivity Disorder Treatments: A Discovery, Transfer, and Blinded Validation Study.
Topics: Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Humans; Male; Methylphenidate; Retrospective Studies; Treatment Outcome | 2023 |
Therapeutic drug monitoring of atomoxetine in children and adolescents with attention-deficit/ hyperactivity disorder: a naturalistic study.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Adult; Atomoxetine Hydrochloride; Attention; Attention Deficit Disorder with Hyperactivity; Child; Drug Monitoring; Drug-Related Side Effects and Adverse Reactions; Humans; Propylamines; Retrospective Studies; Treatment Outcome | 2022 |
Identification of factors associated with the efficacy of atomoxetine in adult attention-deficit/hyperactivity disorder.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Adult; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Humans; Retrospective Studies; Treatment Outcome | 2022 |
A view of response and resistance to atomoxetine treatment in children with ADHD: effects of CYP2C19 polymorphisms and BDNF levels.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Brain-Derived Neurotrophic Factor; Child; Cytochrome P-450 CYP2C19; Humans; Treatment Outcome | 2022 |
Shared and Unique Effects of Long-Term Administration of Methylphenidate and Atomoxetine on Degree Centrality in Medication-Naïve Children With Attention-Deficit/Hyperactive Disorder.
Topics: Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Brain; Central Nervous System Stimulants; Child; Humans; Methylphenidate | 2022 |
The Effects of Drug Treatments for ADHD in Measures of Cognitive Performance.
Topics: Animals; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Cognition; Humans; Methylphenidate; Propylamines | 2022 |
Spontaneous Ejaculation Associated With Atomoxetine.
Topics: Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Ejaculation; Humans; Male | 2022 |
Trends in use of attention deficit hyperactivity disorder medication among children and adolescents in Scandinavia in 2010-2020.
Topics: Adolescent; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Female; Humans; Male; Methylphenidate; Scandinavian and Nordic Countries | 2023 |
The Pharmacogenetic Impact on the Pharmacokinetics of ADHD Medications.
Topics: Adult; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Cytochrome P-450 CYP2D6; Humans; Methylphenidate; Pharmacogenetics | 2022 |
Psychostimulants Modafinil, Atomoxetine and Guanfacine Impair Bone Cell Differentiation and MSC Migration.
Topics: Adult; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Cell Differentiation; Central Nervous System Stimulants; Child; Guanfacine; Humans; Ligands; Methylphenidate; Modafinil; Nootropic Agents; Osteoprotegerin; Receptor Activator of Nuclear Factor-kappa B | 2022 |
Post-treatment symptomatic improvement of the eastern Indian ADHD probands is influenced by
Topics: Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Cytochrome P-450 CYP2D6; Genetic Variation; Humans; Male; Methylphenidate; Treatment Outcome | 2023 |
Novel non-stimulants rescue hyperactive phenotype in an adgrl3.1 mutant zebrafish model of ADHD.
Topics: Animals; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Imidazolines; Methylphenidate; Mice; Phenotype; Zebrafish | 2023 |
Theory of visual attention (TVA) applied to rats performing the 5-choice serial reaction time task: differential effects of dopaminergic and noradrenergic manipulations.
Topics: Amphetamine; Animals; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Dopamine; Humans; Methylphenidate; Norepinephrine; Phenylephrine; Rats; Reaction Time | 2023 |
Prevalence trends and individual patterns of ADHD medication use in pregnancy in Norway and Sweden, 2010-2019.
Topics: Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Female; Humans; Lisdexamfetamine Dimesylate; Methylphenidate; Norway; Pregnancy; Prevalence; Sweden | 2023 |
Reduced attentional lapses in male rats following a combination treatment of low-dose D-serine and atomoxetine.
Topics: Adrenergic Uptake Inhibitors; Animals; Atomoxetine Hydrochloride; Attention; Attention Deficit Disorder with Hyperactivity; Male; Norepinephrine; Rats; Serine | 2023 |
Effect of atomoxetine on ADHD-pain hypersensitization comorbidity in 6-OHDA lesioned mice.
Topics: Adrenergic Uptake Inhibitors; Animals; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Comorbidity; Male; Methylphenidate; Mice; Oxidopamine; Pain; Propylamines | 2023 |
Prescribing patterns for attention deficit hyperactivity disorder among children and adolescents in Taiwan from 2004 to 2017.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Humans; Methylphenidate; Taiwan | 2023 |
Pharmacologic Management of Cognitive Disengagement Syndrome (CDS) and Implications for Attention-Deficit/Hyperactivity Disorder (ADHD) Treatment: Emerging Treatments and Recommendations for Future Research.
Topics: Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Cognition; Humans; Lisdexamfetamine Dimesylate; Methylphenidate | 2023 |
Extended-Release Viloxazine Compared with Atomoxetine for Attention Deficit Hyperactivity Disorder.
Topics: Adrenergic alpha-2 Receptor Agonists; Adrenergic Uptake Inhibitors; Adult; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Double-Blind Method; Humans; Propylamines; Retrospective Studies; Sleep Initiation and Maintenance Disorders; Treatment Outcome; Viloxazine | 2023 |
Relationship between two forms of impulsivity in mice at baseline and under acute and sub-chronic atomoxetine treatment.
Topics: Animals; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Humans; Impulsive Behavior; Male; Mice; Mice, Inbred C57BL; Rodentia | 2023 |
Takotsubo Cardiomyopathy Related to Duloxetine-Atomoxetine Combination in an Adolescent with ADHD and Comorbid GAD.
Topics: Adolescent; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Comorbidity; Duloxetine Hydrochloride; Humans; Takotsubo Cardiomyopathy | 2023 |
Pre- and post-treatment evaluation of routine blood analysis in patients with attention deficit hyperactivity disorder and comparison with the healthy control group.
Topics: Albumins; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Case-Control Studies; Child; Control Groups; Hematologic Tests; Humans; Inflammation | 2023 |
ADHD medication and the inverted U-shaped curve: A pharmacological study in female mice performing the rodent Continuous Performance Test (rCPT).
Topics: Amphetamine; Animals; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Discrimination Learning; Female; Methylphenidate; Mice; Mice, Inbred C57BL; Psychomotor Performance; Rodentia | 2020 |
Psychostimulants/Atomoxetine and Serious Cardiovascular Events in Children with ADHD or Autism Spectrum Disorder.
Topics: Adolescent; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Autism Spectrum Disorder; Cardiovascular Diseases; Cardiovascular System; Case-Control Studies; Central Nervous System Stimulants; Child; Child, Preschool; Comorbidity; Female; Humans; Logistic Models; Male; Retrospective Studies | 2020 |
Atomoxetine Reestablishes Long Term Potentiation in a Mouse Model of Attention Deficit/Hyperactivity Disorder.
Topics: Adrenergic Uptake Inhibitors; Animals; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Long-Term Potentiation; Methylphenidate; Mice; Treatment Outcome | 2020 |
Patterns of long-term ADHD medication use in Australian children.
Topics: Adolescent; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Australia; Central Nervous System Stimulants; Child; Child, Preschool; Dextroamphetamine; Drug Prescriptions; Female; Humans; Longitudinal Studies; Male; Medication Adherence; Methylphenidate; Sex Distribution; Social Class | 2020 |
[Association of microRNA expression before and after drug therapy with clinical symptoms in children with attention deficit hyperactivity disorder].
Topics: Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Humans; MicroRNAs | 2020 |
Simple pharmacokinetic models accounting for drug monitoring results of atomoxetine and its 4-hydroxylated metabolites in Japanese pediatric patients genotyped for cytochrome P450 2D6.
Topics: Adolescent; Asian People; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Cytochrome P-450 CYP2D6; Drug Monitoring; Female; Genotype; Humans; Male; Models, Biological; Phenols; Propylamines | 2020 |
Spontaneous Ejaculation Induced with Atomoxetine.
Topics: Adolescent; Adult; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Ejaculation; Humans; Male; Propylamines; Treatment Outcome | 2020 |
Symptom scores and medication treatment patterns in children with ADHD versus autism.
Topics: Adolescent; Antipsychotic Agents; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Autistic Disorder; Central Nervous System Stimulants; Child; Child, Preschool; Female; Humans; Male; Psychotropic Drugs | 2020 |
Sleep habits of children diagnosed with attention/ deficit/ hyperactivity disorder and effects of treatment on sleep related parameters.
Topics: Adolescent; Atomoxetine Hydrochloride; Attention; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Humans; Methylphenidate; Sleep; Treatment Outcome | 2020 |
Different effects of methylphenidate and atomoxetine on the behavior and brain transcriptome of zebrafish.
Topics: Animals; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Behavior Rating Scale; Brain; Gene Ontology; Lipid Metabolism; Methylphenidate; Signal Transduction; Transcriptome; Zebrafish | 2020 |
The effects of medication on intraocular pressure in children with attention deficit hyperactivity disorder: A prospective study.
Topics: Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Female; Humans; Intraocular Pressure; Male; Manometry; Methylphenidate; Prospective Studies; Time Factors | 2020 |
CDH13 and LPHN3 Gene Polymorphisms in Attention-Deficit/Hyperactivity Disorder: Their Relation to Clinical Characteristics.
Topics: Adolescent; Antigens, CD; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Cadherins; Child; Drug Resistance; Female; Genotype; Humans; Logistic Models; Male; Polymorphism, Single Nucleotide; Receptors, G-Protein-Coupled; Receptors, Peptide; Socioeconomic Factors; Turkey | 2021 |
Metabolic profiling of norepinephrine reuptake inhibitor atomoxetine.
Topics: Animals; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Metabolomics; Mice; Microsomes, Liver; Norepinephrine; Rats | 2020 |
The 10-year trend in drug prescriptions for attention-deficit/hyperactivity disorder (ADHD) in Germany.
Topics: Adolescent; Adult; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Child, Preschool; Dextroamphetamine; Drug Prescriptions; Female; Germany; Guanfacine; Humans; Male; Methylphenidate; Practice Patterns, Physicians'; Young Adult | 2021 |
Review of lisdexamfetamine dimesylate in children and adolescents with attention deficit/hyperactivity disorder.
Topics: Adolescent; Adult; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Humans; Lisdexamfetamine Dimesylate; Quality of Life | 2020 |
Medication utilization among adult patients with attention-deficit/hyperactivity disorder after reimbursement criteria change.
Topics: Adolescent; Adult; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Drug Prescriptions; Female; Humans; Male; Methylphenidate | 2020 |
Lister hooded rats as a novel animal model of attention-deficit/hyperactivity disorder.
Topics: Animals; Atomoxetine Hydrochloride; Attention; Attention Deficit Disorder with Hyperactivity; Disease Models, Animal; Gene Expression Regulation; Guanfacine; Impulsive Behavior; Male; Maze Learning; Prefrontal Cortex; Rats; Rats, Inbred SHR; Rats, Inbred Strains; Rats, Wistar; Social Interaction; Species Specificity | 2020 |
Diagnosis and Management of Comorbid Anxiety and ADHD in Pediatric Primary Care.
Topics: Anxiety; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Comorbidity; Humans; Primary Health Care | 2020 |
Adult attention deficit/hyperactivity disorder in the ambulatory care setting: Erratum.
Topics: Ambulatory Care; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Bupropion; Contraindications, Drug; Dopamine; Feeding and Eating Disorders; Humans; Methylphenidate; Norepinephrine | 2020 |
[Investigation on the status of monotherapy for newly diagnosed tic disorders and its comorbidity in children].
Topics: Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Comorbidity; Female; Humans; Male; Tic Disorders; Tourette Syndrome | 2020 |
Alternations in nuclear factor kappa beta activity (NF-kB) in the rat brain due to long-term use of atomoxetine for treating ADHD: In vivo and in silico studies.
Topics: Adrenergic Uptake Inhibitors; Animals; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Brain; NF-kappa B; Rats; Rats, Wistar | 2021 |
Investigation of serum and brain superoxide dismutase levels depending on atomoxetine used in attention-deficit/hyperactivity disorder treatment: A combination of in vivo and molecular docking studies.
Topics: Administration, Oral; Animals; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Brain; Dose-Response Relationship, Drug; Male; Molecular Docking Simulation; Molecular Structure; Rats; Rats, Wistar; Structure-Activity Relationship; Superoxide Dismutase | 2020 |
Commentary: Identifying individualized predictions of response in ADHD pharmacotherapy - a commentary on Rodrigues et al. (2020).
Topics: Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Autism Spectrum Disorder; Child; Guanfacine; Humans; Methylphenidate | 2021 |
Drug prescription for attention deficit hyperactivity disorder drugs in pediatric outpatients: A retrospective survey of Japanese administrative data (2012-2018).
Topics: Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Drug Prescriptions; Female; Humans; Japan; Male; Methylphenidate; Outpatients; Pharmaceutical Preparations; Retrospective Studies | 2021 |
Treatment of attention deficit/hyperactivity disorder in children with CHD.
Topics: Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Humans; Methylphenidate; Retrospective Studies | 2021 |
Synergistic efficacy and diminished adverse effect profile of composite treatment of several ADHD medications.
Topics: Adrenergic Uptake Inhibitors; Animals; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Behavior, Animal; Disease Models, Animal; Dizocilpine Maleate; Dopamine Uptake Inhibitors; Drug Synergism; Drug Therapy, Combination; Excitatory Amino Acid Antagonists; Fluoxetine; Growth and Development; Methylphenidate; Mice; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Open Field Test; Proto-Oncogene Proteins c-akt; Selective Serotonin Reuptake Inhibitors; Sleep | 2021 |
Retrospective analysis of adverse events associated with non-stimulant ADHD medications reported to the united states food and drug administration.
Topics: Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Humans; Pharmaceutical Preparations; Retrospective Studies; United States; United States Food and Drug Administration | 2021 |
Topics: Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Female; Humans; Liver; Liver Function Tests; Male; Transgender Persons | 2021 |
Determination of atomoxetine levels in human plasma using LC-MS/MS and clinical application to Chinese children with ADHD based on CPIC guidelines.
Topics: Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; China; Chromatography, Liquid; Humans; Reproducibility of Results; Tandem Mass Spectrometry | 2021 |
Prevalence and determinants of attention deficit/hyperactivity disorder (ADHD) medication use during pregnancy: Results from the Quebec Pregnancy/Children Cohort.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Adult; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Cohort Studies; Drug Utilization; Female; Humans; Maternal-Fetal Exchange; Pregnancy; Prevalence; Quebec; Young Adult | 2021 |
Current use of attention-deficit hyperactivity disorder (ADHD) medications and clinical characteristics of child and adolescent psychiatric outpatients prescribed multiple ADHD medications in Japan.
Topics: Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Female; Guanfacine; Humans; Japan; Logistic Models; Male; Methylphenidate; Outpatients; Prospective Studies; Retrospective Studies | 2021 |
Medication Use in the Management of Comorbidities Among Individuals With Autism Spectrum Disorder From a Large Nationwide Insurance Database.
Topics: Adolescent; Amphetamines; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Autism Spectrum Disorder; Bupropion; Child; Child, Preschool; Cohort Studies; Comorbidity; Data Mining; Depressive Disorder, Major; Dexmethylphenidate Hydrochloride; Dextroamphetamine; Female; Health Services Accessibility; Humans; Insurance; Lisdexamfetamine Dimesylate; Male; Managed Care Programs; Prevalence; Retrospective Studies | 2021 |
Medications for attention-deficit/hyperactivity disorder in Japan: A retrospective cohort study of label compliance.
Topics: Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Humans; Japan; Male; Methylphenidate; Pharmaceutical Preparations; Retrospective Studies | 2021 |
Methylphenidate and atomoxetine treatment negatively affect physical growth indexes of school-age children and adolescents with attention-deficit/hyperactivity disorder.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Body Height; Body Mass Index; Body Weight; Central Nervous System Stimulants; Child; China; Female; Humans; Male; Methylphenidate; Schools; Time Factors | 2021 |
The lowest effective plasma concentration of atomoxetine in pediatric patients with attention deficit/hyperactivity disorder: A non-randomized prospective interventional study.
Topics: Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Double-Blind Method; Female; Humans; Male; Prospective Studies; Treatment Outcome | 2021 |
Atomoxetine and circadian gene expression in human dermal fibroblasts from study participants with a diagnosis of attention-deficit hyperactivity disorder.
Topics: Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Circadian Rhythm; Fibroblasts; Gene Expression; Humans; Sleep | 2021 |
Secular trends and regional variations in pharmacotherapy of attention-deficit/hyperactivity disorder (ADHD) among children and adolescents in Germany.
Topics: Adolescent; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Child, Preschool; Germany; Humans; Methylphenidate | 2021 |
Prenatal nicotine exposure decreases the release of dopamine in the medial frontal cortex and induces atomoxetine-responsive neurobehavioral deficits in mice.
Topics: Adrenergic Uptake Inhibitors; Animals; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Cognition Disorders; Dopamine; Female; Male; Mice; Mice, Inbred C57BL; Nicotine; Prefrontal Cortex; Pregnancy; Prenatal Exposure Delayed Effects | 2017 |
Age-related pharmacotherapy of attention deficit hyperactivity disorder in Slovenia in children and adolescents: A population-based study.
Topics: Adolescent; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Databases, Factual; Drug Prescriptions; Female; Humans; Male; Methylphenidate; Research Design; Slovenia | 2017 |
A new locus regulating MICALL2 expression was identified for association with executive inhibition in children with attention deficit hyperactivity disorder.
Topics: Animals; Asian People; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Brain; Child; China; Chromosomes, Human, Pair 7; Ethnicity; Executive Function; Female; Gene Expression; Genome-Wide Association Study; Humans; Impulsive Behavior; Male; Microfilament Proteins; Neuropsychological Tests; Phenotype; Quantitative Trait Loci; Zebrafish | 2018 |
Predictors of relapse or maintenance of response in pediatric and adult patients with attention-deficit/hyperactivity disorder following discontinuation of long-term treatment with atomoxetine.
Topics: Adolescent; Adult; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Female; Humans; Male; Middle Aged; Placebo Effect; Quality of Life; Randomized Controlled Trials as Topic; Recurrence; Risk Factors; Young Adult | 2017 |
Patient and provider characteristics related with prescribing of ADHD medication: Nationwide health insurance claims database study in Korea.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Child, Preschool; Databases, Factual; Drug Prescriptions; Female; Humans; Insurance, Health; Male; Methylphenidate; Physicians; Prevalence; Psychiatry; Republic of Korea | 2018 |
Individual Variability and Medications to Treat Attention-Deficit/Hyperactivity Disorder: The World According to the Caudate.
Topics: Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Corpus Striatum; Humans; Methylphenidate | 2017 |
Association Between Medication Use and Performance on Higher Education Entrance Tests in Individuals With Attention-Deficit/Hyperactivity Disorder.
Topics: Adult; Aptitude Tests; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Case-Control Studies; Central Nervous System Stimulants; Female; Humans; Male; Psychomotor Performance; Registries; Young Adult | 2017 |
ADHD Medication and Substance-Related Problems.
Topics: Adolescent; Adult; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Comorbidity; Female; Humans; Male; Sex Factors; Substance-Related Disorders; United States; Young Adult | 2017 |
Blockade of α2-adrenergic receptors in prelimbic cortex: impact on cocaine self-administration in adult spontaneously hypertensive rats following adolescent atomoxetine treatment.
Topics: Adrenergic alpha-2 Receptor Antagonists; Adrenergic Uptake Inhibitors; Age Factors; Animals; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Cocaine; Cocaine-Related Disorders; Male; Methylphenidate; Prefrontal Cortex; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Self Administration; Species Specificity | 2017 |
Methylphenidate and Atomoxetine-Responsive Prefrontal Cortical Genetic Overlaps in "Impulsive" SHR/NCrl and Wistar Rats.
Topics: Animals; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Choice Behavior; Disease Models, Animal; Impulsive Behavior; Male; Methylphenidate; Prefrontal Cortex; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Rats, Wistar | 2017 |
Atomoxetine Pharmacogenetics: Lessons Learned.
Topics: Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Genotype; Humans | 2017 |
Pharmacotherapy of Attention Deficit Hyperactivity Disorder Symptom Profile in ASD.
Topics: Aripiprazole; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Autism Spectrum Disorder; Clonidine; Comorbidity; Cross-Sectional Studies; Guanfacine; Humans; Methylphenidate; Randomized Controlled Trials as Topic; Risperidone; Social Adjustment; Treatment Outcome | 2017 |
Urinary Hesitancy Associated With Atomoxetine.
Topics: Adrenergic Uptake Inhibitors; Adult; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Depressive Disorder, Major; Humans; Male; Urinary Retention | 2017 |
Atomoxetine-Related Trichotillomania in a Boy with Attention-Deficit/Hyperactivity Disorder.
Topics: Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Humans; Male; Trichotillomania | 2017 |
Placental Complications Associated With Psychostimulant Use in Pregnancy.
Topics: Abruptio Placentae; Adrenergic Uptake Inhibitors; Adult; Amphetamine; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Cohort Studies; Female; Fetal Growth Retardation; Humans; Methylphenidate; Pre-Eclampsia; Pregnancy; Pregnancy Complications; Pregnancy Outcome; Pregnancy Trimesters; Premature Birth; Risk Assessment; Statistics as Topic | 2017 |
Shati/Nat8l knockout mice show behavioral deficits ameliorated by atomoxetine and methylphenidate.
Topics: Acetyltransferases; Amphetamine-Related Disorders; Animals; Aspartic Acid; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Behavior, Animal; Central Nervous System Stimulants; Methylphenidate; Mice, Knockout; Motor Activity | 2018 |
Healthcare utilization and costs of children with attention deficit/hyperactivity disorder initiating atomoxetine versus extended-release guanfacine.
Topics: Adolescent; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Cohort Studies; Delayed-Action Preparations; Female; Guanfacine; Health Care Costs; Humans; Male; Patient Acceptance of Health Care; Retrospective Studies | 2018 |
Case report: Cytochrome P450 implications for comorbid ADHD and OCD pharmacotherapy.
Topics: Adrenergic Uptake Inhibitors; Antidepressive Agents, Second-Generation; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Cytochromes; Fluoxetine; Humans; Male; Obsessive-Compulsive Disorder | 2017 |
Attention deficit hyperactivity disorder pharmacotherapy in Slovenian adults: a population-based study.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Adult; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Databases, Factual; Female; Humans; Male; Methylphenidate; Middle Aged; Population Surveillance; Slovenia; Young Adult | 2018 |
Risk of suicide attempts in adolescents and young adults with attention-deficit hyperactivity disorder: a nationwide longitudinal study.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Adult; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Female; Humans; Longitudinal Studies; Male; Methylphenidate; National Health Programs; Risk Factors; Suicide, Attempted; Taiwan; Young Adult | 2018 |
Semi-Automated Biomarker Discovery from Pharmacodynamic Effects on EEG in ADHD Rodent Models.
Topics: Animals; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Biomarkers; Disease Models, Animal; Electroencephalography; Humans; Linear Models; Methylphenidate; Rats; Rats, Inbred SHR | 2018 |
Evaluation of dystonia in children and adolescents treated with atomoxetine within the Truven MarketScan database: a retrospective cohort study.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Cohort Studies; Databases, Factual; Dystonia; Female; Humans; Incidence; Male; Propensity Score; Proportional Hazards Models; Retrospective Studies; Risk | 2018 |
Pediatric ADHD Medication Exposures Reported to US Poison Control Centers.
Topics: Adolescent; Age Distribution; Amphetamine; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Child, Preschool; Drug Misuse; Humans; Infant; Infant, Newborn; Medication Errors; Methylphenidate; Modafinil; Patient Admission; Poison Control Centers; Retrospective Studies; Suicide, Attempted; United States; Young Adult | 2018 |
Prevalence, incidence and persistence of ADHD drug use in Japan.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Child, Preschool; Cohort Studies; Drug Prescriptions; Female; Humans; Incidence; Infant; Infant, Newborn; Japan; Male; Methylphenidate; Practice Patterns, Physicians'; Prevalence; Psychotropic Drugs; Retrospective Studies; Young Adult | 2019 |
Trends in attention-deficit hyperactivity disorder medication use: a retrospective observational study using population-based databases.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Adult; Asia; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Australia; Central Nervous System Stimulants; Child; Child, Preschool; Europe; Female; Humans; Male; Methylphenidate; Middle Aged; Practice Patterns, Physicians'; Prevalence; Retrospective Studies; United States; Young Adult | 2018 |
Delusional infestation in the treatment of ADHD with atomoxetine.
Topics: Adrenergic Uptake Inhibitors; Adult; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Delusional Parasitosis; Female; Humans | 2018 |
Treatment of Adult ADHD without Stimulants: Effectiveness in A Dually Diagnosed Correctional Population.
Topics: Adrenergic Agents; Adult; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Comorbidity; Diagnosis, Dual (Psychiatry); Female; Follow-Up Studies; Guanfacine; Humans; Male; Mental Disorders; Nortriptyline; Outcome Assessment, Health Care; Prisoners; Retrospective Studies; Severity of Illness Index; Substance-Related Disorders | 2019 |
Facial nerve palsy associated with atomoxetine-induced hypertension.
Topics: Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Facial Paralysis; Humans; Hypertension; Male; Neuroimaging | 2019 |
Effect of ADHD medication in male C57BL/6J mice performing the rodent Continuous Performance Test.
Topics: Amphetamine; Animals; Atomoxetine Hydrochloride; Attention; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Impulsive Behavior; Male; Methylphenidate; Mice; Mice, Inbred C57BL; Neuropsychological Tests; Rodentia | 2019 |
Incidence and risk of attention-deficit hyperactivity disorder in children with amblyopia: A nationwide cohort study.
Topics: Adrenergic Uptake Inhibitors; Amblyopia; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Bupropion; Child; Cohort Studies; Databases, Factual; Dopamine Uptake Inhibitors; Female; Humans; Incidence; Male; Methylphenidate; National Health Programs; Risk Factors; Taiwan; Visual Acuity | 2019 |
Differential effects of ADHD medications on impulsive action in the mouse 5-choice serial reaction time task.
Topics: Adrenergic Uptake Inhibitors; Animals; Atomoxetine Hydrochloride; Attention; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Choice Behavior; Impulsive Behavior; Male; Methylphenidate; Mice; Mice, Inbred C57BL; Reaction Time | 2019 |
[Treatment of attention-deficit/hyperactivity disorder in clinical practice. A retrospective study].
Topics: Adolescent; Adrenergic Uptake Inhibitors; Age Distribution; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Female; Humans; Male; Methylphenidate; Patient Dropouts; Psychotherapy; Retrospective Studies; Sex Distribution | 2019 |
Drug Prescriptions for Children With ADHD in Japan: A Study Based on Health Insurance Claims Data Between 2005 and 2015.
Topics: Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Drug Prescriptions; Humans; Insurance, Health; Japan; Methylphenidate | 2020 |
Delusional infestation in the treatment of ADHD with atomoxetine.
Topics: Adrenergic Uptake Inhibitors; Adult; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Delusional Parasitosis; Female; Humans | 2019 |
Raynaud's Phenomenon Related with Atomoxetine Treatment in a Child with Autism and Attention-Deficit/Hyperactivity Disorder.
Topics: Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Autistic Disorder; Child; Drug-Related Side Effects and Adverse Reactions; Humans; Male; Problem Behavior; Raynaud Disease | 2019 |
Consumption of methylphenidate and atomoxetine in the private healthcare sector in South Africa: a longitudinal study.
Topics: Adolescent; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Databases, Factual; Drug Utilization; Female; Health Care Sector; Humans; Longitudinal Studies; Male; Methylphenidate; Practice Patterns, Physicians'; Private Sector; South Africa | 2019 |
Four-year outcome in psychopharmacologically treated adults with attention-deficit/hyperactivity disorder: a questionnaire survey.
Topics: Adult; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Delayed-Action Preparations; Dextroamphetamine; Female; Follow-Up Studies; Humans; Male; Medication Adherence; Methylphenidate; Norway; Prognosis; Propylamines; Surveys and Questionnaires; Treatment Outcome | 2013 |
Atomoxetine-induced life-threatening long QT syndrome.
Topics: Adolescent; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Female; Humans; Long QT Syndrome; Propylamines | 2013 |
Management of adult attention deficit hyperactivity disorder in UK primary care: a survey of general practitioners.
Topics: Adult; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Data Collection; Dextroamphetamine; General Practitioners; Humans; Male; Medication Adherence; Methylphenidate; Practice Patterns, Physicians'; Primary Health Care; Propylamines; Surveys and Questionnaires; Treatment Outcome; United Kingdom | 2013 |
Successful treatment with atomoxetine of an adolescent boy with attention deficit/hyperactivity disorder, extreme obesity, and reduced melanocortin 4 receptor function.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; DNA Mutational Analysis; Genetic Predisposition to Disease; Humans; Male; Mutation; Obesity; Phenotype; Propylamines; Receptor, Melanocortin, Type 4; Risk Reduction Behavior; Treatment Outcome; Weight Loss | 2013 |
Methylphenidate and atomoxetine for treatment of nocturnal enuresis in a child with attention-deficit hyperactivity disorder.
Topics: Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Female; Humans; Methylphenidate; Nocturnal Enuresis; Propylamines; Treatment Outcome | 2013 |
Atomoxetine response in the inattentive and combined subtypes of attention deficit hyperactivity disorder: a retrospective chart review.
Topics: Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Female; Humans; Male; Medical Records; Propylamines; Psychiatric Status Rating Scales; Retrospective Studies; Treatment Outcome | 2013 |
[ADHD register: post-marketing evaluation of the benefit-risk profile of drugs and promotion of the appropriateness].
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Dopamine Uptake Inhibitors; Drug Industry; Female; Humans; Male; Methylphenidate; Product Surveillance, Postmarketing; Propylamines; Registries; Risk Assessment | 2013 |
Adolescent atomoxetine treatment in a rodent model of ADHD: effects on cocaine self-administration and dopamine transporters in frontostriatal regions.
Topics: Adrenergic Uptake Inhibitors; Animals; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Cocaine; Corpus Striatum; Disease Models, Animal; Dopamine; Dopamine Plasma Membrane Transport Proteins; Dopamine Uptake Inhibitors; Dose-Response Relationship, Drug; Frontal Lobe; Male; Propylamines; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Reinforcement Schedule; Self Administration | 2013 |
Effects of stimulants and atomoxetine on cortisol levels in children with ADHD.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Female; Humans; Hydrocortisone; Male; Methylphenidate; Propylamines; Psychiatric Status Rating Scales; Saliva; Treatment Outcome | 2013 |
Clinical doses of atomoxetine significantly occupy both norepinephrine and serotonin transports: Implications on treatment of depression and ADHD.
Topics: Adrenergic Uptake Inhibitors; Animals; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Brain; Depression; Dose-Response Relationship, Drug; Macaca mulatta; Norepinephrine Plasma Membrane Transport Proteins; Positron-Emission Tomography; Propylamines; Serotonin Plasma Membrane Transport Proteins; Tissue Distribution | 2014 |
A case of severe akathisia with atomoxetine.
Topics: Adrenergic Uptake Inhibitors; Akathisia, Drug-Induced; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Female; Humans; Propylamines; Severity of Illness Index | 2013 |
Dose-dependent Raynaud's phenomenon developing from use of atomoxetine in a girl.
Topics: Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Dose-Response Relationship, Drug; Female; Humans; Propylamines; Raynaud Disease | 2013 |
Comparative efficacy of guanfacine extended release versus atomoxetine for the treatment of attention-deficit/hyperactivity disorder in children and adolescents: applying matching-adjusted indirect comparison methodology.
Topics: Adolescent; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Comparative Effectiveness Research; Delayed-Action Preparations; Dose-Response Relationship, Drug; Guanfacine; Humans; Propylamines; Psychiatric Status Rating Scales; Randomized Controlled Trials as Topic; Severity of Illness Index; Treatment Outcome | 2013 |
Five-fold increase in national prevalence rates of attention-deficit/hyperactivity disorder medications for children and adolescents with autism spectrum disorder, attention-deficit/hyperactivity disorder, and other psychiatric disorders: a Danish registe
Topics: Adolescent; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Child Development Disorders, Pervasive; Denmark; Dextroamphetamine; Female; Humans; Male; Mental Disorders; Methylphenidate; Practice Patterns, Physicians'; Prevalence; Propylamines; Registries | 2013 |
Attention-deficit/hyperactivity disorder drugs and growth: an Italian prospective observational study.
Topics: Adolescent; Adolescent Development; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Body Height; Body Weight; Central Nervous System Stimulants; Child; Child Development; Female; Humans; Italy; Male; Methylphenidate; Propylamines; Prospective Studies; Registries | 2013 |
Toward systems neuroscience of shared and distinct neural effects of medications used to treat attention-deficit/hyperactivity disorder.
Topics: Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Brain; Humans; Male; Methylphenidate; Propylamines | 2013 |
Buspirone use in the treatment of atomoxetine-induced bruxism.
Topics: Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Bruxism; Buspirone; Child; Follow-Up Studies; Humans; Male; Propylamines; Serotonin Receptor Agonists; Treatment Outcome | 2013 |
Atomoxetine-induced mydriasis in a child patient.
Topics: Adrenergic Uptake Inhibitors; Adverse Drug Reaction Reporting Systems; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Male; Mydriasis; Propylamines; Treatment Outcome | 2014 |
Life-threatening QT prolongation in a boy with attention-deficit/hyperactivity disorder on atomoxetine.
Topics: Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Diagnosis, Differential; Echocardiography; Electrocardiography; Follow-Up Studies; Humans; Long QT Syndrome; Male; Propylamines; Takotsubo Cardiomyopathy | 2014 |
The efficacy of atomoxetine as adjunctive treatment for co-morbid substance use disorders and externalizing symptoms.
Topics: Adrenergic Uptake Inhibitors; Adult; Antisocial Personality Disorder; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Female; Humans; Impulsive Behavior; Male; Propylamines; Quality of Life; Substance-Related Disorders; Treatment Outcome | 2013 |
Atomoxetine affects transcription/translation of the NMDA receptor and the norepinephrine transporter in the rat brain--an in vivo study.
Topics: Adrenergic Uptake Inhibitors; Animals; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Brain; Gene Expression Regulation; Glutamic Acid; Injections, Intraperitoneal; Male; Norepinephrine Plasma Membrane Transport Proteins; Propylamines; Rats; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate; RNA, Messenger; Species Specificity; Time Factors; Transcription, Genetic | 2013 |
Reduced short interval cortical inhibition correlates with atomoxetine response in children with attention-deficit hyperactivity disorder (ADHD).
Topics: Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Female; Humans; Inhibition, Psychological; Male; Motor Cortex; Neural Inhibition; Propylamines; Time Factors; Transcranial Direct Current Stimulation | 2014 |
Meta-analysis and moderator analysis: can the field develop further?
Topics: Adrenergic alpha-2 Receptor Agonists; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Humans; Propylamines; Treatment Outcome | 2014 |
Atomoxetine resulting in Takotsubo syndrome: is the locally-released norepinephrine from the autonomic sympathetic cardiac nerves or the blood-borne catecholamines the cause?
Topics: Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Heart; Humans; Male; Norepinephrine; Propylamines; Sympathetic Nervous System; Takotsubo Cardiomyopathy | 2014 |
Atomoxetine-induced hypomania-like symptoms in a preadolescent patient.
Topics: Adrenergic Uptake Inhibitors; Anxiety Disorders; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Bipolar Disorder; Child; Humans; Male; Propylamines | 2014 |
ADHD Medication Trends in Turkey: 2009-2013.
Topics: Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Databases, Factual; Delayed-Action Preparations; Drug Administration Schedule; Drug Prescriptions; Female; Humans; Male; Methylphenidate; Practice Patterns, Physicians'; Seasons; Treatment Outcome; Turkey | 2017 |
[Drug therapy for AD/HD investigation of usefulness of extended-release methylphenidate and atomoxetine from the viewpoint of persistency rate].
Topics: Adolescent; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Child Development Disorders, Pervasive; Drug Therapy, Combination; Female; Humans; Male; Methylphenidate; Propylamines; Treatment Outcome; Young Adult | 2014 |
Atomoxetine-induced increases in monoamine release in the prefrontal cortex are similar in spontaneously hypertensive rats and Wistar-Kyoto rats.
Topics: Animals; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Disease Models, Animal; Dopamine; Male; Norepinephrine; Potassium; Prefrontal Cortex; Propylamines; Rats, Inbred SHR; Rats, Inbred WKY; Serotonin | 2014 |
Prefrontal grey and white matter neurometabolite changes after atomoxetine and methylphenidate in children with attention deficit/hyperactivity disorder: a (1)H magnetic resonance spectroscopy study.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Aspartic Acid; Atomoxetine Hydrochloride; Attention; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Choline; Creatine; Female; Glutamic Acid; Glutamine; Humans; Magnetic Resonance Spectroscopy; Male; Methylphenidate; Nerve Fibers, Myelinated; Nerve Fibers, Unmyelinated; Prefrontal Cortex; Propylamines; Treatment Outcome | 2014 |
A nationwide study of attention-deficit/hyperactivity disorder drug use among adults in Iceland 2003-2012.
Topics: Adult; Age Factors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Female; Humans; Iceland; Male; Methylphenidate; Middle Aged; Practice Patterns, Physicians'; Prevalence; Propylamines; Time Factors; Young Adult | 2014 |
Predictors of pharmacological treatment outcomes with atomoxetine or methylphenidate in patients with attention-deficit/hyperactivity disorder from China, Egypt, Lebanon, Russian Federation, Taiwan, and United Arab Emirates.
Topics: Adolescent; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; China; Egypt; Female; Humans; Lebanon; Male; Methylphenidate; Propylamines; Prospective Studies; Russia; Taiwan; Treatment Outcome; United Arab Emirates | 2014 |
Findings from the observational COMPLY study in children and adolescents with ADHD: core symptoms, ADHD-related difficulties, and patients' emotional expression during psychostimulant or nonstimulant ADHD treatment.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Drug Therapy, Combination; Emotions; Female; Humans; Male; Propylamines; Prospective Studies; Quality of Life; Severity of Illness Index | 2014 |
Addressing the unique issues of student athletes with ADHD.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Diagnosis, Differential; Heat Stress Disorders; Humans; Propylamines; Sports | 2014 |
Cocaine-seeking behavior in a genetic model of attention-deficit/hyperactivity disorder following adolescent methylphenidate or atomoxetine treatments.
Topics: Animals; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Cocaine-Related Disorders; Conditioning, Operant; Drug-Seeking Behavior; Extinction, Psychological; Male; Methylphenidate; Propylamines; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Rats, Wistar; Species Specificity | 2014 |
Detecting and treating adult attention deficit hyperactivity disorder in a patient with schizophrenia.
Topics: Antipsychotic Agents; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Comorbidity; Day Care, Medical; Drug Therapy, Combination; Humans; Male; Patient Admission; Personality Assessment; Propylamines; Psychiatric Status Rating Scales; Schizophrenia; Schizophrenic Psychology; Young Adult | 2014 |
Genetic and pharmacological modulation of the steroid sulfatase axis improves response control; comparison with drugs used in ADHD.
Topics: Adrenergic Uptake Inhibitors; Animals; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Agents; Central Nervous System Stimulants; Coumarins; Dehydroepiandrosterone Sulfate; Disease Models, Animal; Enzyme Inhibitors; Inhibition, Psychological; Male; Methylphenidate; Mice, Transgenic; Neuropsychological Tests; Propylamines; Psychomotor Performance; Steryl-Sulfatase; Sulfonamides | 2014 |
Pay attention to impulsivity: modelling low attentive and high impulsive subtypes of adult ADHD in the 5-choice continuous performance task (5C-CPT) in female rats.
Topics: Analysis of Variance; Animals; Atomoxetine Hydrochloride; Attention; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Choice Behavior; Disease Models, Animal; Female; Impulsive Behavior; Methylphenidate; Propylamines; Rats; Reaction Time | 2014 |
Drug treatment for attention-deficit/hyperactivity disorder and suicidal behaviour: register based study.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Adult; Amphetamine; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Female; Humans; Incidence; Longitudinal Studies; Male; Methylphenidate; Middle Aged; Propylamines; Registries; Suicide; Sweden; Young Adult | 2014 |
Medical treatment of children and youths with attention-deficit/hyperactivity disorder (ADHD): a Norwegian Prescription Registry Based Study.
Topics: Adolescent; Amphetamine; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Child, Preschool; Dextroamphetamine; Drug Utilization; Female; Humans; Male; Methylphenidate; Norway; Practice Patterns, Physicians'; Propylamines; Quality of Life; Registries; Residence Characteristics | 2014 |
Atomoxetine-induced mania with auditory hallucination in an 8-year-old boy with attention-deficit/hyperactivity disorder and tic disorder.
Topics: Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Bipolar Disorder; Child; Hallucinations; Humans; Male; Propylamines; Tic Disorders | 2014 |
Comparison of pregnancy and lactation labeling for attention-deficit hyperactivity disorder drugs marketed in Australia, the USA, Denmark, and the UK.
Topics: Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Australia; Benzhydryl Compounds; Central Nervous System Stimulants; Contraindications; Data Collection; Denmark; Drug Labeling; Female; Humans; Lactation; Methylphenidate; Modafinil; Pregnancy; Propylamines; United Kingdom; United States | 2014 |
Effects of atomoxetine on attention and impulsivity in the five-choice serial reaction time task in rats with lesions of dorsal noradrenergic ascending bundle.
Topics: Adrenergic Agents; Adrenergic Uptake Inhibitors; Afferent Pathways; Animals; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Benzylamines; Brain; Brain Injuries; Choice Behavior; Impulsive Behavior; Male; Microdialysis; Naltrexone; Norepinephrine; Norepinephrine Plasma Membrane Transport Proteins; Propylamines; Rats; Rats, Sprague-Dawley; Reaction Time; Zimeldine | 2015 |
Atomoxetine in the treatment of attention deficit hyperactivity disorder and suicidal ideation.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Dose-Response Relationship, Drug; Female; Humans; Italy; Male; Propylamines; Registries; Self-Injurious Behavior; Suicidal Ideation | 2014 |
Atomoxetine-associated akathisia: a case report.
Topics: Adrenergic Uptake Inhibitors; Akathisia, Drug-Induced; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Humans; Male; Propylamines | 2014 |
Early discontinuation of attention-deficit/hyperactivity disorder drug treatment: a Danish nationwide drug utilization study.
Topics: Adolescent; Adult; Age Factors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Chemistry, Pharmaceutical; Child; Denmark; Drug Prescriptions; Drug Utilization; Female; Health Care Surveys; Humans; Male; Methylphenidate; Middle Aged; Sex Factors; Young Adult | 2015 |
[Pharmacological management of attention deficit hyperactivity disorder with methylphenidate and atomoxetine within a context of epilepsy].
Topics: Adolescent; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Child, Preschool; Disease Management; Electroencephalography; Epilepsy; Female; Follow-Up Studies; Humans; Male; Methylphenidate; Retrospective Studies | 2014 |
Efficacy and Safety Extrapolation Analyses for Atomoxetine in Young Children with Attention-Deficit/Hyperactivity Disorder.
Topics: Adrenergic Uptake Inhibitors; Age Factors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Child, Preschool; Double-Blind Method; Female; Humans; Male; Randomized Controlled Trials as Topic; Safety | 2015 |
Effect of atomoxetine on hyperactivity in an animal model of attention-deficit/hyperactivity disorder (ADHD).
Topics: Adrenergic Uptake Inhibitors; Animals; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Male; Rats; Rats, Inbred SHR; Rats, Inbred WKY | 2014 |
Could atomoxetine improve sluggish cognitive tempo symptoms?
Topics: Adolescent; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Cognition; Cognition Disorders; Humans; Nootropic Agents; Propylamines | 2014 |
Impact of a restrictive drug access program on the risk of cardiovascular encounters in children exposed to ADHD medications.
Topics: Adolescent; Amphetamines; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Cardiovascular Diseases; Case-Control Studies; Central Nervous System Stimulants; Child; Drug Costs; Emergency Service, Hospital; Female; Health Services Accessibility; Hospitalization; Humans; Insurance, Health, Reimbursement; Insurance, Pharmaceutical Services; Logistic Models; Male; Methylphenidate; Odds Ratio; Office Visits; Program Evaluation; Propylamines; Quebec; Risk Assessment; Risk Factors | 2014 |
Treatment receipt and outcomes from a clinic employing the attention-deficit/hyperactivity disorder treatment guideline of the children's medication algorithm project.
Topics: Adolescent; Algorithms; Amphetamine; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Child, Preschool; Female; Humans; Male; Medication Adherence; Methylphenidate; Practice Guidelines as Topic; Propylamines; Treatment Outcome | 2014 |
Treatment compliance or medication adherence in children and adolescents on ADHD medication in clinical practice: results from the COMPLY observational study.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Female; Humans; Male; Medication Adherence; Methylphenidate; Prospective Studies; Time Factors | 2015 |
Suboptimal dosing of Strattera (atomoxetine) for ADHD patients.
Topics: Adrenergic Uptake Inhibitors; Adult; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Dose-Response Relationship, Drug; Humans; Propylamines; Time Factors | 2014 |
Safety and tolerability of atomoxetine in treatment of attention deficit hyperactivity disorder in adult patients: an integrated analysis of 15 clinical trials.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Adult; Aged; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Blood Pressure; Clinical Trials as Topic; Drug Administration Schedule; Female; Heart Rate; Humans; Male; Middle Aged; Propylamines; Treatment Outcome; Young Adult | 2015 |
Effectiveness of one-year pharmacological treatment of adult attention-deficit/hyperactivity disorder (ADHD): an open-label prospective study of time in treatment, dose, side-effects and comorbidity.
Topics: Adrenergic Uptake Inhibitors; Adult; Amphetamine; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Longitudinal Studies; Male; Medication Adherence; Mental Disorders; Methylphenidate; Propylamines; Prospective Studies; Psychiatric Status Rating Scales; Stress, Psychological; Time Factors; Young Adult | 2014 |
Persistent camptocormia associated with atomoxetine in a child with attention-deficit/hyperactivity disorder.
Topics: Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Follow-Up Studies; Humans; Male; Muscular Atrophy, Spinal; Propylamines; Spinal Curvatures | 2014 |
Validation of the adult attention-deficit/hyperactivity disorder quality-of-life scale in European patients: comparison with patients from the USA.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Adult; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Clinical Trials, Phase III as Topic; Europe; Factor Analysis, Statistical; Female; Humans; Male; Middle Aged; Multicenter Studies as Topic; Psychiatric Status Rating Scales; Psychometrics; Quality of Life; Randomized Controlled Trials as Topic; United States; Young Adult | 2015 |
The effects of atomoxetine on emotional control in adults with ADHD: An integrated analysis of multicenter studies.
Topics: Adrenergic Uptake Inhibitors; Adult; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Dose-Response Relationship, Drug; Emotions; Executive Function; Female; Humans; Male; Middle Aged; Quality of Life; Treatment Outcome | 2015 |
Injury prevention by medication among children with attention-deficit/hyperactivity disorder: a case-only study.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Brain Injuries; Central Nervous System Stimulants; Child; Child, Preschool; Germany; Hospitalization; Humans; Incidence; Methylphenidate; Propylamines; Risk; Wounds and Injuries | 2015 |
[Reconsider the diagnosis and treatment approach for ADHD].
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Female; Humans; Male; Methylphenidate; Sex Factors | 2015 |
Differences in abuse potential of ADHD drugs measured by contrasting poison centre and therapeutic use data.
Topics: Adolescent; Adult; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Denmark; Drug Utilization; Female; Humans; Male; Methylphenidate; Poison Control Centers; Propylamines; Registries; Retrospective Studies; Substance-Related Disorders; Young Adult | 2015 |
Trends in attention-deficit/hyperactivity disorder drug consumption in children and adolescents in Slovenia from 2001 to 2012: a drug use study from a national perspective.
Topics: Adolescent; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Databases, Factual; Drug Approval; Drug Costs; Drug Delivery Systems; Humans; Methylphenidate; Practice Patterns, Physicians'; Slovenia | 2015 |
Assessment and treatment of attention-deficit/hyperactivity disorder: part 2.
Topics: Adolescent; Adrenergic alpha-Agonists; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Central Nervous System Stimulants; Child; Child, Preschool; Humans; Methylphenidate | 2015 |
Efficacy of atomoxetine for symptoms of attention-deficit/hyperactivity disorder in children with a history of child abuse.
Topics: Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Child Abuse; Female; Humans; Male; Psychiatric Status Rating Scales; Retrospective Studies; Severity of Illness Index; Treatment Outcome | 2015 |
Effect of Atomoxetine on the Cognitive Functions in Treatment of Attention Deficit Hyperactivity Disorder in Children with Congenital Hypothyroidism: A Pilot Study.
Topics: Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Cognition; Congenital Hypothyroidism; Female; Humans; Male; Outpatients; Pilot Projects; Psychological Tests; Treatment Outcome | 2015 |
[Children's relative age in class and medication for attention-deficit/hyperactivity disorder. A population-based study in a health department in Spain].
Topics: Age Factors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Cross-Sectional Studies; Drug Therapy, Combination; Female; Humans; Male; Methylphenidate; Prevalence; Seasons; Spain; Students | 2015 |
No evidence for predictors of response to atomoxetine treatment of attention-deficit/hyperactivity disorder symptoms in children and adolescents with autism spectrum disorder.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Autism Spectrum Disorder; Child; Female; Humans; Male | 2015 |
Avoiding stimulants may not prevent manic switch: a case report with atomoxetine.
Topics: Adolescent; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Bipolar Disorder; Central Nervous System Stimulants; Female; Humans | 2014 |
Marked exacerbation of ADHD after onset of inhalant use: a case report.
Topics: Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Humans; Inhalant Abuse; Male; Petroleum | 2014 |
Effects of atomoxetine on heart rhythm in children and adolescents.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Drug Administration Schedule; Electrocardiography; Female; Follow-Up Studies; Heart Rate; Humans; Male; Prospective Studies; Time Factors; Treatment Outcome | 2015 |
Effectiveness of Atomoxetine in the Treatment of Children With Encopresis.
Topics: Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Encopresis; Female; Humans; Male; Treatment Outcome | 2015 |
Attention-deficit/hyperactivity disorder Under Treatment Outcomes Research (AUTOR): a European observational study in pediatric subjects.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Europe; Female; Follow-Up Studies; Humans; Longitudinal Studies; Male; Prospective Studies; Quality of Life; Severity of Illness Index; Time Factors; Treatment Outcome | 2015 |
Combined methylphenidate and atomoxetine pharmacotherapy in attention deficit hyperactivity disorder.
Topics: Adolescent; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Diagnostic and Statistical Manual of Mental Disorders; Drug Therapy, Combination; Female; Headache; Humans; Male; Methylphenidate; Psychiatric Status Rating Scales; Severity of Illness Index; Treatment Outcome | 2015 |
Effect of drugs on the risk of injuries in children with attention deficit hyperactivity disorder: a prospective cohort study.
Topics: Accidents; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Child, Preschool; Cohort Studies; Denmark; Dextroamphetamine; Female; Humans; Male; Methylphenidate; Prospective Studies; Wounds and Injuries | 2015 |
Real-World Dosing Patterns of Atomoxetine in Adults with Attention-Deficit/Hyperactivity Disorder.
Topics: Adolescent; Adult; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Databases, Pharmaceutical; Female; Humans; Male; Middle Aged; Practice Patterns, Physicians'; Psychotropic Drugs; Retrospective Studies; Sex Factors; United States; Young Adult | 2015 |
Differential therapeutic effects of 12-week treatment of atomoxetine and methylphenidate on drug-naïve children with attention deficit/hyperactivity disorder: A counting Stroop functional MRI study.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Analysis of Variance; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Brain; Central Nervous System Stimulants; Child; Female; Humans; Image Processing, Computer-Assisted; Magnetic Resonance Imaging; Male; Methylphenidate; Neuropsychological Tests; Oxygen; Psychiatric Status Rating Scales; Taiwan | 2015 |
Attention-deficit hyperactivity disorder, its treatment with medication and the probability of developing a depressive disorder: A nationwide population-based study in Taiwan.
Topics: Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Comorbidity; Depressive Disorder; Female; Humans; Male; Methylphenidate; Probability; Retrospective Studies; Taiwan | 2016 |
Atomoxetine monotherapy compared with combination therapy for the treatment of ADHD: a retrospective chart review study.
Topics: Adrenergic Uptake Inhibitors; Adult; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Drug Therapy, Combination; Humans; Retrospective Studies; Treatment Outcome | 2015 |
Patterns of long-term and short-term responses in adult patients with attention-deficit/hyperactivity disorder in a completer cohort of 12 weeks or more with atomoxetine.
Topics: Adrenergic Uptake Inhibitors; Adult; Atomoxetine Hydrochloride; Attention; Attention Deficit Disorder with Hyperactivity; Cluster Analysis; Female; Humans; Longitudinal Studies; Male; Middle Aged; Time; Treatment Outcome | 2015 |
Attention-deficit hyperactivity disorder, its pharmacotherapy, and the risk of developing bipolar disorder: A nationwide population-based study in Taiwan.
Topics: Adolescent; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Bipolar Disorder; Central Nervous System Stimulants; Child; Cohort Studies; Comorbidity; Female; Follow-Up Studies; Humans; Male; Methylphenidate; Risk; Survival Analysis; Taiwan | 2016 |
Impact of negative media publicity on attention-deficit/hyperactivity disorder medication in Taiwan.
Topics: Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Databases, Factual; Female; Humans; Inappropriate Prescribing; Insurance, Pharmaceutical Services; Male; Medical Overuse; Methylphenidate; Social Media; Taiwan | 2016 |
Single dose, CYP2D6 genotype-stratified pharmacokinetic study of atomoxetine in children with ADHD.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Alleles; Area Under Curve; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Biotransformation; Child; Cohort Studies; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2D6; Female; Genotype; Humans; Longitudinal Studies; Male; Precision Medicine | 2016 |
Exploratory analysis of early treatment discontinuation and clinical outcomes of patients with attention-deficit/hyperactivity disorder.
Topics: Adolescent; Atomoxetine Hydrochloride; Attention; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; China; Female; Humans; Male; Medication Adherence; Methylphenidate; Treatment Outcome | 2017 |
Risk of Injury According to Attention Deficit Hyperactivity Disorder, Comorbid Mental Illness, and Medication Therapy.
Topics: Adolescent; Adult; Amphetamine; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Child, Preschool; Comorbidity; Female; Humans; Infant; Male; Methylphenidate; Middle Aged; Neurotic Disorders; Personality Disorders; Psychoses, Substance-Induced; Psychotic Disorders; United States; Wounds and Injuries; Young Adult | 2016 |
Seasonal Patterns of Medications for Treating Attention-Deficit/Hyperactivity Disorder: Comparison of Methylphenidate and Atomoxetine.
Topics: Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Chemistry, Pharmaceutical; Child; Child, Preschool; Databases, Factual; Female; Humans; Male; Methylphenidate; Seasons; Taiwan | 2016 |
Switch in Therapy from Methylphenidate to Atomoxetine in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: An Analysis of Patient Records.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Denmark; Drug Substitution; Electronic Health Records; Female; Humans; Male; Medication Adherence; Methylphenidate; Patient Preference; Time Factors; Treatment Outcome | 2016 |
Atomoxetine Increased Effect over Time in Adults with Attention-Deficit/Hyperactivity Disorder Treated for up to 6 Months: Pooled Analysis of Two Double-Blind, Placebo-Controlled, Randomized Trials.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Adult; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Middle Aged; Multicenter Studies as Topic; Psychiatric Status Rating Scales; Randomized Controlled Trials as Topic; Retrospective Studies; Time Factors; Treatment Outcome; United States; Young Adult | 2016 |
The impact of a model-based clinical regional registry for attention-deficit hyperactivity disorder.
Topics: Adolescent; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Child, Preschool; Electronic Health Records; Female; Health Information Exchange; Humans; Italy; Male; Medical Informatics; Methylphenidate; Psychotropic Drugs; Registries | 2017 |
Characterization of Atomoxetine Biotransformation and Implications for Development of PBPK Models for Dose Individualization in Children.
Topics: Adolescent; Adult; Age Factors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Biotransformation; Central Nervous System Stimulants; Child; Cytochrome P-450 Enzyme System; Drug Dosage Calculations; Genotype; Humans; Hydroxylation; Infant; Isoenzymes; Methylation; Microsomes, Liver; Middle Aged; Models, Biological; Phenols; Phenotype; Propylamines; Substrate Specificity; Young Adult | 2016 |
Factors predicting treatment adherence in patients with adult attention-deficit/hyperactivity disorder: a preliminary study.
Topics: Adolescent; Adult; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Female; Humans; Male; Medication Adherence; Methylphenidate; Middle Aged; Risk Factors; Young Adult | 2016 |
The quantified EEG characteristics of responders and non-responders to long-term treatment with atomoxetine in children with attention deficit hyperactivity disorders.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Brain Mapping; Brain Waves; Child; Electroencephalography; Electromyography; Female; Humans; Longitudinal Studies; Male; Psychiatric Status Rating Scales; Surveys and Questionnaires; Time Factors | 2016 |
Atomoxetine-related Takotsubo Cardiomyopathy.
Topics: Adrenergic Uptake Inhibitors; Adult; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Drug Interactions; Female; Fluoxetine; Humans; Selective Serotonin Reuptake Inhibitors; Takotsubo Cardiomyopathy | 2016 |
A cost-effectiveness analysis of off-label atypical antipsychotic treatment in children and adolescents with ADHD who have failed stimulant therapy.
Topics: Adolescent; Antipsychotic Agents; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Clonidine; Cost-Benefit Analysis; Decision Support Techniques; Guanfacine; Health Care Costs; Humans; Monte Carlo Method; Quality-Adjusted Life Years; Treatment Failure | 2016 |
Relationships Between Functional Outcomes and Symptomatic Improvement in Atomoxetine-Treated Adult Patients with Attention-Deficit/Hyperactivity Disorder: Post Hoc Analysis of an Integrated Database.
Topics: Adrenergic Uptake Inhibitors; Adult; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Databases, Factual; Female; Humans; Male; Middle Aged; Propylamines; Psychiatric Status Rating Scales; Quality of Life; Self Report; Severity of Illness Index; Treatment Outcome | 2016 |
Effects of Atomoxetine in Individuals with Attention-Deficit/Hyperactivity Disorder and Low-Functioning Autism Spectrum Disorder.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Autism Spectrum Disorder; Child; Female; Humans; Male; Psychiatric Status Rating Scales; Retrospective Studies; Time Factors; Treatment Outcome | 2016 |
Atomoxetine for the Treatment of ADHD in Incarcerated Adolescents.
Topics: Adolescent; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Comorbidity; Humans; Male; Prisoners; Substance-Related Disorders; Treatment Outcome; Young Adult | 2016 |
Risk of Suicidal Events With Atomoxetine Compared to Stimulant Treatment: A Cohort Study.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Antidepressive Agents; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Child, Preschool; Humans; Propensity Score; Proportional Hazards Models; Retrospective Studies; Suicidal Ideation; Suicide; Suicide, Attempted | 2016 |
Atomoxetine, ADHD, and the ongoing debate about increased risk of suicidal behaviors: the understudied role of kappa opioid receptor agonism Response to: Capuano A, Scavone C, Rafaniello C, et al. Atomoxetine in the treatment of attention deficit hyperact
Topics: Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Humans; Propylamines; Receptors, Opioid, kappa; Suicidal Ideation | 2016 |
Atomoxetine Use in Attention-Deficit/Hyperactivity Disorder and Comorbid Tic Disorder in Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Autoimmune Diseases; Child; Female; Humans; Male; Obsessive-Compulsive Disorder; Streptococcal Infections; Tic Disorders; Treatment Outcome | 2017 |
Event-related potentials reflect the efficacy of pharmaceutical treatments in children and adolescents with attention deficit/hyperactivity disorder.
Topics: Acoustic Stimulation; Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention; Attention Deficit Disorder with Hyperactivity; Case-Control Studies; Child; Event-Related Potentials, P300; Evoked Potentials; Female; Humans; Male; Pharmaceutical Preparations; Treatment Outcome | 2016 |
Prevalence rates of youths diagnosed with and medicated for ADHD in a nationwide survey in Taiwan from 2000 to 2011.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Cohort Studies; Female; Humans; Male; Medical Overuse; Methylphenidate; Population Surveillance; Prevalence; Taiwan | 2017 |
Clinical Impact of Not Achieving Recommended Dose on Duration of Atomoxetine Treatment in Adults with Attention-Deficit/Hyperactivity Disorder.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Adult; Age Factors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Cohort Studies; Databases, Factual; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Predictive Value of Tests; Time Factors; Treatment Outcome; Young Adult | 2016 |
Differences in Utilization Patterns among Medications in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: a 36-Month Retrospective Study Using the Korean Health Insurance Review and Assessment Claims Database.
Topics: Administration, Oral; Adolescent; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Databases, Factual; Drug Compounding; Female; Humans; Insurance Claim Review; Logistic Models; Male; Medication Adherence; Methylphenidate; Odds Ratio; Republic of Korea; Retrospective Studies | 2016 |
[Atomoxetine Treatment For Encopresis In A Child With Attention Deficit Hyperactivity Disorder].
Topics: Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Diagnosis, Differential; Encopresis; Humans; Male | 2016 |
Atomoxetine ameliorates nocturnal enuresis with subclinical attention-deficit/hyperactivity disorder.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Drug Administration Schedule; Female; Humans; Male; Nocturnal Enuresis; Retrospective Studies; Treatment Outcome | 2017 |
Development of a refill pattern method to measure polypharmacy in administrative claims databases.
Topics: Adolescent; Algorithms; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Databases, Factual; Dexmethylphenidate Hydrochloride; Female; Humans; Male; Methylphenidate; Pharmacoepidemiology; Polypharmacy; Time Factors | 2016 |
A Cost-Utility Analysis of Lisdexamfetamine Versus Atomoxetine in the Treatment of Children and Adolescents with Attention-Deficit/Hyperactivity Disorder and Inadequate Response to Methylphenidate.
Topics: Adolescent; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Cost-Benefit Analysis; Female; Health Resources; Humans; Lisdexamfetamine Dimesylate; Male; Methylphenidate; Probability; Quality-Adjusted Life Years; Treatment Outcome | 2016 |
Differential effects of methylphenidate and atomoxetine on intrinsic brain activity in children with attention deficit hyperactivity disorder.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Brain; Child; Dopamine Uptake Inhibitors; Female; Frontal Lobe; Functional Neuroimaging; Humans; Magnetic Resonance Imaging; Male; Methylphenidate; Occipital Lobe; Parietal Lobe; Somatosensory Cortex; Treatment Outcome | 2016 |
Use of drugs for ADHD among adults-a multinational study among 15.8 million adults in the Nordic countries.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Adult; Amphetamine; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Databases, Factual; Dextroamphetamine; Drug Utilization; Female; Humans; Male; Methylphenidate; Middle Aged; Psychotropic Drugs; Scandinavian and Nordic Countries; Young Adult | 2016 |
Evaluating Matching-Adjusted Indirect Comparisons in Practice: A Case Study of Patients with Attention-Deficit/Hyperactivity Disorder.
Topics: Adrenergic alpha-2 Receptor Agonists; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Bias; Child; Comparative Effectiveness Research; Female; Guanfacine; Humans; Male; Treatment Outcome | 2017 |
Atomoxetine for hoarding disorder: A pre-clinical and clinical investigation.
Topics: Adrenergic Uptake Inhibitors; Adult; Animals; Antidepressive Agents, Second-Generation; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Behavior, Animal; Disease Models, Animal; Female; Fluoxetine; Follow-Up Studies; Hoarding Disorder; Humans; Impulsive Behavior; Locomotion; Male; Mice; Middle Aged; Motor Activity; Psychiatric Status Rating Scales; Rotarod Performance Test; Statistics, Nonparametric | 2016 |
Prevalence of medically treated children with ADHD and type 1 diabetes in Germany - Analysis of two representative databases.
Topics: Adolescent; Age Factors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Cohort Studies; Comorbidity; Dextroamphetamine; Diabetes Mellitus, Type 1; Drug Prescriptions; Female; Germany; Humans; Hypoglycemic Agents; Insulin; Male; Methylphenidate; Neurotransmitter Uptake Inhibitors; Prevalence; Prospective Studies; Risk Factors; Sex Factors | 2016 |
Use of atomoxetine and suicidal ideation in children and adolescents: Results of an observational cohort study within general practice in England.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Cohort Studies; England; Female; General Practice; Humans; Incidence; Male; Suicidal Ideation; Surveys and Questionnaires | 2017 |
Comparative treatment patterns, healthcare resource utilization and costs of atomoxetine and long-acting methylphenidate among children and adolescents with attention-deficit/hyperactivity disorder in Germany.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Delayed-Action Preparations; Female; Germany; Health Resources; Humans; Male; Methylphenidate; Models, Econometric; Retrospective Studies | 2017 |
Long term pharmacotherapy by methylfenidate or atomoxetine DAT 1 10/10 ADHD children in correlation with results of the imaging methods.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Brain; Central Nervous System Stimulants; Dopamine Plasma Membrane Transport Proteins; Female; Gray Matter; Humans; Magnetic Resonance Imaging; Male; Methylphenidate; Occipital Lobe; Organ Size; Polymorphism, Genetic; Prefrontal Cortex; Prognosis | 2016 |
Prescribing patterns for attention deficit hyperactivity disorder medications among children and adolescents in Korea, 2007-2011.
Topics: Adolescent; Age Distribution; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Child, Preschool; Drug Prescriptions; Female; Humans; Infant; Insurance Claim Review; Male; Methylphenidate; Practice Patterns, Physicians'; Prevalence; Republic of Korea | 2016 |
Utilization of Stimulants and Atomoxetine for Attention-Deficit/Hyperactivity Disorder among 5.4 Million Children Using Population-Based Longitudinal Data.
Topics: Adolescent; Age Factors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Child, Preschool; Drug Prescriptions; Drug Therapy, Combination; Drug Utilization; Female; Humans; Infant; Longitudinal Studies; Male; Psychotropic Drugs; Registries; Scandinavian and Nordic Countries; Sex Factors | 2017 |
Sex Differences in the Effect of Atomoxetine on the QT Interval in Adult Patients With Attention-Deficit Hyperactivity Disorder.
Topics: Adrenergic Uptake Inhibitors; Adult; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Electrocardiography; Female; Humans; Male; Sex Factors; Young Adult | 2017 |
A cost-effectiveness analysis of lisdexamfetamine dimesylate in the treatment of adults with attention-deficit/hyperactivity disorder in the UK.
Topics: Adult; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Cost-Benefit Analysis; Humans; Lisdexamfetamine Dimesylate; Review Literature as Topic; Treatment Outcome; United Kingdom | 2018 |
Care Provision and Prescribing Practices of Physicians Treating Children and Adolescents With ADHD.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Child Psychiatry; Drug Prescriptions; Female; Humans; Male; Physicians, Primary Care; Practice Patterns, Physicians' | 2017 |
Improving decision making in the treatment of ADHD.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Cross-Over Studies; Decision Support Techniques; Humans; Methylphenidate; Practice Guidelines as Topic; Propylamines; Randomized Controlled Trials as Topic; Treatment Outcome | 2008 |
Pharmacotherapy of ADHD in adults.
Topics: Adrenergic Uptake Inhibitors; Adult; Amphetamines; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Humans; Methylphenidate; Propylamines | 2008 |
Atomoxetine reverses attentional deficits produced by noradrenergic deafferentation of medial prefrontal cortex.
Topics: Adrenergic Uptake Inhibitors; Animals; Atomoxetine Hydrochloride; Attention; Attention Deficit Disorder with Hyperactivity; Behavior, Animal; Discrimination Learning; Disease Models, Animal; Dose-Response Relationship, Drug; Norepinephrine; Prefrontal Cortex; Propylamines; Psychomotor Performance; Rats; Rats, Long-Evans | 2008 |
[Comment on the European guidelines for use of delayed action drugs for treatment of hyperkinetic disorders].
Topics: Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Delayed-Action Preparations; Europe; Evidence-Based Medicine; Humans; Methylphenidate; Practice Guidelines as Topic; Propylamines; Psychotherapy; Treatment Outcome | 2008 |
Does atomoxetine increase the risk of aggression and hostility in children with attention deficit hyperactivity disorder?
Topics: Adolescent; Adrenergic Uptake Inhibitors; Aggression; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Hostility; Humans; Male; Propylamines | 2008 |
Atomoxetine-associated hemospermia: a case report.
Topics: Adult; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Drug Administration Schedule; Hemospermia; Humans; Male; Methylphenidate; Propylamines | 2008 |
The effect of pharmacotherapy for attention deficit hyperactivity disorder on risk of seizures in pediatric patients as assessed in an insurance claims database.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Bupropion; Central Nervous System Stimulants; Child; Consumer Product Safety; Databases as Topic; Dopamine Uptake Inhibitors; Female; Humans; Incidence; Insurance Claim Reporting; Logistic Models; Male; Odds Ratio; Propylamines; Retrospective Studies; Risk Assessment; Risk Factors; Seizures; United States | 2008 |
Diagnosis and management of attention-deficit/hyperactivity disorder in children, young people, and adults: summary of NICE guidance.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Adult; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Child, Preschool; Counseling; Diet; Humans; Methylphenidate; Parents; Practice Guidelines as Topic; Propylamines; Teaching | 2008 |
Simulated driving changes in young adults with ADHD receiving mixed amphetamine salts extended release and atomoxetine.
Topics: Adrenergic Uptake Inhibitors; Adult; Amphetamine; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Automobile Driving; Central Nervous System Stimulants; Computer Simulation; Delayed-Action Preparations; Drug Administration Schedule; Female; Humans; Male; Pilot Projects; Propylamines; Young Adult | 2009 |
Abdominal Tics During Atomoxetine Treatment in a Child With ADHD: Evaluation and Differential Diagnosis.
Topics: Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Diagnosis, Differential; Humans; Propylamines; Tic Disorders; Tics | 2008 |
Atomoxetine-induced mydriasis.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Female; Humans; Mydriasis; Propylamines | 2008 |
Acute suicidality after commencing atomoxetine.
Topics: Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Humans; Male; Propylamines; Suicide, Attempted | 2008 |
Successful medication withdrawal after cognitive-behavioral therapy in a treatment-resistant preadolescent male with obsessive-compulsive disorder.
Topics: Adrenergic Uptake Inhibitors; Antipsychotic Agents; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Cognitive Behavioral Therapy; Combined Modality Therapy; Comorbidity; Drug Resistance; Drug Therapy, Combination; Follow-Up Studies; Humans; Male; Obsessive-Compulsive Disorder; Propylamines; Risperidone; Selective Serotonin Reuptake Inhibitors; Sertraline; Substance Withdrawal Syndrome | 2009 |
German experts cause controversy after calling for atomoxetine to be withdrawn.
Topics: Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Drug Approval; Drug Industry; Germany; Humans; Propylamines | 2008 |
Attention-deficit hyperactivity disorder: treatment discontinuation in adolescents and young adults.
Topics: Adolescent; Adult; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Cohort Studies; Cross-Sectional Studies; Dextroamphetamine; Dopamine Uptake Inhibitors; Female; Humans; Male; Methylphenidate; Practice Patterns, Physicians'; Prevalence; Propylamines; United Kingdom; Withholding Treatment; Young Adult | 2009 |
[Electroencephalographic study of children with attention deficit hyperactivity disorder before and after treatment with strattera].
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Dose-Response Relationship, Drug; Electroencephalography; Female; Follow-Up Studies; Humans; Male; Propylamines; Treatment Outcome | 2008 |
[Attention deficit hyperactivity disorder in adults].
Topics: Adolescent; Adrenergic Uptake Inhibitors; Adult; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Cognitive Behavioral Therapy; Comorbidity; Female; Humans; Male; Memory Disorders; Methylphenidate; Propylamines; Social Behavior; Surveys and Questionnaires | 2009 |
How we say no: norepinephrine, inferior frontal gyrus, and response inhibition.
Topics: Adrenergic Agonists; Animals; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Frontal Lobe; Humans; Inhibition, Psychological; Norepinephrine; Propylamines; Reaction Time | 2009 |
Clinical responses to atomoxetine in attention-deficit/hyperactivity disorder: the Integrated Data Exploratory Analysis (IDEA) study.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Analysis of Variance; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Dose-Response Relationship, Drug; Female; Humans; Logistic Models; Male; Propylamines; Psychiatric Status Rating Scales; Randomized Controlled Trials as Topic; Retrospective Studies; Treatment Outcome | 2009 |
Cytochrome P450 2D6 genotyping: potential role in improving treatment outcomes in psychiatric disorders.
Topics: Adult; Antipsychotic Agents; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Cytochrome P-450 CYP2D6; Genotype; Humans; Mental Disorders; Pharmacogenetics; Polymorphism, Genetic; Propylamines; Psychotropic Drugs; Treatment Outcome | 2009 |
Prospective, naturalistic, pilot study of open-label atomoxetine treatment in preschool children with attention-deficit/hyperactivity disorder.
Topics: Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child, Preschool; Female; Humans; Male; Pilot Projects; Propylamines; Prospective Studies; Psychological Tests | 2009 |
Determinants of initial pharmacological treatment for youths with attention-deficit/hyperactivity disorder.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Age Factors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Child, Preschool; Cohort Studies; Comorbidity; Demography; Family Practice; Female; Foster Home Care; Humans; Male; Mental Disorders; Practice Patterns, Physicians'; Propylamines; Psychotropic Drugs; Retrospective Studies; Sex Factors | 2009 |
[Attention deficit hyperactivity syndrome: evolution, clinical presentations, treatment].
Topics: Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Female; Humans; Male; Pregnancy; Pregnancy Complications; Propylamines | 2009 |
A modelled economic evaluation comparing atomoxetine with methylphenidate in the treatment of children with attention-deficit/hyperactivity disorder in Spain.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Controlled Clinical Trials as Topic; Cost-Benefit Analysis; Humans; Markov Chains; Methylphenidate; Models, Economic; Propylamines; Spain | 2009 |
[Without treatment the crash threatens].
Topics: Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Diagnosis, Differential; Early Diagnosis; Humans; Learning Disabilities; Methylphenidate; Prognosis; Propylamines | 2009 |
Second opinions improve ADHD prescribing in a medicaid-insured community population.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Child, Preschool; Cost Savings; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Costs; Drug-Related Side Effects and Adverse Reactions; Evidence-Based Medicine; Female; Health Expenditures; Humans; Male; Medicaid; Propylamines; Referral and Consultation; Treatment Outcome; United States; Washington | 2009 |
Atomoxetine versus stimulants in the community treatment of children with ADHD: an electronic diary study.
Topics: Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Child Behavior; Child Behavior Disorders; Computers, Handheld; Drug Administration Schedule; Female; Humans; Male; Mother-Child Relations; Mothers; Parenting; Patient Compliance; Propylamines; Surveys and Questionnaires | 2010 |
Atomoxetine hydrochloride-associated transient psychosis in an adolescent with attention-deficit/hyperactivity disorder and mild mental retardation.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Humans; Intellectual Disability; Male; Propylamines; Psychoses, Substance-Induced | 2009 |
Attention deficit hyperactivity disorder in prison.
Topics: Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Drug and Narcotic Control; Humans; Prisoners; Propylamines; Substance-Related Disorders | 2009 |
Acute atomoxetine effects on the EEG of children with attention-deficit/hyperactivity disorder.
Topics: Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Behavior; Child; Female; Humans; Male; Propylamines | 2009 |
[Effectiveness of strattera in children and adolescents with attention deficit hyperactivity disorder].
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention; Attention Deficit Disorder with Hyperactivity; Child; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Male; Outpatients; Propylamines; Treatment Outcome | 2009 |
Atomoxetine may improve methylphenidates' efficacy in treatment of ADHD?
Topics: Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Male; Methylphenidate; Propylamines; Treatment Outcome | 2009 |
Mortality associated with attention-deficit hyperactivity disorder (ADHD) drug treatment: a retrospective cohort study of children, adolescents and young adults using the general practice research database.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Cause of Death; Central Nervous System Stimulants; Child; Child, Preschool; Cohort Studies; Databases, Factual; Death, Sudden; Dextroamphetamine; Female; Humans; Male; Methylphenidate; Propylamines; Retrospective Studies; Risk Factors; Suicide; United Kingdom; Young Adult | 2009 |
The MTA at 8.
Topics: Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Central Nervous System Stimulants; Child; Combined Modality Therapy; Follow-Up Studies; Humans; Long-Term Care; Multicenter Studies as Topic; Propylamines; Randomized Controlled Trials as Topic; Social Environment; Treatment Outcome | 2009 |
The MTA at 8.
Topics: Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Central Nervous System Stimulants; Child; Follow-Up Studies; Humans; Multicenter Studies as Topic; Propylamines; Randomized Controlled Trials as Topic; Treatment Outcome | 2009 |
Sensitivity of parent reports in the MTA.
Topics: Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Bias; Central Nervous System Stimulants; Child; Combined Modality Therapy; Humans; Multicenter Studies as Topic; Patient Compliance; Personality Assessment; Propylamines; Psychometrics; Randomized Controlled Trials as Topic; Reproducibility of Results | 2009 |
Cessation of attention deficit hyperactivity disorder drugs in the young (CADDY)--a pharmacoepidemiological and qualitative study.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Attitude to Health; Central Nervous System Stimulants; Continuity of Patient Care; Cross-Sectional Studies; Dextroamphetamine; Drug Utilization Review; Family Practice; Female; Humans; Male; Medication Adherence; Methylphenidate; Outcome and Process Assessment, Health Care; Pharmacoepidemiology; Practice Patterns, Physicians'; Propylamines; Quality of Life; Survival Analysis; United Kingdom; Withholding Treatment; Young Adult | 2009 |
Attention-deficit hyperactivity disorder: recent advances in paediatric pharmacotherapy.
Topics: Administration, Oral; Adolescent; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Clonidine; Dexmethylphenidate Hydrochloride; Dextroamphetamine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Approval; Drug Therapy, Combination; Half-Life; Health Care Costs; Humans; Lisdexamfetamine Dimesylate; Methylphenidate; Pediatrics; Prodrugs; Propylamines; Psychiatric Status Rating Scales; Randomized Controlled Trials as Topic; Treatment Outcome | 2010 |
Occurrence and treatment of ADHD in adults.
Topics: Adrenergic Uptake Inhibitors; Adult; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Clinical Trials as Topic; Humans; Propylamines | 2010 |
Prepuberal subchronic methylphenidate and atomoxetine induce different long-term effects on adult behaviour and forebrain dopamine, norepinephrine and serotonin in Naples high-excitability rats.
Topics: Adrenergic Uptake Inhibitors; Aging; Animals; Atomoxetine Hydrochloride; Attention; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Disease Models, Animal; Dopamine; Male; Maze Learning; Methylphenidate; Norepinephrine; Propylamines; Prosencephalon; Random Allocation; Rats; Serotonin; Time Factors | 2010 |
Trends in incidence and characteristics of children, adolescents, and adults initiating immediate- or extended-release methylphenidate or atomoxetine in the Netherlands during 2001-2006.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Adult; Age Factors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Delayed-Action Preparations; Drug Administration Schedule; Drug Prescriptions; Female; Humans; Incidence; Male; Methylphenidate; Netherlands; Propylamines; Sex Factors; Time Factors; Treatment Outcome | 2010 |
Pharmacological treatment patterns among patients with attention-deficit/hyperactivity disorder: retrospective claims-based analysis of a managed care population.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Adult; Age Factors; Amphetamine; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Delayed-Action Preparations; Drug Utilization Review; Female; Health Maintenance Organizations; Humans; Male; Medication Adherence; Methamphetamine; Middle Aged; Practice Patterns, Physicians'; Propylamines; Retrospective Studies; United States | 2010 |
Pre-existing cardiovascular conditions and pharmacological treatment of adult ADHD.
Topics: Adult; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Cardiovascular Diseases; Central Nervous System Stimulants; Cohort Studies; Drug Utilization; Female; Humans; Insurance Claim Review; Logistic Models; Male; Middle Aged; Multivariate Analysis; Propylamines; Retrospective Studies; Young Adult | 2010 |
The discrepancy in attention deficit hyperactivity disorder (ADHD) medications diffusion: 1994-2003--a global pharmaceutical data analysis.
Topics: Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Benzhydryl Compounds; Central Nervous System Stimulants; Drug Costs; Drug Industry; Economics; Healthcare Disparities; Humans; Methylphenidate; Modafinil; Propylamines; Time Factors; United States | 2010 |
Effects of atomoxetine on levels of monoamines and related substances in discrete brain regions in mice intermittently deprived of rapid eye movement sleep.
Topics: Adrenergic Uptake Inhibitors; Animals; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Behavior, Animal; Disease Models, Animal; Dopamine; Frontal Lobe; Hyperkinesis; Male; Mice; Mice, Inbred Strains; Movement; Norepinephrine; Propylamines; Sleep Deprivation; Sleep, REM | 2010 |
Atomoxetine acts as an NMDA receptor blocker in clinically relevant concentrations.
Topics: Adrenergic Uptake Inhibitors; Animals; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Cell Line; Cells, Cultured; Cerebral Cortex; Hippocampus; Humans; Neurons; Patch-Clamp Techniques; Propylamines; Rats; Receptors, N-Methyl-D-Aspartate | 2010 |
Atomoxetine. Attention-deficit/hyperactivity disorder: no better than methylphenidate.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Humans; Meta-Analysis as Topic; Methylphenidate; Propylamines; Randomized Controlled Trials as Topic | 2010 |
Factors associated with atomoxetine efficacy for treatment of attention-deficit/hyperactivity disorder in children and adolescents.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Anxiety; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Child, Preschool; Depression; Drug Therapy, Combination; Electronic Health Records; Female; Humans; Male; Propylamines; Retrospective Studies; Treatment Outcome | 2010 |
Aripiprazole for the tic symptoms in a child receiving atomoxetine treatment for ADHD.
Topics: Adrenergic Uptake Inhibitors; Antipsychotic Agents; Aripiprazole; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Humans; Male; Piperazines; Propylamines; Quinolones; Tic Disorders | 2010 |
Cardiovascular safety of ADHD medications: rationale for and design of an investigator-initiated observational study.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Amphetamines; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Cardiovascular Diseases; Central Nervous System Stimulants; Child; Cohort Studies; Databases, Factual; Humans; Methylphenidate; Myocardial Infarction; Propylamines; Research Design; United States | 2010 |
Newly approved once-daily formulations of medications for the treatment of Attention Deficit (Hyperactivity) Disorder (ADHD) in children and adolescents.
Topics: Administration, Cutaneous; Adolescent; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Delayed-Action Preparations; Dextroamphetamine; Drug Administration Schedule; Guanfacine; Humans; Lisdexamfetamine Dimesylate; Locus Coeruleus; Methylphenidate; Neurons; Nutrition Surveys; Prefrontal Cortex; Propylamines | 2010 |
Efficacy of atomoxetine in children with severe autistic disorders and symptoms of ADHD: an open-label study.
Topics: Adolescent; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Autistic Disorder; Central Nervous System Stimulants; Child; Female; Humans; Male; Pilot Projects; Propylamines; Treatment Outcome | 2011 |
Sub-chronic exposure to atomoxetine up-regulates BDNF expression and signalling in the brain of adolescent spontaneously hypertensive rats: comparison with methylphenidate.
Topics: Adrenergic Uptake Inhibitors; Animals; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Brain; Brain-Derived Neurotrophic Factor; Central Nervous System Stimulants; Humans; Male; Methylphenidate; Propylamines; Rats; Rats, Inbred SHR; RNA, Messenger; Signal Transduction; Up-Regulation | 2010 |
Recognition of impaired atomoxetine metabolism because of low CYP2D6 activity.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Cytochrome P-450 CYP2D6; Dose-Response Relationship, Drug; Genotype; Humans; Pharmacogenetics; Propylamines; Retrospective Studies | 2010 |
Methylphenidate and atomoxetine enhance prefrontal function through α2-adrenergic and dopamine D1 receptors.
Topics: Adrenergic Uptake Inhibitors; Animals; Appetitive Behavior; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Brain Mapping; Central Nervous System Stimulants; Child; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Humans; Macaca mulatta; Male; Memory, Short-Term; Methylphenidate; Nerve Net; Orientation; Prefrontal Cortex; Propylamines; Pyramidal Cells; Receptors, Adrenergic, alpha-2; Receptors, Dopamine D1; Saccades | 2010 |
Treatment stabilization in children and adolescents with attention-deficit/hyperactivity disorder: data from the Netherlands.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Cohort Studies; Female; Humans; Male; Medical Audit; Methylphenidate; Netherlands; Outcome Assessment, Health Care; Practice Patterns, Physicians'; Propylamines; Retrospective Studies | 2010 |
Response requirement and increases in accuracy produced by stimulant drugs in a 5-choice serial reaction-time task in rats.
Topics: Animals; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Choice Behavior; Dextroamphetamine; Male; Methylphenidate; Nicotine; Nicotinic Agonists; Propylamines; Rats; Rats, Sprague-Dawley; Reaction Time; Reinforcement Schedule; Signal Detection, Psychological | 2011 |
European guidelines on managing adverse effects of medication for ADHD.
Topics: Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Cardiovascular Diseases; Central Nervous System Stimulants; Child; Clinical Trials as Topic; Drug Administration Schedule; Drug Dosage Calculations; Drug Tolerance; Drug Utilization Review; Europe; Humans; Monitoring, Physiologic; Propylamines; Risk Assessment; Substance-Related Disorders; Suicide, Attempted | 2011 |
Effects of atomoxetine, desipramine, d-amphetamine and methylphenidate on impulsivity in juvenile rats, measured in a T-maze procedure.
Topics: Adrenergic Uptake Inhibitors; Animals; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Behavior, Animal; Central Nervous System Stimulants; Desipramine; Dextroamphetamine; Impulsive Behavior; Male; Methylphenidate; Propylamines; Rats; Rats, Wistar | 2011 |
Tolerability of atomoxetine for treatment of pediatric attention-deficit/hyperactivity disorder in the context of epilepsy.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Child, Preschool; Epilepsy; Female; Humans; Male; Medical Records; Propylamines; Retrospective Studies; Treatment Outcome | 2011 |
Atomoxetine-induced myocardial infarction.
Topics: Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Female; Heart; Humans; Myocardial Infarction; Propylamines; Young Adult | 2011 |
Less discontinuation of ADHD drug use since the availability of long-acting ADHD medication in children, adolescents and adults under the age of 45 years in the Netherlands.
Topics: Adolescent; Adult; Age Factors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Child, Preschool; Community Pharmacy Services; Delayed-Action Preparations; Drug Utilization; Female; Humans; Infant; Male; Methylphenidate; Middle Aged; Netherlands; Propylamines; Sex Characteristics | 2010 |
The evidence-based pharmacological treatment of paediatric ADHD.
Topics: Adolescent; Adrenergic alpha-2 Receptor Agonists; Adrenergic Uptake Inhibitors; Adult; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Child, Preschool; Clinical Trials as Topic; Evidence-Based Medicine; Humans; Pediatrics; Propylamines | 2012 |
Response to atomoxetine in boys with high-functioning autism spectrum disorders and attention deficit/hyperactivity disorder.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Child Development Disorders, Pervasive; Diagnostic and Statistical Manual of Mental Disorders; Health Status Indicators; Humans; Male; Norway; Outpatients; Propylamines; Prospective Studies; Psychometrics; Sex Factors; Statistics, Nonparametric; Treatment Outcome | 2011 |
Combining carbamazepine, neuroleptics and acetylcholinesterase inhibitors with methylphenidate only reduces adverse side effects, but is less effective than a combination with atomoxetine.
Topics: Aggression; Antipsychotic Agents; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Carbamazepine; Child; Cholinesterase Inhibitors; Drug Synergism; Humans; Male; Methylphenidate; Propylamines; Time Factors; Treatment Outcome | 2011 |
Risks and benefits of available treatments for adult ADHD.
Topics: Adult; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Humans; Patient Education as Topic; Propylamines; Risk Assessment | 2011 |
Transitioning to OROS(®) methylphenidate from atomoxetine is effective in children and adolescents with ADHD.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Delayed-Action Preparations; Drug Administration Schedule; Female; Humans; Male; Methylphenidate; Propylamines; Prospective Studies; Psychiatric Status Rating Scales; Quality of Life; Treatment Outcome | 2011 |
Pharmacologic treatment of attention-deficit/hyperactivity disorder in children: incidence, prevalence, and treatment patterns in the Netherlands.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Dextroamphetamine; Drug Therapy, Combination; Drug Utilization; Humans; Incidence; Medical Records; Methylphenidate; Netherlands; Patient Compliance; Prevalence; Propylamines; Retrospective Studies | 2011 |
Drugs for treatment of ADHD.
Topics: Adolescent; Adrenergic alpha-2 Receptor Agonists; Adult; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Female; Humans; Male; Propylamines; Young Adult | 2011 |
Conditioned place preference studies with atomoxetine in an animal model of ADHD: effects of previous atomoxetine treatment.
Topics: Animals; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Behavior, Animal; Conditioning, Psychological; Disease Models, Animal; Propylamines; Rats; Reward | 2011 |
Lower IQ is associated with decreased clinical response to atomoxetine in children and adolescents with attention-deficit hyperactivity disorder.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Child, Preschool; Female; Humans; Intelligence; Male; Patient Dropouts; Propylamines; Retrospective Studies; Severity of Illness Index; Treatment Outcome | 2011 |
Idiosyncratic liver failure probably associated with atomoxetine: a case report.
Topics: Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Chemical and Drug Induced Liver Injury; Child; Humans; Liver Transplantation; Male; Propylamines; Severity of Illness Index | 2011 |
Effects of atomoxetine on cardiovascular functions and on QT dispersion in children with attention deficit hyperactivity disorder.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Blood Pressure; Cardiovascular Physiological Phenomena; Child; Echocardiography; Electrocardiography; Female; Heart Rate; Humans; Male; Propylamines; Turkey | 2012 |
ADHD medication use, adherence, persistence and cost among Texas Medicaid children.
Topics: Adolescent; Amphetamine; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Child, Preschool; Female; Humans; Male; Medicaid; Medication Adherence; Methylphenidate; Prodrugs; Propylamines; Regression Analysis; Retrospective Studies; Texas; United States | 2011 |
Psychometric properties of the quality of life scale Child Health and Illness Profile-Child Edition in a combined analysis of five atomoxetine trials.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Clinical Trials as Topic; Factor Analysis, Statistical; Female; Humans; Male; Propylamines; Psychiatric Status Rating Scales; Psychometrics; Quality of Life | 2011 |
Development and validation of a liquid chromatography-tandem mass spectrometry assay for hair analysis of atomoxetine and its metabolites: Application in clinical practice.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Chromatography, Liquid; Female; Hair; Humans; Male; Medication Adherence; Phenols; Phenyl Ethers; Propylamines; Tandem Mass Spectrometry | 2012 |
The change of the cortisol levels in children with ADHD treated by methylphenidate or atomoxetine.
Topics: Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Dopamine Uptake Inhibitors; Humans; Hydrocortisone; Hypothalamo-Hypophyseal System; Male; Methylphenidate; Pituitary-Adrenal System; Propylamines; Treatment Outcome | 2012 |
Treatment practices in Tourette syndrome: the European perspective.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Anxiety; Aripiprazole; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Clonidine; Depression; Europe; Fluoxetine; Fluvoxamine; Health Care Surveys; Humans; Methylphenidate; Obsessive-Compulsive Disorder; Physicians; Piperazines; Propylamines; Psychiatry; Quinolones; Risperidone; Sertraline; Sulpiride; Tourette Syndrome | 2012 |
Validation of the AQT color-form additive model for screening and monitoring pharmacological treatment of ADHD.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Adult; Association Learning; Atomoxetine Hydrochloride; Attention; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Color Perception; Female; Humans; Male; Mass Screening; Memory, Short-Term; Methylphenidate; Middle Aged; Neuropsychological Tests; Pattern Recognition, Visual; Propylamines; Psychometrics; Reaction Time; Reference Values; Reproducibility of Results; Retrospective Studies; Semantics; Treatment Outcome; Young Adult | 2013 |
Differential effects of methylphenidate and atomoxetine on attentional processes in children with ADHD: an event-related potential study using the Attention Network Test.
Topics: Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention; Attention Deficit Disorder with Hyperactivity; Child; Cross-Over Studies; Dopamine Uptake Inhibitors; Evoked Potentials; Female; Humans; Male; Methylphenidate; Neuropsychological Tests; Photic Stimulation; Propylamines; Reaction Time | 2012 |
The use of dopaminergic and stimulant drugs for the treatment of depression.
Topics: Amphetamines; Antidepressive Agents; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Benzhydryl Compounds; Brain; Central Nervous System Stimulants; Depressive Disorder, Major; Dextroamphetamine; Dopamine; Dopamine Agents; Drug Therapy, Combination; Epinephrine; Humans; Lisdexamfetamine Dimesylate; Methylphenidate; Modafinil; Norepinephrine; Propylamines | 2012 |
Health-related quality of life in ADHD: a pooled analysis of gender differences in five atomoxetine trials.
Topics: Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Canada; Child; Clinical Trials as Topic; Europe; Female; Health Status; Humans; Male; Propylamines; Quality of Life; Severity of Illness Index; Sex Characteristics | 2012 |
Atomoxetine treatment outcomes in adolescents and young adults with attention-deficit/hyperactivity disorder: results from a post hoc, pooled analysis.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Female; Humans; Male; Propylamines; Randomized Controlled Trials as Topic; Treatment Outcome; Young Adult | 2012 |
The need to develop more sensitive tools to accurately detect clinical response to treatment in ADHD.
Topics: Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Clinical Protocols; Humans; Propylamines; Sensitivity and Specificity | 2012 |
Altered cortical morphology in sensorimotor processing regions in adolescents and adults with attention-deficit/hyperactivity disorder.
Topics: Adolescent; Adult; Age Factors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Brain Mapping; Central Nervous System Stimulants; Cohort Studies; Cross-Sectional Studies; Female; Humans; Imaging, Three-Dimensional; Magnetic Resonance Imaging; Male; Methylphenidate; Middle Aged; Motor Cortex; Propylamines; Somatosensory Cortex; Surveys and Questionnaires; Young Adult | 2012 |
[Atomoxetine in ADHD: caution].
Topics: Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Central Nervous System Stimulants; Cognition; Humans; Methylphenidate; Motor Activity; Propylamines; Randomized Controlled Trials as Topic; Seizures; Treatment Failure; Treatment Outcome | 2011 |
Atomoxetine for encopresis in 2 children with attention-deficit/hyperactivity disorder.
Topics: Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Encopresis; Humans; Male; Propylamines; Treatment Outcome | 2012 |
Attention-deficit/hyperactivity disorder among children and adolescents in the United States: trend in diagnosis and use of pharmacotherapy by gender.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Child, Preschool; Cross-Sectional Studies; Female; Humans; Male; Propylamines; Sex Distribution; United States | 2012 |
The selective norepinephrine reuptake inhibitor atomoxetine counteracts behavioral impairments in trimethyltin-intoxicated rats.
Topics: Aging; Animals; Animals, Newborn; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Avoidance Learning; Behavior, Animal; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Male; Memory; Motor Activity; Neurotransmitter Uptake Inhibitors; Norepinephrine; Pregnancy; Prenatal Exposure Delayed Effects; Propylamines; Random Allocation; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Trimethyltin Compounds | 2012 |
Successful treatment of early ropivacaine toxicity with intralipid in a patient with attention deficit hyperactivity disorder.
Topics: Adolescent; Amides; Anesthesia, General; Anesthetics, Local; Arthroscopy; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Confusion; Emulsions; Hallucinations; Humans; Hypnotics and Sedatives; Intraoperative Complications; Male; Midazolam; Nerve Block; Phospholipids; Propylamines; Ropivacaine; Shoulder; Soybean Oil; Speech Disorders | 2011 |
[Update on Current Care guidelines: ADHD (attention-deficit/hyperactivity disorder, children and adolescents)].
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Delivery of Health Care, Integrated; Dextroamphetamine; Humans; Methylphenidate; Practice Guidelines as Topic; Propylamines | 2012 |
The ADHD-susceptibility gene lphn3.1 modulates dopaminergic neuron formation and locomotor activity during zebrafish development.
Topics: Animals; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Diencephalon; Disease Models, Animal; Dopamine Uptake Inhibitors; Dopaminergic Neurons; Gene Knockdown Techniques; Methylphenidate; Molecular Imaging; Motor Activity; Nerve Degeneration; Propylamines; Receptors, Peptide; Zebrafish | 2012 |
Comparative effectiveness research using matching-adjusted indirect comparison: an application to treatment with guanfacine extended release or atomoxetine in children with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorde
Topics: Adolescent; Atomoxetine Hydrochloride; Attention Deficit and Disruptive Behavior Disorders; Attention Deficit Disorder with Hyperactivity; Child; Comparative Effectiveness Research; Delayed-Action Preparations; Guanfacine; Humans; Outcome and Process Assessment, Health Care; Pharmacoepidemiology; Propylamines; Randomized Controlled Trials as Topic | 2012 |
Concentrations of atomoxetine and its metabolites in plasma and oral fluid from paediatric patients with attention deficit/hyperactivity disorder.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Humans; Propylamines; Saliva | 2013 |
Treatment patterns, adherence, and persistence in ADHD: a Canadian perspective.
Topics: Adolescent; Adrenergic alpha-2 Receptor Agonists; Adrenergic Uptake Inhibitors; Analysis of Variance; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Clonidine; Cross-Sectional Studies; Drug Prescriptions; Drug Utilization Review; Female; Guanfacine; Humans; Male; Patient Compliance; Propylamines; Quebec; Retrospective Studies | 2012 |
The epidemiology of pharmacologically treated attention deficit hyperactivity disorder (ADHD) in children, adolescents and adults in UK primary care.
Topics: Adolescent; Adult; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Child, Preschool; Cohort Studies; Dextroamphetamine; Female; Humans; Incidence; Male; Methylphenidate; Middle Aged; Prevalence; Primary Health Care; Propylamines; Retrospective Studies; United Kingdom; Young Adult | 2012 |
A population-based study of stimulant drug treatment of ADHD and academic progress in children.
Topics: Achievement; Age Factors; Amphetamine; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Educational Measurement; Female; Humans; Iceland; Language Arts; Male; Mathematics; Methylphenidate; Multivariate Analysis; Odds Ratio; Propylamines; Registries; Sex Factors; Treatment Outcome | 2012 |
Atomoxetine improves communication in a girl with semantic-pragmatic disorder.
Topics: Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Communication; Female; Humans; Language Development Disorders; Propylamines | 2012 |
Effects of ADHD therapeutic agents, methylphenidate and atomoxetine, on hippocampal neurogenesis in the adolescent mouse dentate gyrus.
Topics: Animals; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Brain-Derived Neurotrophic Factor; Cell Differentiation; Cell Proliferation; Dentate Gyrus; Doublecortin Protein; Immunohistochemistry; Male; Methylphenidate; Mice; Mice, Inbred ICR; Neurogenesis; Neurons; Propylamines | 2012 |
Age-specific prevalence, incidence of new diagnoses, and drug treatment of attention-deficit/hyperactivity disorder in Germany.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Age Factors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Child, Preschool; Databases, Factual; Female; Germany; Humans; Incidence; International Classification of Diseases; Male; Methylphenidate; Prevalence; Propylamines; Sex Factors; Time Factors | 2012 |
Is there a relationship between hyperactivity/inattention symptoms and poor oral health? Results from the GINIplus and LISAplus study.
Topics: Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Cohort Studies; Dental Caries; Dental Enamel Hypoplasia; Dentition, Permanent; DMF Index; Female; Germany; Health Surveys; Humans; Logistic Models; Male; Methylphenidate; Oral Health; Oral Hygiene; Parents; Propylamines; Social Class; Surveys and Questionnaires; Tooth Injuries | 2013 |
Does Comorbid Disruptive Behavior Modify the Effects of Atomoxetine on ADHD Symptoms as Measured by a Continuous Performance Test and a Motion Tracking Device?
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit and Disruptive Behavior Disorders; Attention Deficit Disorder with Hyperactivity; Comorbidity; Conduct Disorder; Double-Blind Method; Female; Humans; Male; Personality Assessment; Propylamines; Quality of Life; Reaction Time; Treatment Outcome | 2015 |
Sweat testing for the detection of atomoxetine from paediatric patients with attention deficit/ hyperactivity disorder: application to clinical practice.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Drug Monitoring; Female; Humans; Male; Propylamines; Sweat; Tandem Mass Spectrometry | 2013 |
Atomoxetine use during a period of FDA actions.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Drug Labeling; Drug Utilization; Female; Humans; Male; Product Surveillance, Postmarketing; Propylamines; United States; United States Food and Drug Administration | 2012 |
Physical exercise and catecholamine reuptake inhibitors affect orienting behavior and social interaction in a rat model of attention-deficit/hyperactivity disorder.
Topics: Adrenergic Uptake Inhibitors; Animals; Atomoxetine Hydrochloride; Attention; Attention Deficit Disorder with Hyperactivity; Behavior, Animal; Catecholamines; Disease Models, Animal; Dopamine Uptake Inhibitors; Female; Methylphenidate; Motor Activity; Physical Conditioning, Animal; Propylamines; Rats; Rats, Inbred SHR; Rats, Wistar; Social Behavior | 2012 |
Improving visual memory, attention, and school function with atomoxetine in boys with attention-deficit/hyperactivity disorder.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention; Attention Deficit Disorder with Hyperactivity; Behavior; Child; Diagnostic and Statistical Manual of Mental Disorders; Humans; Male; Memory; Neuropsychological Tests; Pattern Recognition, Visual; Propylamines; Psychometrics; Psychomotor Performance; Reaction Time; Schools; Social Adjustment; Space Perception; Taiwan; Treatment Outcome; Visual Perception; Wechsler Scales | 2012 |
Potential serious adverse interactions between linezolid and atomoxetine.
Topics: Acetamides; Anti-Bacterial Agents; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Bacterial Infections; Child; Cystic Fibrosis; Drug Interactions; Female; Humans; Linezolid; Monoamine Oxidase Inhibitors; Oxazolidinones; Propylamines; Sputum | 2012 |
Combination therapy patterns and predictors of ADHD in commercially insured and Medicaid populations.
Topics: Adolescent; Adrenergic alpha-2 Receptor Agonists; Adrenergic Uptake Inhibitors; Anxiety; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Comorbidity; Depression; Drug Therapy, Combination; Female; Humans; Insurance, Health; Male; Medicaid; Practice Patterns, Physicians'; Propylamines; Retrospective Studies; United States | 2012 |
Atomoxetine increases fronto-parietal functional MRI activation in attention-deficit/hyperactivity disorder: a pilot study.
Topics: Adrenergic Uptake Inhibitors; Adult; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Frontal Lobe; Humans; Magnetic Resonance Imaging; Nerve Net; Parietal Lobe; Pilot Projects; Propylamines | 2013 |
Persistence of pharmacological treatment into adulthood, in UK primary care, for ADHD patients who started treatment in childhood or adolescence.
Topics: Adolescent; Adult; Age Factors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Dextroamphetamine; Female; Humans; Kaplan-Meier Estimate; Male; Methylphenidate; Patient Compliance; Propylamines; United Kingdom | 2012 |
Atomoxetine-induced vocal tics in a patient with schizophrenia.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Antipsychotic Agents; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Benzodiazepines; Humans; Male; Olanzapine; Propylamines; Schizophrenia; Tics | 2012 |
Safety of attention-deficit/hyperactivity disorder medications in children: an intensive pharmacosurveillance monitoring study.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Adverse Drug Reaction Reporting Systems; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Databases, Factual; Female; Humans; Italy; Male; Methylphenidate; Pharmacovigilance; Propylamines; Registries | 2012 |
Effects of atomoxetine on locomotor activity and impulsivity in the spontaneously hypertensive rat.
Topics: Adrenergic Uptake Inhibitors; Amphetamine; Animals; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Behavior, Animal; Central Nervous System Sensitization; Disease Models, Animal; Impulsive Behavior; Male; Maze Learning; Motor Activity; Neuropsychological Tests; Propylamines; Rats; Rats, Inbred SHR | 2013 |
Adrenergic neurotransmitter system transporter and receptor genes associated with atomoxetine response in attention-deficit hyperactivity disorder children.
Topics: Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Dose-Response Relationship, Drug; Female; Gene Frequency; Genotype; Humans; Male; Norepinephrine Plasma Membrane Transport Proteins; Pharmacogenetics; Polymorphism, Single Nucleotide; Propylamines; Receptors, Adrenergic, alpha-1; Receptors, Adrenergic, alpha-2 | 2013 |
A cohort study of the risk of seizures in a pediatric population treated with atomoxetine or stimulant medications.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Cohort Studies; Female; Humans; Male; Propylamines; Retrospective Studies; Risk; Seizures | 2013 |
Effects of FDA advisories on the pharmacologic treatment of ADHD, 2004-2008.
Topics: Adolescent; Adrenergic alpha-2 Receptor Agonists; Adrenergic Uptake Inhibitors; Amphetamines; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Bupropion; Central Nervous System Stimulants; Child; Clonidine; Dopamine Uptake Inhibitors; Drug Utilization; Guanfacine; Humans; Practice Patterns, Physicians'; Propylamines; United States; United States Food and Drug Administration | 2013 |
Cardiovascular measures in children and adolescents with attention-deficit/hyperactivity disorder who are new users of methylphenidate and atomoxetine.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Blood Pressure; Cardiovascular Diseases; Central Nervous System Stimulants; Child; Electrocardiography; Female; Follow-Up Studies; Heart Rate; Humans; Italy; Male; Methylphenidate; Propylamines; Prospective Studies; Registries | 2012 |
Performance on a strategy set shifting task during adolescence in a genetic model of attention deficit/hyperactivity disorder: methylphenidate vs. atomoxetine treatments.
Topics: Adrenergic Uptake Inhibitors; Animals; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Conditioning, Operant; Dopamine Uptake Inhibitors; Male; Methylphenidate; Propylamines; Rats; Reversal Learning; Species Specificity; Time Factors | 2013 |
Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder.
Topics: Animals; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Dopamine; Drug Synergism; Humans; Male; Norepinephrine; Prefrontal Cortex; Propylamines; Rats; Rats, Sprague-Dawley | 2002 |
Drug development process for a product with a primary pediatric indication.
Topics: Antidepressive Agents; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Clinical Trials as Topic; Drug Approval; Drug Evaluation; Drug Industry; Drugs, Investigational; Humans; Pediatrics; Propylamines; United States; United States Food and Drug Administration | 2002 |
Atomoxetine (strattera) for ADHD.
Topics: Adult; Antidepressive Agents; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Dose-Response Relationship, Drug; Drug Interactions; Humans; Intestinal Absorption; Nausea; Propylamines; Randomized Controlled Trials as Topic | 2003 |
Effect of hepatic impairment on the pharmacokinetics of atomoxetine and its metabolites.
Topics: Administration, Oral; Adult; Antidepressive Agents; Area Under Curve; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Case-Control Studies; Cytochrome P-450 CYP2D6; Debrisoquin; Female; Humans; Liver Cirrhosis; Male; Metabolic Clearance Rate; Middle Aged; Propylamines; Severity of Illness Index; Sorbitol | 2003 |
Glutamatergic changes with treatment in attention deficit hyperactivity disorder: a preliminary case series.
Topics: Antidepressive Agents; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Creatinine; Female; Glutamic Acid; Humans; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Male; Methylphenidate; Neostriatum; Prefrontal Cortex; Propylamines; Psychiatric Status Rating Scales | 2002 |
Neurotransmission of cognition, part 2. Selective NRIs are smart drugs: exploiting regionally selective actions on both dopamine and norepinephrine to enhance cognition.
Topics: Adrenergic Uptake Inhibitors; Antidepressive Agents; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Cognition; Dopamine; Dopamine Plasma Membrane Transport Proteins; Frontal Lobe; Humans; Membrane Glycoproteins; Membrane Transport Proteins; Nerve Tissue Proteins; Norepinephrine; Norepinephrine Plasma Membrane Transport Proteins; Propylamines; Symporters; Synaptic Transmission | 2003 |
Updates on attention deficit hyperactivity disorder, child abuse and neglect, and sudden infant death syndrome.
Topics: Adrenergic Uptake Inhibitors; Amphetamines; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Child Abuse; Child Abuse, Sexual; Desipramine; Dopamine Uptake Inhibitors; Humans; Infant; Methylphenidate; Prone Position; Propylamines; Risk Factors; Sudden Infant Death | 2003 |
Atomoxetine and pregnancy.
Topics: Adolescent; Adrenergic Antagonists; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Female; Humans; Patient Selection; Pregnancy; Propylamines | 2003 |
Atomoxetine for ADHD.
Topics: Adult; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Humans; Propylamines | 2003 |
First new ADHD treatment in 30 years.
Topics: Adolescent; Adult; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Double-Blind Method; Humans; Nursing Care; Propylamines; Randomized Controlled Trials as Topic | 2003 |
New drugs 04, part 1.
Topics: Adalimumab; Alefacept; alpha-Galactosidase; Anisoles; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antioxidants; Antiprotozoal Agents; Antirheumatic Agents; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Drug Approval; Drug Therapy; Fabry Disease; Gefitinib; Humans; Iduronidase; Indoles; Isoenzymes; Lentigo; Lung Neoplasms; Migraine Disorders; Mucopolysaccharidosis I; Nitro Compounds; Patient Education as Topic; Propylamines; Psoriasis; Pyrrolidines; Quinazolines; Recombinant Fusion Proteins; Serotonin Receptor Agonists; Thiazoles; Tryptamines | 2004 |
[New therapeutic options in the treatment of attention deficit/hyperactivity disorder].
Topics: Antidepressive Agents; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Brain; Central Nervous System Stimulants; Clinical Trials as Topic; Dopamine; Dopamine Uptake Inhibitors; Humans; Methylphenidate; Norepinephrine; Propylamines | 2004 |
[Tourette syndrome: an analysis of its comorbidity and specific treatment].
Topics: Adrenergic alpha-Agonists; Antipsychotic Agents; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Comorbidity; Guanfacine; Humans; Obsessive-Compulsive Disorder; Propylamines; Tourette Syndrome | 2004 |
Atomoxetine and stimulants in combination for treatment of attention deficit hyperactivity disorder: four case reports.
Topics: Adolescent; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Drug Therapy, Combination; Female; Humans; Male; Propylamines | 2004 |
Atomoxetine hydrochloride.
Topics: Adolescent; Adult; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Humans; Propylamines; Randomized Controlled Trials as Topic | 2004 |
Synthesis and biological evaluation of the major metabolite of atomoxetine: elucidation of a partial kappa-opioid agonist effect.
Topics: Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Humans; Propylamines; Receptors, Opioid, kappa; Structure-Activity Relationship | 2004 |
Atomoxetine (Strattera) revisited.
Topics: Adolescent; Adult; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Humans; Propylamines; Randomized Controlled Trials as Topic | 2004 |
Atomoxetine and tics in ADHD.
Topics: Adolescent; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Dose-Response Relationship, Drug; Humans; Male; Propylamines; Recurrence; Tics | 2004 |
Aggression, mania, and hypomania induction associated with atomoxetine.
Topics: Aggression; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Bipolar Disorder; Child; Humans; Neurotransmitter Uptake Inhibitors; Norepinephrine; Propylamines | 2004 |
Mania induction associated with atomoxetine.
Topics: Aggression; Anger; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Bipolar Disorder; Child; Drug Therapy, Combination; Guanfacine; Humans; Irritable Mood; Male; Propylamines; Sympathomimetics; Violence | 2004 |
A lifetime of distractions. ADHD is no longer just a children's disease. Many adults are being diagnosed and treated for the condition.
Topics: Adolescent; Adult; Age Factors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Humans; Propylamines | 2004 |
Evaluation of the reinforcing effects of monoamine reuptake inhibitors under a concurrent schedule of food and i.v. drug delivery in rhesus monkeys.
Topics: Adrenergic Uptake Inhibitors; Animals; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Brain; Central Nervous System Stimulants; Cocaine; Desipramine; Dextroamphetamine; Disease Models, Animal; Dose-Response Relationship, Drug; Eating; Female; Infusion Pumps; Macaca mulatta; Methylphenidate; Propylamines; Reinforcement, Psychology; Self Administration; Substance-Related Disorders | 2005 |
Atomoxetine for the treatment of pediatric nocturnal enuresis.
Topics: Adolescent; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Enuresis; Humans; Male; Propylamines | 2004 |
Review of new compounds available in Australia for the treatment of attention-deficit hyperactivity disorder.
Topics: Adolescent; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Australia; Biological Availability; Central Nervous System Stimulants; Child; Delayed-Action Preparations; Drug Administration Schedule; Drug Approval; Drug Costs; Drug Utilization; Humans; Inactivation, Metabolic; Metabolic Clearance Rate; Methylphenidate; Personality Assessment; Propylamines; Randomized Controlled Trials as Topic; Therapeutic Equivalency; Treatment Outcome | 2004 |
Benign clinical course following atomoxetine overdose.
Topics: Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Diagnosis, Differential; Drug Overdose; Emergency Treatment; Humans; Male; Propylamines | 2005 |
Atomoxetine blocks motor hyperactivity in neonatal 6-hydroxydopamine-lesioned rats: implications for treatment of attention-deficit hyperactivity disorder.
Topics: Adrenergic Agents; Adrenergic Uptake Inhibitors; Analysis of Variance; Animals; Animals, Newborn; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Disease Models, Animal; Hyperkinesis; Male; Oxidopamine; Propylamines; Rats; Rats, Sprague-Dawley; Time Factors | 2005 |
Atomoxetine and tics in ADHD.
Topics: Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Humans; Norepinephrine; Propylamines; Tics | 2005 |
Increased blood pressure and atomoxetine.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Antidepressive Agents; Atomoxetine Hydrochloride; Attention Deficit and Disruptive Behavior Disorders; Attention Deficit Disorder with Hyperactivity; Child; Depressive Disorder; Dose-Response Relationship, Drug; Drug Interactions; Drug Therapy, Combination; Humans; Male; Norepinephrine; Propylamines | 2005 |
The answerable question and a hierarchy of evidence.
Topics: Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Databases, Factual; Evidence-Based Medicine; Humans; Male; Methylphenidate; Personality Assessment; Propylamines; Quality Assurance, Health Care; Randomized Controlled Trials as Topic; Software; Treatment Outcome | 2005 |
Atomoxetine hydrochloride and executive function in children with attention-deficit/hyperactivity disorder.
Topics: Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Humans; Neuropsychological Tests; Pilot Projects; Propylamines; Psychomotor Performance; Reaction Time | 2005 |
Atomoxetine use associated with onset of a motor tic.
Topics: Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Humans; Male; Propylamines; Tic Disorders; Tics | 2005 |
[The entire day counts].
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Delayed-Action Preparations; Drug Administration Schedule; Humans; Norepinephrine; Propylamines; Treatment Outcome | 2005 |
Atomoxetine in the treatment of patients with ADHD.
Topics: Adult; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Humans; Propylamines | 2005 |
Effects of atomoxetine on growth after 2-year treatment among pediatric patients with attention-deficit/hyperactivity disorder.
Topics: Adolescent; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Body Height; Child; Growth; Humans; Propylamines | 2005 |
Psychometric validation of the child health questionnaire (CHQ) in a sample of children and adolescents with attention-deficit/hyperactivity disorder.
Topics: Adolescent; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Child Behavior; Emotions; Family; Female; Humans; Male; Propylamines; Psychometrics; Quality of Life; Sickness Impact Profile; Surveys and Questionnaires | 2005 |
Assessment of health state utilities for attention-deficit/hyperactivity disorder in children using parent proxy report.
Topics: Adult; Analysis of Variance; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Child Behavior; Cost-Benefit Analysis; Female; Humans; Male; Parents; Propylamines; Severity of Illness Index; Sickness Impact Profile; Surveys and Questionnaires | 2005 |
Predictors of selecting atomoxetine therapy for children with attention-deficit-hyperactivity disorder.
Topics: Adolescent; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Child Behavior; Child, Preschool; Cohort Studies; Female; Humans; Infant; Infant, Newborn; Male; Managed Care Programs; Propylamines; Retrospective Studies | 2005 |
Patients with attention-deficit/hyperactivity disorder without observed apneic episodes in sleep or daytime sleepiness have normal sleep on polysomnography.
Topics: Adolescent; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Cross-Over Studies; Disorders of Excessive Somnolence; Double-Blind Method; Female; Humans; Male; Methylphenidate; Nocturnal Myoclonus Syndrome; Polysomnography; Propylamines; Sleep; Sleep Apnea, Obstructive; Sleep Stages | 2005 |
Suicidal ideation among children taking atomoxetine (Strattera).
Topics: Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Humans; Propylamines; Psychology, Child; Suicide | 2005 |
Atomoxetine for the treatment of attention-deficit/hyperactivity disorder in children and adolescents with bipolar disorders.
Topics: Adolescent; Antimanic Agents; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Bipolar Disorder; Comorbidity; Drug Therapy, Combination; Humans; Male; Propylamines; Retrospective Studies; Treatment Outcome | 2005 |
Hyperactivity really IS common...and a new warning about treatment.
Topics: Adolescent; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Child, Preschool; Female; Humans; Male; Propylamines; Sex Distribution | 2005 |
Postmortem tissue distribution of atomoxetine following fatal and nonfatal doses--three case reports.
Topics: Adrenergic Uptake Inhibitors; Adult; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Chromatography, Gas; Drug Interactions; Drug Overdose; Female; Humans; Male; Molecular Structure; Norepinephrine; Postmortem Changes; Propylamines; Suicide; Tissue Distribution | 2006 |
New developments in the treatment of ADHD.
Topics: Antidepressive Agents, Tricyclic; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Benzhydryl Compounds; Bupropion; Central Nervous System Stimulants; Child; Clonidine; Cognitive Behavioral Therapy; Guanfacine; Humans; Modafinil; Nicotinic Agonists; Physician's Role; Primary Health Care; Propylamines; Treatment Outcome | 2006 |
What is the significance of the new warnings about suicide risk with Strattera?
Topics: Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Humans; Propylamines; Suicide | 2005 |
A comparison of North American versus non-North American ADHD study populations.
Topics: Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Europe; Female; Humans; Male; Propylamines; Prospective Studies; Severity of Illness Index; Sex Distribution; United States | 2006 |
Absence of unfavorable effect of atomoxetine on growth in pediatric patients is still not demonstrated.
Topics: Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Growth; Humans; Propylamines | 2006 |
Nonstimulant medications for the treatment of ADHD.
Topics: Adrenergic alpha-Agonists; Antidepressive Agents, Tricyclic; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Clonidine; Desipramine; Humans; Propylamines; Receptors, Adrenergic, alpha-2; Selective Serotonin Reuptake Inhibitors | 2006 |
[Atomoxetine in the treatment of ADHD].
Topics: Adult; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Humans; Propylamines | 2006 |
[Atomoxetine--an addition].
Topics: Adolescent; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Humans; Propylamines; Risk Factors | 2006 |
[Creutzfeld Disease Innovation Award].
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Awards and Prizes; Child; Clinical Trials as Topic; Drug Administration Schedule; Humans; Propylamines; Treatment Outcome | 2005 |
Factors associated with initiation with atomoxetine versus stimulants in the treatment of adults with ADHD: retrospective analysis of administrative claims data.
Topics: Adrenergic Uptake Inhibitors; Adult; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Databases, Factual; Female; Humans; Male; Managed Care Programs; Mental Disorders; Middle Aged; Propylamines; Retrospective Studies | 2006 |
The Texas Children's Medication Algorithm Project: revision of the algorithm for pharmacotherapy of attention-deficit/hyperactivity disorder.
Topics: Adrenergic Uptake Inhibitors; Algorithms; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Community Mental Health Centers; Humans; Practice Guidelines as Topic; Propylamines; Psychopharmacology; Texas; United States | 2006 |
Concomitant use of atomoxetine and OROS-methylphenidate in a 10-year-old child suffering from attention-deficit/hyperactivity disorder with comorbid bipolar disorder and Tourette syndrome.
Topics: Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Bipolar Disorder; Central Nervous System Stimulants; Child; Clonidine; Comorbidity; Drug Therapy, Combination; Humans; Male; Methylphenidate; Propylamines; Tics; Tourette Syndrome | 2006 |
Decreased use of clonidine following treatment with atomoxetine in children with ADHD.
Topics: Adolescent; Adrenergic alpha-Agonists; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Child, Preschool; Clonidine; Cohort Studies; Drug Utilization Review; Female; Humans; Male; Propylamines; Treatment Outcome | 2006 |
Acute urinary retention associated with atomoxetine use.
Topics: Acute Disease; Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Humans; Male; Propylamines; Urinary Retention | 2006 |
Isolated atomoxetine (Strattera) ingestions commonly result in toxicity.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Adult; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Child, Preschool; Cognition Disorders; Drug Overdose; Humans; Infant; Poison Control Centers; Propylamines; Retrospective Studies; Tachycardia; Vomiting | 2006 |
Dimensional analysis of ADHD subtypes in rats.
Topics: Adrenergic Uptake Inhibitors; Animals; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Cluster Analysis; Disease Models, Animal; Disruptive, Impulse Control, and Conduct Disorders; Environment; Habituation, Psychophysiologic; Locomotion; Male; Methylphenidate; Photic Stimulation; Propylamines; Psychomotor Performance; Rats; Rats, Sprague-Dawley; Time Factors; Treatment Outcome | 2007 |
Open-label atomoxetine for attention-deficit/ hyperactivity disorder symptoms associated with high-functioning pervasive developmental disorders.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Asperger Syndrome; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Autistic Disorder; Body Weight; Child; Child Development Disorders, Pervasive; Comorbidity; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Intelligence; Irritable Mood; Male; Neuropsychological Tests; Pilot Projects; Propylamines; Prospective Studies; Treatment Outcome | 2006 |
Atomoxetine for attention-deficit/hyperactivity disorder symptoms in children with pervasive developmental disorders: a pilot study.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Child Development Disorders, Pervasive; Comorbidity; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Impulsive Behavior; Male; Personality Assessment; Pilot Projects; Propylamines; Treatment Outcome | 2006 |
Atomoxetine-induced electrocardiogram changes.
Topics: Adrenergic Uptake Inhibitors; Arrhythmias, Cardiac; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Electrocardiography; Humans; Male; Propylamines | 2006 |
Pharmacological management of a youth with ADHD and a seizure disorder.
Topics: Adrenergic Uptake Inhibitors; Anticonvulsants; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Carbamazepine; Central Nervous System Stimulants; Child; Epilepsy; Humans; Male; Methylphenidate; Propylamines | 2006 |
ADHD update: new data on the risks of medication.
Topics: Adrenergic Uptake Inhibitors; Adult; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Death, Sudden, Cardiac; Drug Overdose; Growth Disorders; Humans; Methylphenidate; Propylamines | 2006 |
Methylphenidate and atomoxetine increase histamine release in rat prefrontal cortex.
Topics: Animals; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Histamine Release; Male; Methylphenidate; Prefrontal Cortex; Propylamines; Rats; Rats, Sprague-Dawley | 2007 |
First case of sialolithiasis associated with atomoxetine.
Topics: Adrenergic Uptake Inhibitors; Adult; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Humans; Male; Propylamines; Salivary Gland Calculi; Submandibular Gland Diseases | 2007 |
CYP2D6 and clinical response to atomoxetine in children and adolescents with ADHD.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Biotransformation; Child; Cytochrome P-450 CYP2D6; Dose-Response Relationship, Drug; Double-Blind Method; Female; Genotype; Humans; Male; Meta-Analysis as Topic; Polymorphism, Genetic; Propylamines; Randomized Controlled Trials as Topic; Treatment Outcome | 2007 |
[Atomoxetine--Strattera. Oral preparation].
Topics: Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Contraindications; Humans; Propylamines | 2006 |
Dyskinesias associated with atomoxetine in combination with other psychoactive drugs.
Topics: Adolescent; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Diphenhydramine; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Humans; Male; Propylamines; Psychotropic Drugs; Treatment Outcome | 2007 |
Atomoxetine-induced hyponatremia.
Topics: Adrenergic Uptake Inhibitors; Adult; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Humans; Hyponatremia; Inappropriate ADH Syndrome; Male; Patient Care Team; Propylamines; Referral and Consultation | 2007 |
The neurobiology of attention-deficit/hyperactivity disorder.
Topics: Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Brain; Central Nervous System Stimulants; Cerebellum; Child; Corpus Striatum; Disruptive, Impulse Control, and Conduct Disorders; Dopamine; Frontal Lobe; Humans; Methylphenidate; Nerve Net; Norepinephrine; Propylamines; Synaptic Transmission | 2007 |
Atomoxetine treatment of ADHD in Tourette syndrome: reduction in motor cortex inhibition correlates with clinical improvement.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Cohort Studies; Female; Humans; Male; Motor Cortex; Neural Inhibition; Propylamines; Severity of Illness Index; Single-Blind Method; Time Factors; Tourette Syndrome; Transcranial Magnetic Stimulation; Treatment Outcome | 2007 |
Seizure risk in patients with attention-deficit-hyperactivity disorder treated with atomoxetine.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Child, Preschool; Databases, Factual; Female; Humans; Male; Meta-Analysis as Topic; Methylphenidate; Product Surveillance, Postmarketing; Propylamines; Risk; Seizures | 2007 |
Indication and use of drug products used to treat attention-deficit/hyperactivity disorder: a cross-sectional study with inference on the likelihood of treatment in adulthood.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Adult; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Child, Preschool; Cross-Sectional Studies; Drug Utilization; Health Care Surveys; Humans; Infant; Insurance Claim Review; Middle Aged; Practice Patterns, Physicians'; Propylamines | 2007 |
Treatment of adult ADHD and comorbid disorders.
Topics: Adult; Amphetamines; Antidepressive Agents, Tricyclic; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Clinical Trials as Topic; Humans; Methylphenidate; Propylamines; Psychotropic Drugs; Selective Serotonin Reuptake Inhibitors; Treatment Outcome | 2006 |
Health care costs of adults treated for attention-deficit/hyperactivity disorder who received alternative drug therapies.
Topics: Adrenergic Uptake Inhibitors; Adult; Amphetamines; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Costs and Cost Analysis; Databases, Factual; Delayed-Action Preparations; Female; Health Care Costs; Humans; Insurance, Health; Insurance, Pharmaceutical Services; Male; Managed Care Programs; Methylphenidate; Middle Aged; Multivariate Analysis; Propylamines; Reproducibility of Results; Time Factors | 2007 |
[Prescribing of stimulants for ADHD in Nordland County].
Topics: Adolescent; Adrenergic Uptake Inhibitors; Adult; Amphetamine; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Child, Preschool; Dextroamphetamine; Drug Prescriptions; Drug Utilization; Female; Humans; Male; Methylphenidate; Norway; Propylamines | 2007 |
Sleep disturbances and ADHD medications.
Topics: Adolescent; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Cross-Over Studies; Double-Blind Method; Drug Administration Schedule; Humans; Methylphenidate; Polysomnography; Propylamines; Randomized Controlled Trials as Topic; Sleep Initiation and Maintenance Disorders | 2007 |
Nicotine as a conditioned stimulus: impact of attention-deficit/hyperactivity disorder medications.
Topics: Animals; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Behavior, Animal; Bupropion; Cocaine; Conditioning, Operant; Conditioning, Psychological; Discrimination Learning; Dopamine Uptake Inhibitors; Dose-Response Relationship, Drug; Generalization, Psychological; Male; Methylphenidate; Nicotine; Nicotinic Antagonists; Piperazines; Propylamines; Rats; Rats, Sprague-Dawley | 2007 |
Interactions of attention-deficit/hyperactivity disorder therapeutic agents with the efflux transporter P-glycoprotein.
Topics: Adenosine Triphosphate; Amphetamine; Animals; Atomoxetine Hydrochloride; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Attention Deficit Disorder with Hyperactivity; Benzhydryl Compounds; Biological Transport; Central Nervous System Stimulants; Cyclosporins; Dose-Response Relationship, Drug; Doxorubicin; Isomerism; LLC-PK1 Cells; Methylphenidate; Modafinil; Propylamines; Reproducibility of Results; Rhodamine 123; Swine; Transfection | 2008 |
Effects of atomoxetine on growth in children with attention-deficit/hyperactivity disorder following up to five years of treatment.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Body Height; Body Mass Index; Body Weight; Child; Female; Growth; Humans; Longitudinal Studies; Male; Propylamines; Psychiatric Status Rating Scales | 2007 |
Utilization of pharmacologic treatment in youths with attention deficit/hyperactivity disorder in Medicaid database.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Adult; Age Factors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Child, Preschool; Cross-Sectional Studies; Databases, Factual; Humans; Incidence; Infant; Longitudinal Studies; Medicaid; Practice Patterns, Physicians'; Prevalence; Propylamines; Racial Groups; Sex Factors; Time Factors; United States | 2008 |
Effects of atomoxetine on attention-deficit/hyperactivity disorder in clinical pediatric treatment settings: a naturalistic study.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Adult; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Female; Humans; Male; Propylamines; Prospective Studies; Psychological Tests; Treatment Outcome | 2008 |
Is NICE infallible? A qualitative study of its assessment of treatments for attention-deficit/hyperactivity disorder (ADHD).
Topics: Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Cost-Benefit Analysis; Dextroamphetamine; Evidence-Based Medicine; Humans; Methylphenidate; Models, Economic; Outcome and Process Assessment, Health Care; Propylamines; Qualitative Research; Technology Assessment, Biomedical; United Kingdom | 2008 |
Gender differences in 2 clinical trials of adults with attention-deficit/hyperactivity disorder: a retrospective data analysis.
Topics: Adrenergic Uptake Inhibitors; Adult; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Emotions; Female; Humans; Male; Middle Aged; Multicenter Studies as Topic; Propylamines; Randomized Controlled Trials as Topic; Retrospective Studies; Sex Factors; Treatment Outcome; Women's Health | 2008 |
Enhancement of atomoxetine serum levels by co-administration of paroxetine.
Topics: Adrenergic Uptake Inhibitors; Adult; Atomoxetine Hydrochloride; Attention; Attention Deficit Disorder with Hyperactivity; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Drug Interactions; Drug Therapy, Combination; Enzyme Inhibitors; Humans; Male; Paroxetine; Propylamines | 2008 |
Latino versus Caucasian response to atomoxetine in attention-deficit/hyperactivity disorder.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Cytochrome P-450 CYP2D6; Female; Hispanic or Latino; Humans; Male; Propylamines; White People | 2008 |
Methylphenidate disrupts social play behavior in adolescent rats.
Topics: Adrenergic Antagonists; Adrenergic Uptake Inhibitors; Animals; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Behavior, Animal; Brain; Central Nervous System Stimulants; Dose-Response Relationship, Drug; Exploratory Behavior; Male; Methylphenidate; Norepinephrine; Play and Playthings; Propylamines; Rats; Rats, Wistar; Social Behavior | 2008 |
The Life Participation Scale for Attention-Deficit/Hyperactivity Disorder--Child Version: psychometric properties of an adaptive change instrument.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Emotions; Factor Analysis, Statistical; Female; Humans; Male; Methylphenidate; Multicenter Studies as Topic; Parents; Propylamines; Psychiatric Status Rating Scales; Psychometrics; Quality of Life; Randomized Controlled Trials as Topic; Reproducibility of Results; Social Behavior | 2007 |
Atomoxetine increases histamine release and improves learning deficits in an animal model of attention-deficit hyperactivity disorder: the spontaneously hypertensive rat.
Topics: Adrenergic Uptake Inhibitors; Animals; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Behavior, Animal; Disease Models, Animal; Histamine; Injections, Intraperitoneal; Learning; Male; Maze Learning; Memory; Prefrontal Cortex; Propylamines; Rats; Rats, Inbred SHR; Water | 2008 |
Tricyclic antidepressants (TCA) may improve atomoxetine's efficacy.
Topics: Adrenergic Uptake Inhibitors; Antidepressive Agents, Tricyclic; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Drug Synergism; Drug Therapy, Combination; Humans; Propylamines | 2008 |
Development of tics in a thirteen-year-old male following atomoxetine use.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Anticonvulsants; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Clonazepam; Clonidine; Drug Therapy, Combination; Humans; Male; Propylamines; Sympatholytics; Tic Disorders | 2008 |
Tic exacerbation and precipitation during atomoxetine treatment in two children with attention-deficit hyperactivity disorder.
Topics: Adrenergic Uptake Inhibitors; Antipsychotic Agents; Anxiety Disorders; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Citalopram; Dibenzothiazepines; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Humans; Male; Propylamines; Quetiapine Fumarate; Selective Serotonin Reuptake Inhibitors; Tics | 2007 |